<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83527</article-id><article-id pub-id-type="doi">10.7554/eLife.83527</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>A chronic signaling TGFb zebrafish reporter identifies immune response in melanoma</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-293243"><name><surname>Noonan</surname><given-names>Haley R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0519-4065</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-358943"><name><surname>Thornock</surname><given-names>Alexandra M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0511-4376</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293244"><name><surname>Barbano</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293245"><name><surname>Xifaras</surname><given-names>Michael E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293246"><name><surname>Baron</surname><given-names>Chloe S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293247"><name><surname>Yang</surname><given-names>Song</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293248"><name><surname>Koczirka</surname><given-names>Katherine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293249"><name><surname>McConnell</surname><given-names>Alicia M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-3910"><name><surname>Zon</surname><given-names>Leonard I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0860-926X</contrib-id><email>zon@enders.tch.harvard.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/006w34k90</institution-id><institution>Stem Cell Program and Division of Hematology/Oncology, Boston Children’s Hospital and Dana Farber Cancer Institute, Howard Hughes Medical Institute</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Stem Cell and Regenerative Biology Department, Harvard University</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wevmz92</institution-id><institution>Harvard Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Biological and Biomedical Sciences Program, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Immunology Program, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Tamplin</surname><given-names>Owen J</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01y2jtd41</institution-id><institution>University of Wisconsin–Madison</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ojala</surname><given-names>Paivi M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040af2s02</institution-id><institution>University of Helsinki</institution></institution-wrap><country>Finland</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>14</day><month>06</month><year>2024</year></pub-date><volume>13</volume><elocation-id>e83527</elocation-id><history><date date-type="received" iso-8601-date="2022-09-17"><day>17</day><month>09</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2024-04-15"><day>15</day><month>04</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-09-30"><day>30</day><month>09</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.09.29.510035"/></event></pub-history><permissions><copyright-statement>© 2024, Noonan, Thornock et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Noonan, Thornock et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83527-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83527-figures-v1.pdf"/><abstract><p>Developmental signaling pathways associated with growth factors such as TGFb are commonly dysregulated in melanoma. Here we identified a human TGFb enhancer specifically activated in melanoma cells treated with TGFB1 ligand. We generated stable transgenic zebrafish with this TGFb Induced Enhancer driving green fluorescent protein (<italic>TIE:EGFP</italic>). <italic>TIE:EGFP</italic> was not expressed in normal melanocytes or early melanomas but was expressed in spatially distinct regions of advanced melanomas. Single-cell RNA-sequencing revealed that <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells down-regulated interferon response while up-regulating a novel set of chronic TGFb target genes. ChIP-sequencing demonstrated that AP-1 factor binding is required for activation of chronic TGFb response. Overexpression of <italic>SATB2</italic>, a chromatin remodeler associated with tumor spreading, showed activation of TGFb signaling in early melanomas. Confocal imaging and flow cytometric analysis showed that macrophages localize to <italic>TIE:EGFP<sup>+</sup></italic> regions and preferentially phagocytose <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells compared to <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells. This work identifies a TGFb induced immune response and demonstrates the need for the development of chronic TGFb biomarkers to predict patient response to TGFb inhibitors.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>melanoma</kwd><kwd>TGFb</kwd><kwd>zebrafish</kwd><kwd>macrophages</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>NCI R01CA103846</award-id><principal-award-recipient><name><surname>Noonan</surname><given-names>Haley R</given-names></name><name><surname>Thornock</surname><given-names>Alexandra M</given-names></name><name><surname>Barbano</surname><given-names>Julia</given-names></name><name><surname>Xifaras</surname><given-names>Michael</given-names></name><name><surname>Baron</surname><given-names>Chloe S</given-names></name><name><surname>Yang</surname><given-names>Song</given-names></name><name><surname>Koczirka</surname><given-names>Katherine</given-names></name><name><surname>McConnell</surname><given-names>Alicia M</given-names></name><name><surname>Zon</surname><given-names>Leonard I</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005190</institution-id><institution>Melanoma Research Alliance</institution></institution-wrap></funding-source><award-id>Grant given via University of Edinburgh United Kingdom project number TBD</award-id><principal-award-recipient><name><surname>Thornock</surname><given-names>Alexandra M</given-names></name><name><surname>Xifaras</surname><given-names>Michael</given-names></name><name><surname>Baron</surname><given-names>Chloe S</given-names></name><name><surname>Yang</surname><given-names>Song</given-names></name><name><surname>Zon</surname><given-names>Leonard I</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P01CA163222</award-id><principal-award-recipient><name><surname>Noonan</surname><given-names>Haley R</given-names></name><name><surname>Thornock</surname><given-names>Alexandra M</given-names></name><name><surname>Barbano</surname><given-names>Julia</given-names></name><name><surname>Xifaras</surname><given-names>Michael E</given-names></name><name><surname>Baron</surname><given-names>Chloe S</given-names></name><name><surname>Yang</surname><given-names>Song</given-names></name><name><surname>Koczirka</surname><given-names>Katherine</given-names></name><name><surname>McConnell</surname><given-names>Alicia M</given-names></name><name><surname>Zon</surname><given-names>Leonard I</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>An in vivo reporter of TGFb signaling in zebrafish reveals that melanoma cells undergoing chronic TGFb signaling up-regulate extracellular matrix genes, down-regulate IFN, and are preferentially phagocytosed by macrophages compared to non-TGFb responsive melanoma cells.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Melanoma, arising from pigment producing melanocytes, is the deadliest form of skin cancer, with an estimated 100,640 new cases and 8,290 deaths in the United States in 2024 alone (<xref ref-type="bibr" rid="bib66">Siegel et al., 2024</xref>). The most common mutation in melanoma is BRAF<sup>V600E</sup>, which accounts for approximately 50% of melanoma cases and results in activation of the MAPK pathway promoting cell growth and survival (<xref ref-type="bibr" rid="bib3">Akbani et al., 2015</xref>; <xref ref-type="bibr" rid="bib42">Lo and Fisher, 2014</xref>). In addition, developmental signaling pathways are commonly dysregulated. Melanoma cells have increased expression and secretion of TGFb ligands compared to normal melanocytes, and TGFb ligand expression correlates with melanoma progression (<xref ref-type="bibr" rid="bib77">Van Belle et al., 1996</xref>; <xref ref-type="bibr" rid="bib5">Albino et al., 1991</xref>; <xref ref-type="bibr" rid="bib60">Rodeck et al., 1991</xref>; <xref ref-type="bibr" rid="bib61">Rodeck et al., 1994</xref>; <xref ref-type="bibr" rid="bib35">Krasagakis et al., 1998</xref>; <xref ref-type="bibr" rid="bib28">Javelaud et al., 2008</xref>; <xref ref-type="bibr" rid="bib56">Perrot et al., 2013</xref>; <xref ref-type="bibr" rid="bib57">Rak et al., 1996</xref>; <xref ref-type="bibr" rid="bib15">Cerami et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Gao et al., 2013</xref>; <xref ref-type="bibr" rid="bib40">Lauden et al., 2014</xref>; <xref ref-type="bibr" rid="bib64">Schmid et al., 1995</xref>). TGFb ligand binding to receptors on the cell surface results in phosphorylation and activation of SMAD2 and SMAD3 transcription factors. SMAD2 and SMAD3 translocate to the nucleus with SMAD4 to modulate gene expression (<xref ref-type="bibr" rid="bib10">Batlle and Massagué, 2019</xref>). In normal melanocytes and early melanoma, TGFb acts as a tumor suppressor. However, in advanced melanoma TGFb is pro-tumorigenic as it induces growth, invasion, and metastasis (<xref ref-type="bibr" rid="bib56">Perrot et al., 2013</xref>). As current targeted MAPK and immune checkpoint inhibitors often result in resistance, there is a need to study additional pathways perturbed in melanoma, such as TGFb.</p><p>Most cells in the tumor microenvironment can respond to and initiate TGFb signaling, although this often occurs in a heterogenous manner (<xref ref-type="bibr" rid="bib16">Derynck et al., 2021</xref>). Generally, TGFb has an immunosuppressive effect in advanced tumors, resulting in inactivation of cytotoxic CD8<sup>+</sup> T cells, expansion of immune suppressive regulatory T cells, inhibition of dendritic cell antigen presentation, and conversion of macrophages to an anti-inflammatory and pro-angiogenic M2-like state (<xref ref-type="bibr" rid="bib10">Batlle and Massagué, 2019</xref>; <xref ref-type="bibr" rid="bib16">Derynck et al., 2021</xref>; <xref ref-type="bibr" rid="bib53">Naganuma et al., 1996</xref>; <xref ref-type="bibr" rid="bib2">Ahmadzadeh and Rosenberg, 2005</xref>; <xref ref-type="bibr" rid="bib17">Donkor et al., 2011</xref>; <xref ref-type="bibr" rid="bib20">Fridlender et al., 2009</xref>; <xref ref-type="bibr" rid="bib43">Mantovani et al., 2002</xref>; <xref ref-type="bibr" rid="bib68">Standiford et al., 2011</xref>; <xref ref-type="bibr" rid="bib33">Kobie et al., 2003</xref>). TGFb can act as a chemoattractant for macrophages and monocytes to areas of inflammation. Recruitment of monocytes by TGFb results in differentiation into macrophages that attach to the extracellular matrix (ECM) or promote blood vessel leakiness allowing for tumor cell extravasation (<xref ref-type="bibr" rid="bib8">Arwert et al., 2018</xref>; <xref ref-type="bibr" rid="bib31">Kelly et al., 2018</xref>; <xref ref-type="bibr" rid="bib32">Kim et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Allen et al., 1990</xref>; <xref ref-type="bibr" rid="bib80">Wahl et al., 1993</xref>). In colorectal and urothelial cancers, TGFb in the tumor microenvironment was found to mediate immune evasion such that TGFb inhibition rendered these tumors susceptible to anti-PD-1/PD-L1 immune checkpoint inhibitors (<xref ref-type="bibr" rid="bib74">Tauriello et al., 2018</xref>; <xref ref-type="bibr" rid="bib44">Mariathasan et al., 2018</xref>). Due to its immunosuppressive effect, several TGFb inhibitors are in clinical trials in combination with immune checkpoint inhibitors (<xref ref-type="bibr" rid="bib38">Lan et al., 2018</xref>; <xref ref-type="bibr" rid="bib55">Paz-Ares et al., 2020</xref>; <xref ref-type="bibr" rid="bib69">Strauss et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Martin et al., 2020</xref>; <xref ref-type="bibr" rid="bib82">Welsh et al., 2021</xref>).</p><p>Here, we visualized TGFb response across zebrafish melanoma tumorigenesis. A human melanoma enhancer, induced upon TGFB1 signaling was identified, and stable transgenic zebrafish with this enhancer driving EGFP were generated (<italic>TIE:EGFP</italic>). This TGFb inducible enhancer reporter is expressed in spatially distinct regions in advanced zebrafish melanomas and is characterized by up-regulation of a series of novel chronic TGFb target genes involved in the extracellular matrix. Single-cell RNA-seq and confocal microscopy revealed that <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells down-regulate interferon response and are preferentially phagocytosed by macrophages. Overexpression of the chromatin remodeler <italic>SATB2</italic>, which is associated with tumor spreading, shows early activation of TGFb signaling in these melanomas, suggesting that specific melanoma genotypes may benefit from TGFb inhibition. Overall, this work demonstrates the need for biomarker development to predict response to TGFb inhibitors in advanced or aggressive melanoma subtypes.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>A TGFb enhancer reporter is inducible and specific in zebrafish</title><p>To visualize dynamic TGFb response across melanoma development, we designed a TGFb Inducible Enhancer (TIE) reporter using human melanoma cell (A375) ChIP-seq data following a 2-hr TGFB1 treatment. RNA-sequencing indicated that following a 2-hr treatment of A375 cells with 10 ng/mL human recombinant TGFB1, 223 genes were significantly up-regulated (q&lt;0.05) including typical TGFb target genes SMAD7, JUNB, and PMEPA1, while 94 genes were down-regulated (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>, left). Hallmark gene set enrichment analysis (GSEA) of genes ranked by log2 fold-change (log2fc) confirmed that TGFb was the top up-regulated pathway following 2-hr treatment (q=0) (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>, right). This indicates that a 2-hr treatment with human recombinant TGFB1 ligand is sufficient to activate the TGFb pathway.</p><p>To identify a TGFB1 inducible enhancer region, we selected a region of chromatin that was exclusively open upon stimulation, based on H3K27ac ChIP-seq, with unique SMAD2/3 binding following treatment (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The enhancer region under the SMAD2/3 peak was cloned upstream of a beta-globin minimal promoter and EGFP in a Tol2 vector backbone. <italic>TIE:EGFP</italic> was tested for inducibility in the presence of ubiquitously expressed constitutively active SMAD2 and SMAD3 (<italic>ubi:caSMAD2/3</italic>) by electroporation of adult zebrafish skin, with ubiquitous BFP (<italic>ubi:BFP</italic>) as a control for electroporation efficiency. <italic>TIE:EGFP</italic> reporter activity was significantly increased in the presence <italic>of ubi:caSMAD2</italic> and <italic>ubi:caSMAD3</italic>, confirming that the reporter is inducible (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Novel <italic>TIE:EGFP</italic> zebrafish enhancer reporter is expressed in advanced melanomas.</title><p>(<bold>A</bold>) TGFb-induced enhancer (TIE) used to construct <italic>TIE:EGFP</italic> reporter determined by H3K27ac, SMAD2/3, and MITF ChIP-seq peaks in A375s+/-TGFB1. There is unique H3K27ac and SMAD2/3 binding upon stimulus. (<bold>B</bold>) <italic>TIE:EGFP</italic> expression throughout zebrafish development. Scale bars represent 500 µm. (<bold>C</bold>) <italic>TIE:EGFP</italic> expression across melanomagenesis indicated by arrowheads. Representative images shown. Additional tumors shown in <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>. Illustrated fish diagram in (<bold>C</bold>) created with <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender.com</ext-link>, and published using a CC BY-NC-ND license with permission.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83527-fig1-v1.tif"/><permissions><copyright-statement>© 2024, BioRender Inc</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>BioRender Inc</copyright-holder><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Figure 1 was created using <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender</ext-link>, and is published under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND</ext-link> license. Further reproductions must adhere to the terms of this license.</license-p></license></permissions></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title><italic>TIE:EGFP</italic> zebrafish enhancer reporter is inducible and specific.</title><p>(<bold>A</bold>) <italic>TIE:EGFP</italic> reporter is induced upon electroporation with <italic>ubi:caSMAD2</italic> and <italic>ubi:caSMAD3</italic> in adult zebrafish flank skin. <italic>Ubi:BFP</italic> was used as a control for varying electroporation efficiency. <italic>TIE:EGFP</italic> intensity/BFP area was quantified (right). Two-tailed unpaired Welch’s t-test was used to calculate significance. Representative images shown. n=8 fish per condition. (<bold>B</bold>) <italic>TIE:EGFP</italic> embryos treated at 1 day post fertilization for 24 hr with E3 (zebrafish water), DMSO (vehicle control), 50 µM or 100 µM TGFb inhibitor SB431542. <italic>TIE:EGFP</italic> channel (top) and white light (bottom). Representative images shown. Scale bars represent 500 µm. (<bold>C</bold>) In situ hybridization (ISH) was performed probing for GFP in embryos treated with DMSO (n=26), 50 µM (n=30), or 100 µM (n=31) TGFb inhibitor SB431542 for 24 hr starting at 1 day post fertilization. Embryos were grouped into three qualitative groups based on GFP intensity: low, medium, and high, and the percentage of embryos in each are graphed below. (<bold>D</bold>) Representative image of <italic>mitfa:mCherry<sup>+</sup></italic> zebrafish fin melanocytes expressing <italic>TIE:EGFP</italic>. The uppermost EGFP<sup>+</sup> region not overlapping with mCherry signal is residual spinal expression of <italic>TIE:EGFP</italic>. (<bold>E</bold>) Early melanomas, indicated by arrowheads, do not express <italic>TIE:EGFP</italic>. The EGFP<sup>+</sup> region not overlapping with mCherry signal is residual brain expression of <italic>TIE:EGFP</italic>. Representative images shown. Illustrated fish diagrams in (<bold>A, D, E</bold>) created with <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender.com</ext-link>, and published using a CC BY-NC-ND license with permission.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83527-fig1-figsupp1-v1.tif"/><permissions><copyright-statement>© 2024, BioRender Inc</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>BioRender Inc</copyright-holder><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Figure 1—figure supplement 1 was created using BioRender, and is published under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0</ext-link>. Further reproductions must adhere to the terms of this license.</license-p></license></permissions></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Treatment with human recombinant TGFB1 activates the TGFb pathway in human melanoma cells.</title><p>(<bold>A</bold>) (Left) RNA-sequencing indicated that following a 2-hr treatment with 10 ng/mL TGFB1, 223 genes were significantly up-regulated (q&lt;0.05), including typical TGFb target genes such as SMAD7, JUNB, and PMEPA1, while 94 genes were down-regulated. This Volcano plot indicates top up- and down-regulated genes upon TGFB1 treatment. (Right) Hallmark gene set enrichment analysis (GSEA) of genes ranked by log2 fold-change (log2fc) confirmed that TGFb was the top up-regulated pathway (q=0). RNA-seq was performed in triplicate. (<bold>B</bold>) <italic>TIE:EGFP<sup>+</sup></italic> melanoma #2 expressing <italic>MCR:MCS. TIE:EGFP</italic> expression across melanomagenesis. Representative images shown. Illustrated fish diagrams in (<bold>B</bold>) created with <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender.com</ext-link>, and published using a CC BY-NC-ND license with permission.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83527-fig1-figsupp2-v1.tif"/><permissions><copyright-statement>© 2024, BioRender Inc</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>BioRender Inc</copyright-holder><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Figure 1—figure supplement 2 was created using BioRender, and is published under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0</ext-link>. Further reproductions must adhere to the terms of this license.</license-p></license></permissions></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title><italic>TIE:EGFP</italic> expression across melanomagenesis in several additional <italic>TIE:EGFP;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup>;MCR:MCS;mitfa:mCherry;tyr<sup>-/-</sup></italic> fish.</title><p>Clusters of <italic>TIE:EGFP<sup>+</sup></italic> cells indicated by white arrowheads.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83527-fig1-figsupp3-v1.tif"/></fig></fig-group><p>The <italic>TIE:EGFP</italic> reporter construct was microinjected into <italic>Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup></italic> zebrafish in order to generate melanomas. <italic>TIE:EGFP;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup></italic> stable embryos have EGFP expression in the anterior brain at 24 hr post fertilization (hpf) extending along the brain and spinal cord beginning at 48 hpf (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). This expression pattern is consistent with that previously found in a Smad3 zebrafish reporter, although in our hands this Smad3 reporter was not active in adults (<xref ref-type="bibr" rid="bib13">Casari et al., 2014</xref>). <italic>TIE:EGFP</italic> embryos were treated at 24 hpf with 50 or 100 µM of SB431542, a TGFb type I receptor kinase inhibitor, and imaged at 48 hpf (<xref ref-type="bibr" rid="bib32">Kim et al., 2021</xref>). Treatment with this TGFb inhibitor for 24 hr drastically reduced <italic>TIE:EGFP</italic> signal (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B, C</xref>). This indicates that the <italic>TIE:EGFP</italic> reporter is specific to TGFb signaling.</p></sec><sec id="s2-2"><title><italic>TIE:EGFP</italic> reporter is expressed in advanced zebrafish melanomas</title><p>To visualize TGFb response across melanoma development, single cell <italic>Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup></italic> embryos stably expressing <italic>TIE:EGFP</italic> were injected with an empty MiniCoopR vector (<italic>MCR:MCS</italic>) containing the <italic>mitfa</italic> minigene to generate melanomas. <italic>Tyrosinase</italic> gRNA and Cas9 protein were also injected to knock-out melanocyte pigment as well as <italic>mitfa:mCherry</italic> to allow for melanocyte visualization. Normal melanocytes rarely had <italic>TIE:EGFP</italic> expression, with the exception of occasional fin melanocytes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). <italic>TIE:EGFP</italic> has yet to be observed in <italic>mitfa:mCherry</italic> high early melanomas (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). However, of the fish with melanoma formation (n=56), 55% turned on <italic>TIE:EGFP</italic> in advanced melanomas defined by protrusion from the body plane (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). <italic>TIE:EGFP<sup>+</sup></italic> cells often occur in clusters throughout the tumor and these cells are <italic>TIE:EGFP<sup>+</sup></italic> for many weeks at a time. This data indicates that advanced zebrafish melanomas develop TGFb responsive zones.</p></sec><sec id="s2-3"><title><italic>TIE:EGFP</italic> expressing melanoma cells down-regulate interferon signaling</title><p>To understand the transcriptional differences between <italic>TIE:EGFP<sup>+</sup></italic> and <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells, single <italic>TIE:EGFP<sup>+</sup></italic> and <italic>mitfa:mCherry<sup>+</sup></italic> cells from <italic>TIE:EGFP</italic> expressing melanomas were processed for single cell RNA-sequencing at 23 and 42 weeks post fertilization (wpf), respectively (melanomas used are depicted in <xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). We used SORT-seq to sequence flow cytometry-sorted single cells and in silico linked transcriptomes to fluorescence intensities as recorded by FACS indexing (<xref ref-type="bibr" rid="bib52">Muraro et al., 2016</xref>). A UMAP of the sequencing results from our combined replicates is shown (<xref ref-type="fig" rid="fig2">Figure 2A</xref>; UMAP with no batch correction in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Most cells were identified as melanoma cells expressing <italic>mitfa</italic> and/or <italic>sox10</italic>, but we identified an <italic>mpeg1.1</italic>-expressing <italic>TIE:EGFP<sup>+</sup></italic> macrophage cluster as well (<xref ref-type="fig" rid="fig2">Figure 2A</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>TGFb responsive melanoma cells in <italic>MCR:MCS</italic> tumors up-regulate chronic extracellular matrix TGFb target genes and AP-1 binding is required for TGFb responsiveness.</title><p>(<bold>A</bold>) (Left) UMAP depicting seven cell clusters identified by SORT-seq, combined two <italic>MCR:MCS</italic> biological replicates. Approximately 2256 <italic>TIE:EGFP<sup>+</sup></italic> cells and 752 <italic>mitfa:mCherry<sup>+</sup>;TIE:EGFP<sup>-</sup></italic> cells (as a control) were sorted by flow cytometry for scRNA-seq. <italic>TIE:EGFP<sup>+</sup></italic> cells were both <italic>mitfa:mCherry<sup>+</sup> and mitfa:mCherry<sup>-</sup></italic>. In analysis of the scRNA-seq data, melanoma cells were identified as being <italic>mitfa</italic> and <italic>sox10</italic> positive, while macrophages were identified as <italic>mpeg1.1</italic> and <italic>marco</italic> positive. (<bold>B</bold>) Dotplot depicting TGFb immediate-early target gene expression in <italic>TIE:EGFP<sup>high</sup></italic>, <italic>TIE:EGFP<sup>low</sup>,</italic> and <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells. Melanoma cells can be segregated into <italic>TIE:EGFP<sup>high</sup></italic> vs. <italic>TIE:EGFP<sup>low</sup></italic> based on EGFP intensity during sorting. (<bold>C</bold>) Dotplot depicting extracellular matrix TGFb target gene expression in <italic>TIE:EGFP<sup>high</sup>, TIE:EGFP<sup>low</sup>,</italic> and <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells. (<bold>D</bold>) HOMER motif analysis of regulatory regions bound by SMAD2/3 upon stimulation in A375 cells. (<bold>E</bold>) Heatmap showing binding of JUNB and ATF3 pre-stimulus at 12,000 SMAD2/3-responsive elements in A375. (<bold>F</bold>) (Top) IGV plot of H3K27ac, SMAD2/3, ATF3 and JUNB ChIP-seq +/- TGFB1 stimulus at the TGFb-induced enhancer. Inset depicts sequence under SMAD2/3 ChIP-seq peak and highlights AP-1 (orange) and SMAD2/3 (red) binding sites. (Bottom) Firefly luciferase luminescence of full TIE reporter or reporter lacking AP-1 or SMAD2/3 sites. Normalized to Renilla transfection control. Experiment performed three times with three technical replicates each. A two-way multiple comparison ANOVA was used to calculate significance.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83527-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>TGFb responsive melanoma cells down-regulate interferon target genes.</title><p>(<bold>A</bold>) UMAP with no batch correction of 2 <italic>MCR:MCS</italic> replicate melanomas combined in <xref ref-type="fig" rid="fig2">Figure 2A</xref>. Approximately 2,256 <italic>TIE:EGFP<sup>+</sup></italic> cells and 752 <italic>mitfa:mCherry<sup>+</sup>; TIE:EGFP<sup>-</sup></italic> cells (as a control) were sorted for scRNA-seq. (<bold>B</bold>) (Top) Dotplot depicting interferon target gene expression in <italic>TIE:EGFP<sup>high</sup>, TIE:EGFP<sup>low</sup>,</italic> and <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells. (Bottom) GSEA enrichment plot reveal down-regulated interferon gamma (q=0.01) in <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells. The internal control for these comparisons was <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells from the same tumor.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83527-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Mutated TGFb inducible enhancer sequences used for luciferase assays in <xref ref-type="fig" rid="fig2">Figure 2F</xref>.</title><p>AP-1 motifs are in orange, SMAD2/3 motif is in red.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Editable version of <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="postscript" xlink:href="elife-83527-fig2-figsupp2-data1-v1.ai"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83527-fig2-figsupp2-v1.tif"/></fig></fig-group><p>The melanoma cell population was separated into <italic>TIE:EGFP<sup>-</sup>, TIE:EGFP<sup>low</sup></italic>, and <italic>TIE:EGFP<sup>high</sup></italic> based on FACS intensities. We found that immediate-early TGFb target genes, identified following an acute 2 hr TGFB1 treatment in zebrafish melanoma cells, ZMEL1, were down-regulated in <italic>TIE:EGFP<sup>high</sup></italic> cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). However, we identified 29 genes that were up-regulated in <italic>TIE:EGFP<sup>high</sup></italic> cells. We termed these genes, related to the extracellular matrix, ‘chronic’ TGFb targets (<xref ref-type="fig" rid="fig2">Figure 2C</xref>; <xref ref-type="bibr" rid="bib30">Katsuno et al., 2019</xref>; <xref ref-type="bibr" rid="bib78">Verrecchia et al., 2001</xref>). At the time of dissociation, these melanomas had <italic>TIE:EGFP<sup>+</sup></italic> cells for several weeks, therefore they were likely not in an acute TGFb response phase (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). Using GSEA analysis we found that the top down-regulated pathways in <italic>TIE:EGFP<sup>high</sup></italic> cells were interferon alpha and gamma (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). This suggests that TGFb has an immune suppressive effect in these melanomas.</p></sec><sec id="s2-4"><title>AP-1 factors are required for induction of the chronic TIE reporter</title><p>Although the vast majority of literature focuses on acute TGFb signaling, our <italic>TIE:EGFP</italic> reporter remains on in melanoma, reading out chronic TGFb signal. We next asked what transcription factors are necessary for induction of our novel chronic TGFb reporter and therefore required for chronic TGFb signaling. We performed HOMER motif analysis of ~12,000 SMAD2/3 responsive regulatory elements. These regions were identified in A375 melanoma cells stimulated with TGFB1 and were bound by SMAD2/3 upon stimulus. We found that these SMAD2/3 bound regions are highly enriched for AP-1 motifs (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). ChIP-seq in A375 cells in the presence or absence of TGFB1 treatment confirmed the binding of AP-1 transcription factors JUNB and ATF3 (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). ATF3 and JUNB were bound at 19% and 48% of SMAD2/3 responsive elements, respectively, before TGFB1 treatment was administered. This data indicates that AP-1 factors, in particular JUNB, may be important for SMAD binding to chromatin.</p><p>We hypothesized that AP-1 factors occupy SMAD responsive elements prior to stimulation, stabilizing open chromatin to allow the TGFb response to occur quickly upon stimulation. To test this hypothesis, we deleted AP-1 motifs in our TIE enhancer driving luciferase. We identified AP-1 motifs (highlighted in orange) in our TGFb-induced enhancer using MoLoTool and HOCOMOCO motifs (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, top; <xref ref-type="bibr" rid="bib36">Kulakovskiy et al., 2018</xref>). AP-1 motif #1 was the most significant (p=8.4e<sup>–6</sup>), and AP-1 motif #2 had a lesser p-value of 8.2e<sup>–4</sup>. We deleted either AP-1 site #1 alone, AP-1 site #2 alone, or both AP-1 sites, as well as the most significant SMAD2/3 motif (p=6.7e<sup>–6</sup>), shown in red (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). In A375 cells, loss of AP-1 site #1 rendered the enhancer region unresponsive to TGFb signaling, however loss of AP-1 site #2 did not alter inducibility (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, bottom). This result indicates that AP-1 site #1 is necessary for TGFb inducibility at this enhancer. Deletion of the SMAD site also destroyed TGFB1 responsiveness. This data suggests that AP-1 binding is required for responsiveness of this chronic TGFb inducible enhancer in melanoma.</p></sec><sec id="s2-5"><title>Macrophages preferentially phagocytose <italic>TIE:EGFP</italic> expressing melanoma cells</title><p>We identified <italic>TIE:EGFP<sup>+</sup></italic> macrophages in <italic>TIE:EGFP;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup>;MCR:MCS</italic> melanomas that express <italic>mitfa</italic> and <italic>sox10</italic>, suggesting recent phagocytosis of melanoma cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). There are two potential models for why macrophages are <italic>TIE:EGFP<sup>+</sup></italic>: (1) macrophages express <italic>TIE:EGFP</italic> themselves, or (2) macrophages are engulfing <italic>TIE:EGFP<sup>+</sup></italic> cells. To test these hypotheses, we crossed <italic>TIE:EGFP;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup></italic> zebrafish to a <italic>mpeg:mCherry</italic> reporter line that labels macrophages with mCherry (<xref ref-type="bibr" rid="bib18">Ellett et al., 2011</xref>). These embryos were injected with <italic>MCR:BRAF<sup>V600E</sup>, 2x U6:p53/Tyr gRNA mitfa:Cas9,</italic> and <italic>mitfa:BFP</italic> to generate pigmentless, BFP<sup>+</sup> melanomas. As the <italic>TIE:EGFP</italic> reporter is cytoplasmic, if <italic>mpeg:mCherry<sup>+</sup></italic> macrophages are endogenously expressing <italic>TIE:EGFP</italic>, we would expect the entire macrophage to appear yellow via imaging. Confocal imaging of these tumors showed that the majority of a <italic>TIE:EGFP<sup>+</sup></italic> region of the tumor is composed of clustered <italic>TIE:EGFP<sup>+</sup></italic> macrophages. Within these regions, we observed that a subset of macrophages contain only puncta of <italic>TIE:EGFP</italic> signal, suggesting phagocytosis of <italic>TIE:EGFP<sup>+</sup></italic> cells, while a separate subset are entirely yellow (suggesting endogenous reporter expression; <xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). In 10 out of 13 tumors analyzed by confocal microscopy, about 60–80% of <italic>TIE:EGFP<sup>+</sup></italic> macrophages contained <italic>TIE:EGFP</italic> fragments, while the remaining <italic>TIE:EGFP<sup>+</sup></italic> macrophages were diffusely <italic>TIE:EGFP<sup>+</sup></italic>. In the remaining three tumors, about 30% of <italic>TIE:EGFP<sup>+</sup></italic> macrophages contained <italic>TIE:EGFP</italic> fragments, while the remaining were diffusely <italic>TIE:EGFP<sup>+</sup></italic>. Therefore, in most tumors (with rare exceptions), the majority of <italic>TIE:EGFP<sup>+</sup></italic> macrophages are EGFP<sup>+</sup> because they phagocytosed a <italic>TIE:EGFP<sup>+</sup></italic> cell. Indeed, we observed macrophages actively phagocytosing <italic>TIE:EGFP<sup>+</sup></italic> cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). In three out of 13 tumors imaged by confocal microscopy, we observed that in <italic>TIE:EGFP<sup>+</sup></italic> patches, macrophages were engaged closely with a cluster of <italic>TIE:EGFP<sup>+</sup>;mitfa:BFP<sup>+</sup></italic> tumor cells, likely in the process of phagocytosis (<xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Together, this data reveals that a large proportion of macrophages engulf a <italic>TIE:EGFP<sup>+</sup></italic> cell population that includes melanoma cells.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Macrophages preferentially phagocytose <italic>TIE:EGFP<sup>+</sup></italic> cells.</title><p>(<bold>A</bold>) UMAP depicting <italic>mitfa, sox10,</italic> and <italic>mpeg1.1</italic> expression in clusters identified by SORT-seq, combined two <italic>MCR:MCS</italic> melanoma replicates. Inset shows expression of these genes in the macrophage cluster. (<bold>B</bold>) Representative image from a zebrafish melanoma acquired on an upright confocal, n=13 fish. Additional images shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>. Melanoma cells are blue, macrophages are red, and <italic>TIE:EGFP<sup>+</sup></italic> cells are green. Yellow indicates a macrophage that has phagocytosed a TGFb responsive cell, which often appears as fragments within macrophages. A macrophage that expresses the <italic>TIE:EGFP</italic> endogenously would express EGFP throughout the entire cell, rather than in fragments. Cyan indicates a <italic>TIE:EGFP<sup>+</sup></italic> melanoma cell. When phagocytosed by macrophages, <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells appear white, which are indicated within in the white boxes. (<bold>C</bold>) Representative <italic>TIE:EGFP<sup>+</sup>;mpeg:mCherry<sup>+</sup>;mitfa:BFP<sup>+</sup></italic> melanoma used for flow analysis of macrophages. Scale bars indicate 1000 µm. The EGFP<sup>+</sup> region adjacent to the tumor is endogenous <italic>TIE:EGFP<sup>+</sup></italic> expression of the brain. (<bold>D</bold>) (Far left) Viable cells were separated into <italic>TIE:EGFP<sup>-</sup></italic> and <italic>TIE:EGFP<sup>+</sup></italic>. (Middle) FACS plots showing <italic>TIE:EGFP<sup>-</sup></italic> and <italic>TIE:EGFP<sup>+</sup></italic> cells relative to <italic>mpeg:mCherry</italic> and <italic>mitfa:BFP</italic>. Q1 in the <italic>TIE:EGFP<sup>-</sup></italic> plot represents macrophages that have not phagocytosed any melanoma cells. Q2 represents macrophages that have phagocytosed <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells. Q1 in the <italic>TIE:EGFP<sup>+</sup></italic> plot represents macrophages that have not phagocytosed melanoma cells, but rather express the <italic>TIE:EGFP</italic> reporter endogenously or phagocytosed a <italic>TIE:EGFP<sup>+</sup></italic> non-melanoma cell. Q2 represents macrophages that have phagocytosed <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells. (Far right) Q2 of both plots are graphed to represent the percentage of all <italic>TIE:EGFP<sup>-</sup></italic> or <italic>TIE:EGFP<sup>+</sup></italic> live cells that are melanoma cells phagocytosed by macrophages. Two-tailed unpaired Welch’s t-test was used to calculate significance. n=3 fish with two technical replicates each. Illustrated fish diagram in (<bold>C</bold>) created with <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender.com</ext-link>, and published using a CC BY-NC-ND license with permission.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83527-fig3-v1.tif"/><permissions><copyright-statement>© 2024, BioRender Inc</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>BioRender Inc</copyright-holder><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Figure 3 was created using <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender</ext-link>, and is published under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND</ext-link> license. Further reproductions must adhere to the terms of this license.</license-p></license></permissions></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Macrophages phagocytose <italic>TIE:EGFP<sup>+</sup></italic> cells.</title><p>Representative images showing several zebrafish melanomas acquired on an upright confocal microscope. Fish were anesthetized using tricaine and images were acquired of tumors in live fish. Melanoma cells are blue, macrophages are red, and <italic>TIE:EGFP<sup>+</sup></italic> cells are green. Yellow indicates <italic>TIE:EGFP<sup>+</sup></italic> macrophages, which results from endogenous reporter expression or from phagocytosis of a <italic>TIE:EGFP<sup>+</sup></italic> cell, in which case yellow signal appears as fragments within macrophages. Cyan indicates a <italic>TIE:EGFP<sup>+</sup></italic> melanoma cell. When phagocytosed by macrophages, <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells appear white because of <italic>mitfa:BFP, TIE:EGFP,</italic> and <italic>mpeg:mCh</italic> co-localization. (<bold>A</bold>) (Left) White boxes indicate diffusely yellow macrophages that express <italic>TIE:EGFP</italic> endogenously. (Right) Higher magnification in a different tumor shows that <italic>TIE:EGFP<sup>+</sup></italic> fragments are contained in macrophages occasionally in endosome-like structures, seen most clearly by the cell indicated by the lowest white arrowhead. Z projection, single frame. (<bold>B</bold>) (Left) White cells (indicating macrophages that have phagocytosed <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells) are indicated within white boxes. (Right) A <italic>TIE:EGFP<sup>+</sup></italic> patch in a separate tumor is composed of macrophages engaged with <italic>TIE:EGFP<sup>+</sup></italic> tumor cells. White signal represents <italic>mpeg:mCh<sup>+</sup></italic> macrophages that have engulfed <italic>TIE:EGFP<sup>+</sup> mitfa:BFP<sup>+</sup></italic> tumor cells. Z projection, single frame. (<bold>C</bold>) Image of a macrophage actively phagocytosing a <italic>TIE:EGFP<sup>+</sup></italic> cell in a tumor. Image taken via optical sectioning, single frame. In total, n=13 tumors analyzed by confocal microscopy.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83527-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>qPCR shows that <italic>TIE:EGFP<sup>+</sup></italic> macrophages express higher levels of melanocyte markers <italic>mitfa</italic> and <italic>sox10</italic> (compared to <italic>TIE:EGFP<sup>-</sup></italic> macrophages), validating that macrophages preferentially phagocytose TGFb responsive melanoma cells.</title><p>Two <italic>Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup>;MCR:MCS</italic> tumors expressing <italic>TIE:EGFP</italic> and <italic>mpeg:mCherry</italic> were dissected and <italic>TIE:EGFP<sup>+</sup>;mpeg:mCherry<sup>+</sup></italic> macrophages and <italic>TIE:EGFP<sup>-</sup>;mpeg:mCherry<sup>+</sup></italic> macrophages were isolated by FACS. RNA was extracted, reverse transcribed, and qPCR was performed. Graphed here are individual replicate values and their mean, and error bars represent standard deviation. Two-tailed unpaired t-test was used to calculate significance. n=2 fish with three technical replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83527-fig3-figsupp2-v1.tif"/></fig></fig-group><p>To determine if macrophages are preferentially phagocytosing <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells, three <italic>TIE:EGFP<sup>+</sup>;mpeg:mCherry<sup>+</sup>;mitfa:BFP<sup>+</sup></italic> melanoma were excised, digested, and processed for flow cytometry analysis (<xref ref-type="fig" rid="fig3">Figure 3C–D</xref>). Viable cells were separated into <italic>TIE:EGFP<sup>-</sup></italic> and <italic>TIE:EGFP<sup>+</sup></italic> (<xref ref-type="fig" rid="fig3">Figure 3D</xref>, far left). In all three tumors, less than 1% of sorted cells were <italic>TIE:EGFP<sup>+</sup>,</italic> indicating this TGFb responsive population is rare. <italic>TIE:EGFP<sup>-</sup></italic> and <italic>TIE:EGFP<sup>+</sup></italic> (<xref ref-type="fig" rid="fig3">Figure 3D</xref>, middle) cells were plotted relative to <italic>mpeg:mCherry</italic> and <italic>mitfa:BFP</italic>. Q2 represents the total percentage of <italic>TIE:EGFP<sup>-</sup></italic> or <italic>TIE:EGFP<sup>+</sup></italic> cells that were melanoma cells phagocytosed by macrophages. The percentage given in Q2 is plotted for several tumors in <xref ref-type="fig" rid="fig3">Figure 3D</xref> (far right). Macrophages phagocytose a significantly higher percentage of <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells compared to <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells. This was confirmed by qPCR, which showed that <italic>mitfa</italic> and <italic>sox10</italic> expression is enriched in <italic>TIE:EGFP<sup>+</sup></italic> macrophages compared to <italic>TIE:EGFP<sup>-</sup></italic> macrophages (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Altogether, scRNA-seq, confocal imaging and flow cytometry analyses demonstrate that macrophages preferentially phagocytose <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells compared to <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells.</p></sec><sec id="s2-6"><title><italic>SATB2</italic> expression leads to early TGFb activation</title><p>The chromatin remodeler <italic>SATB2</italic> is amplified in 4–8% of melanoma patients and its expression correlates with patient outcome. Our lab has previously shown that <italic>SATB2</italic> overexpression leads to accelerated melanoma onset, produces more aggressive, metastatic tumors, and induces a TGFb signature (<xref ref-type="bibr" rid="bib19">Fazio et al., 2021</xref>). <italic>SATB2</italic> was overexpressed under the <italic>mitfa</italic> promoter in the MiniCoopR backbone (<italic>MCR:SATB2</italic>) in <italic>TIE:EGFP;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup></italic> zebrafish. Of the fish with S<italic>ATB2</italic> melanomas (n=27), 68% turned on <italic>TIE:EGFP</italic> in tumors, and its signal was expressed throughout the tumor volume (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). To understand the transcriptional differences between <italic>TIE:EGFP<sup>+</sup></italic> and <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells, we sequenced the transcriptome of single cells from an <italic>MCR:SATB2</italic> expressing melanoma at 30 wpf using SORT-seq (tumor used shown in <xref ref-type="fig" rid="fig4">Figure 4A</xref>, top). We identified most cells as melanoma cells with <italic>mitfa</italic> and/or <italic>sox10</italic> expression, and again an <italic>mpeg1.1</italic> expressing <italic>TIE:EGFP<sup>+</sup></italic> macrophage population (<xref ref-type="fig" rid="fig4">Figure 4B</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title><italic>SATB2</italic> expressing melanomas exhibit <italic>TIE:EGFP</italic> expression in early initiating lesions.</title><p>(<bold>A</bold>) (Top) Development of a representative tumor overexpressing <italic>MCR:SATB2</italic> in <italic>TIE:EGFP;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup></italic> zebrafish. Arrowhead indicates <italic>TIE:EGFP<sup>+</sup></italic> early melanoma before tumor formation. This EGFP<sup>+</sup> region is separate from the endogenous <italic>TIE:EGFP<sup>+</sup></italic> expression of the brain. (Bottom) Development of a control <italic>MCR:MCS</italic> tumor in <italic>TIE:EGFP;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup></italic> zebrafish, for reference. (<bold>B</bold>) UMAP depicting <italic>mitfa, sox10,</italic> and <italic>mpeg1.1</italic> expression in clusters identified by SORT-seq of <italic>SATB2</italic> expressing tumor in (<bold>A</bold>). Inset shows expression of these genes in the macrophage cluster. (<bold>C</bold>) Dotplot depicting extracellular matrix TGFb target gene expression in <italic>TIE:EGFP<sup>high</sup></italic>, <italic>TIE:EGFP<sup>low</sup></italic>, and <italic>TIE:EGFP<sup>-</sup> SATB2</italic> expressing melanoma cells. Genes shown in red are genes that are also upregulated in control <italic>MCR:MCS</italic> tumors. (<bold>D</bold>) Early initiating melanoma (arrowhead) overexpressing <italic>MCR:SATB2</italic> in <italic>TIE:EGFP;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup></italic> zebrafish. Representative image chosen. 40% of <italic>MCR:SATB2</italic> early melanomas (n=27) express <italic>TIE:EGFP</italic>, compared to 0% of <italic>MCR:MCS</italic> early melanomas (n=56) (quantification on right). Illustrated fish diagrams in (<bold>A, D</bold>) created with <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender.com</ext-link>, and published using a CC BY-NC-ND license with permission.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83527-fig4-v1.tif"/><permissions><copyright-statement>© 2024, BioRender Inc</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>BioRender Inc</copyright-holder><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Figure 4 was created using <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender</ext-link>, and is published under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND</ext-link> license. Further reproductions must adhere to the terms of this license.</license-p></license></permissions></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Single-cell RNA-seq identifies <italic>TIE:EGFP<sup>+</sup></italic> macrophages and melanoma cells in an <italic>MCR:SATB2</italic> tumor.</title><p>(<bold>A</bold>) (Left) UMAP depicting six cell clusters identified by SORT-seq. Approximately 867 <italic>TIE:EGFP<sup>+</sup></italic> cells and 376 <italic>mitfa:mCherry<sup>+</sup>;TIE:EGFP<sup>-</sup></italic> cells (as a control) were sorted into individual wells using flow cytometry. <italic>TIE:EGFP<sup>+</sup></italic> cells were both <italic>mitfa:mCherry<sup>+</sup></italic> and <italic>mitfa:mCherry<sup>-</sup></italic>. In scRNA-seq data analysis, melanoma cells were identified as being <italic>mitfa</italic> and <italic>sox10</italic> positive, while macrophages were identified as <italic>mpeg1.1</italic> and <italic>marco</italic> positive. (<bold>B</bold>) Macrophages were subset from the UMAP, and this dotplot depicts M1-like and M2-like transcriptional marker expression in <italic>TIE:EGFP<sup>+</sup></italic> and <italic>TIE:EGFP<sup>-</sup></italic> macrophages. The top row indicates <italic>TIE:EGFP<sup>-</sup></italic> macrophages (which happen to be <italic>mitfa:mCherry<sup>+</sup></italic> because they phagocytosed <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells). The bottom row indicates macrophages that express <italic>TIE:EGFP</italic> endogenously or phagocytosed <italic>TIE:EGFP<sup>+</sup></italic> cells. Some of these macrophages expressed <italic>mitfa:mCherry</italic>, representing macrophages that had phagocytosed <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells. (<bold>C</bold>) (Top) Dotplot depicting expression of interferon alpha and gamma GSEA pathway genes in <italic>TIE:EGFP<sup>high</sup>, TIE:EGFP<sup>low</sup></italic>, and <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells. (Bottom) GSEA enrichment plots reveal down-regulated interferon alpha (q=0) and gamma (q=0.0) in <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83527-fig4-figsupp1-v1.tif"/></fig></fig-group><p>To determine if there is a change in state of the macrophages that express <italic>TIE:EGFP</italic> (either endogenously or via phagocytosis), we subset macrophages from the <italic>SATB2</italic> expressing melanoma and separated macrophages that were <italic>TIE:EGFP<sup>+</sup></italic> or <italic>TIE:EGFP<sup>-</sup></italic> based on flow cytometry intensity. TGFb is known to convert macrophages from a pro-inflammatory M1-like to an anti-inflammatory M2-like state which can be characterized by gene expression. In the zebrafish, these include M1 markers <italic>acod1, tnfa, csf3a/b,</italic> and <italic>socs3b,</italic> as well as M2 markers <italic>mrc1b, vegfaa, alox5ap,</italic> and <italic>marco</italic> (<xref ref-type="bibr" rid="bib79">Viola et al., 2019</xref>; <xref ref-type="bibr" rid="bib85">Wu et al., 2015</xref>; <xref ref-type="bibr" rid="bib29">Jeannin et al., 2018</xref>; <xref ref-type="bibr" rid="bib84">Wilson, 2014</xref>; <xref ref-type="bibr" rid="bib47">Martinez and Gordon, 2014</xref>; <xref ref-type="bibr" rid="bib27">Hwang et al., 2020</xref>; <xref ref-type="bibr" rid="bib86">Ye et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Georgoudaki et al., 2016</xref>). We found that although <italic>TIE:EGFP<sup>+</sup></italic> macrophages are not clearly polarized, they express a combination of M1-like and M2-like marker genes (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>).</p><p>To understand the transcriptional differences between <italic>TIE:EGFP<sup>+</sup></italic> and <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells, <italic>SATB2</italic> expressing melanoma cells were divided into <italic>TIE:EGFP<sup>-</sup>, TIE:EGFP<sup>low</sup>,</italic> and <italic>TIE:EGFP<sup>high</sup></italic> cells based on flow cytometry intensity. These <italic>MCR:SATB2</italic> results confirmed what was observed in the <italic>TIE:EGFP<sup>+</sup> MCR:MCS</italic> tumors. We found that in <italic>TIE:EGFP<sup>high</sup></italic> melanoma cells, chronic extracellular matrix TGFb target genes were up-regulated and the top down-regulated pathways by GSEA again were interferon alpha and gamma (<xref ref-type="fig" rid="fig4">Figure 4C</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). Down-regulation of interferon suggests that the TGFb responsive melanoma cells likely evade adaptive immune responses, such as interferon-mediated antigen presentation to CD8<sup>+</sup> T cells. Finally, 40% of the <italic>MCR:SATB2</italic> fish with melanomas (n=27) had <italic>TIE:EGFP</italic> expressed in early melanomas. These lesions are <italic>mitfa:mCherry</italic> high, indicating a proliferation of melanoma cells, but do not yet extend off the body plane. Meanwhile, 0% of <italic>MCR:MCS</italic> fish with melanomas (n=56) had <italic>TIE:EGFP<sup>+</sup></italic> early melanomas (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). This shows that overexpression of <italic>SATB2</italic> leads to acceleration of TGFb response in melanoma and suggests patients with this amplification may be more susceptible to TGFb inhibitors.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we identified an inducible and specific TGFb enhancer reporter and visualized TGFb response throughout melanomagenesis in zebrafish. <italic>TIE:EGFP</italic> is off in early melanoma but is expressed in most advanced melanomas, and remains on, reading out chronic TGFb signaling. These TGFb responsive melanoma cells down-regulate interferon, up-regulate a series of novel chronic TGFb target genes, and are preferentially phagocytosed by macrophages. This work identifies a TGFb induced immune response and novel biomarkers of chronic TGFb signaling in melanoma.</p><p>We have shown that our reporter, generated from human ChIP-seq data, is able to read out chronic TGFb signaling. Most literature on developmental signaling focuses on acute signaling with stimulus for several hours in vitro. There are multiple explanations for why <italic>TIE:EGFP</italic> is a chronic TGFb reporter and once turned on, remains activated. Once the <italic>TIE:EGFP</italic> reporter is activated, it may remain active because chromatin is held in an open state by epigenetic modifications or AP-1 factors. We showed that AP-1 factors are necessary for TGFb induction of our TIE reporter and luciferase assays indicated that loss of AP-1 motifs eliminates basal levels of reporter transcription. AP-1 factors may be holding TIE chromatin open, therefore potentiating its ability to drive downstream reporter expression. Simultaneously, AP-1 factors likely hold chromatin open for other TGFb target genes to potentiate the TGFb response. This may allow for a rapid signaling response upon TGFb activation and suggests that AP-1 inhibitors could disrupt TGFb induction.</p><p>The <italic>TIE:EGFP</italic> scRNA-seq data indicates that melanoma cells responding to TGFb for several weeks see down-regulation of acute TGFb target genes. They exhibit up-regulation of 29 chronic TGFb target genes that are more representative of the downstream phenotypes imposed by TGFb signal, such as extracellular matrix genes. Based on the literature, these targets degrade extracellular matrix, promoting migration (<xref ref-type="bibr" rid="bib78">Verrecchia et al., 2001</xref>). Some of the chronic TGFb targets were identified in one of the few reports of long-term TGFb signaling in human mammary epithelial cells for 12 or 24 days (<xref ref-type="fig" rid="fig2">Figures 2C</xref> and <xref ref-type="fig" rid="fig4">4C</xref>). Prolonged TGFb treatment was found to stabilize EMT, stem cell state, and drug resistance in breast cancer cells (<xref ref-type="bibr" rid="bib30">Katsuno et al., 2019</xref>). According to TCGA data in cBioPortal, a subset of melanoma patients exhibit up-regulation of these genes (<xref ref-type="bibr" rid="bib15">Cerami et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Gao et al., 2013</xref>). In the future, this signature could be used as biomarkers to identify patients with chronic TGFb signaling and these patients may benefit from treatment with TGFb inhibitors.</p><p>Overexpression of <italic>SATB2</italic> resulted in <italic>TIE:EGFP</italic> expression in early melanoma lesions, which was not observed in controls. Cancer cells are thought to circumvent the tumor suppressive effects of TGFb via mutations or epigenetic modifications (<xref ref-type="bibr" rid="bib16">Derynck et al., 2021</xref>; <xref ref-type="bibr" rid="bib32">Kim et al., 2021</xref>; <xref ref-type="bibr" rid="bib48">Massagué et al., 2000</xref>; <xref ref-type="bibr" rid="bib88">Zhang et al., 2017</xref>; <xref ref-type="bibr" rid="bib65">Seoane and Gomis, 2017</xref>; <xref ref-type="bibr" rid="bib72">Suriyamurthy et al., 2019</xref>; <xref ref-type="bibr" rid="bib49">Miyazawa and Miyazono, 2017</xref>; <xref ref-type="bibr" rid="bib73">Tang et al., 2018</xref>). It is possible that melanomas up-regulating the epigenetic regulator <italic>SATB2</italic> may overcome the tumor-suppressive effects of TGFb signaling earlier in tumor development, leading to more aggressive and invasive melanomas (<xref ref-type="bibr" rid="bib19">Fazio et al., 2021</xref>). Investigating the activation of TGFb signaling in the context of different patient mutations may provide insight into who may benefit from TGFb inhibitors, allowing for the identification of biomarkers of TGFb inhibitor response. It is expected that aggressive melanoma subtypes like <italic>SATB2</italic>, which activate TGFb very early in melanoma development, would be most responsive to early intervention with TGFb inhibitors.</p><p><italic>TIE:EGFP</italic> expression often occurs in patches throughout the tumor. In the tumor pictured in <xref ref-type="fig" rid="fig3">Figure 3C</xref>, there is general co-localization of <italic>mpeg:mCherry</italic> and <italic>TIE:EGFP</italic> signal indicating that macrophages may cluster in TGFb positive regions of the tumor. Using confocal imaging, we confirmed that <italic>TIE:EGFP</italic> signal is most often found in macrophages clustered in these zones. The <italic>TIE:EGFP</italic> reporter appears in some macrophages as a diffuse, cytoplasmic signal indicative of endogenous TGFb signaling. However in the majority of EGFP<sup>+</sup> macrophages, the reporter appears as fragments (sometimes even in endosome-like structures), indicating that many macrophages are <italic>TIE:EGFP<sup>+</sup></italic> because they phagocytosed a <italic>TIE:EGFP<sup>+</sup></italic> cell. We occasionally captured through confocal imaging macrophages in contact with <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells, suggesting that macrophages phagocytose these tumor cell populations (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Indeed, our scRNA-seq data identified <italic>TIE:EGFP<sup>+</sup></italic> macrophage subclusters that express <italic>mitfa</italic> and/or <italic>sox10</italic>, providing additional evidence for phagocytosis of melanoma cells. Using flow cytometry analysis, we showed that macrophages preferentially phagocytose <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells. The regionality of TGFb response could occur due to gradients in the TGFb morphogen, possibly induced by TGFb signaling within tumor cells in particular regions of the tumor. As mentioned above, TGFb can act as a chemoattractant for macrophages and induces an anti-inflammatory M2-like state. Once macrophages arrive to the TGFb region, they may phagocytose <italic>TIE:EGFP<sup>+</sup></italic> tumor cells, thus explaining the presence of EGFP<sup>+</sup> fragments within macrophages. This data suggests that local TGFb signaling within the tumor may influence macrophage localization and phagocytosis, likely leading to changes in their behavior.</p><p>One factor we identified in our single cell RNA-seq data that may mediate this interaction is <italic>serpine1. Serpine1</italic> mRNA was differentially upregulated in <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells, and its receptor, <italic>lrp1ab</italic> was expressed on <italic>TIE:EGFP<sup>+</sup></italic> macrophages (data not shown). SERPINE1, which encodes plasminogen activator inhibitor-1 (PAI-1), has been shown to promote cancer cell invasiveness and macrophage recruitment in an esophageal squamous cell carcinoma model (<xref ref-type="bibr" rid="bib62">Sakamoto et al., 2021</xref>). <italic>TIE:EGFP<sup>high</sup></italic> macrophages differentially express <italic>mmp14b</italic> and the cysteine protease <italic>legumain</italic>, both of which have been described to promote TGFb bioavailability (<xref ref-type="bibr" rid="bib9">Bai et al., 2019</xref>; <xref ref-type="bibr" rid="bib67">Sounni et al., 2010</xref>; <xref ref-type="bibr" rid="bib59">Robertson and Rifkin, 2016</xref>). Together, these preliminary transcriptional data may indicate a mechanism by which macrophages are recruited to <italic>TIE:EGFP<sup>+</sup></italic> regions by PAI-1 gradients. Recruited macrophages may phagocytose <italic>TIE:EGFP<sup>+</sup></italic> tumor cells and then go on to amplify the pool of active, bioavailable TGFb through the activity of enzymes such as mmp14b and lgmn. Such a model would explain the local clustering of macrophages in TGFb-responding regions of the tumor, where a subset phagocytoses <italic>TIE:EGFP<sup>+</sup></italic> melanoma and non-melanoma cells and others experience endogenous TGFb signaling (likely from local paracrine signaling).</p><p>Single cell RNA-seq data from the <italic>MCR:SATB2</italic> melanoma suggests that <italic>TIE:EGFP<sup>+</sup></italic> macrophages (which are either TGFb responsive themselves or had phagocytosed a TGFb responding cell) are not clearly polarized, expressing transcriptional markers of both M1 and M2 states. This may indicate that a transition is occurring from the M1-like to the M2-like phenotype. In our model, macrophages are attracted to TGFb expressing regions of the melanoma, and while phagocytosing in the vicinity of TGFb cytokines, begin to transition to an M2 state. M2 macrophages are known to be anti-inflammatory, immunosuppressive, and pro-angiogenic. Preliminary evidence comparing the transcriptional signatures of macrophages in the <italic>SATB2</italic> expressing tumor indicates that <italic>TIE:EGFP<sup>+</sup></italic> macrophages have higher expression of cholesterol and fatty acid genes (i.e. <italic>abca1a, npc2</italic>) as well as apoptotic genes (i.e. <italic>casp3b, caspa</italic>) compared to <italic>TIE:EGFP<sup>-</sup></italic> macrophages. This indicates that intrinsic TGFb signaling or phagocytosis of <italic>TIE:EGFP<sup>+</sup></italic> cells may induce a stress phenotype within macrophages, resulting in death. In this case, death of macrophages over time would allow the tumor cells to evade phagocytosis. This, in conjunction with down-regulation of interferon by <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells (as seen in <italic>MCR:MCS</italic> and <italic>MCR:SATB2</italic> tumors), may lead to immune inactivation within the melanoma. Moreover, the interferon target gene, <italic>β–2-microglobulin (b2m</italic>) is one of the top down-regulated genes in <italic>TIE:EGFP</italic> expressing melanoma cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Loss of B2M, part of the MHC Class I molecules, is a known mechanism of immunotherapy resistance (<xref ref-type="bibr" rid="bib4">Alavi et al., 2018</xref>). Together, this data suggests that activation of TGFb in melanoma is immunosuppressive, potentially by way of interferon modulation and effects on macrophage behavior and supports the need for more work on combination TGFb and immune checkpoint inhibitors.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Plasmids</title><p><italic>Tgfb-Induced-Enhancer:Beta-globin-minimal-promoter-EGFP:pA pDestTol2pA2</italic> was cloned by PCR amplifying the enhancer (chr1:22747452–22747734) in <xref ref-type="fig" rid="fig1">Figure 1A</xref> using A375 human melanoma gDNA (Forward primer: <named-content content-type="sequence">TTCTTTGTCATCCTGGTAGAGCAAATCGAG</named-content>, Reverse primer: <named-content content-type="sequence">GACAGGTCGCACCTGAGTCC</named-content>) (Advantage 2 PCR Kit, Clontech #639207, Kyoto, Japan). PCR product was gel purified (Qiagen #28604, Hilden, Germany) and cloned into a pENTR-5’TOPO vector (Invitrogen #45–0711, Waltham, MA, USA). This 5 ’entry vector was Gateway recombined upstream of a mouse <italic>beta-globin-minimal-promoter-EGFP</italic> middle entry vector, a 3 ’entry polyA, and the pDestTol2pA2 backbone (ThermoFisher #12538120, Waltham, MA, USA). <italic>Mitfa:mCherry</italic> was Gateway recombined using the <italic>mitfa</italic> zebrafish promoter and a <italic>mCherry</italic> middle entry plasmid (ThermoFisher #12538120). <italic>Ubi:caSMAD2</italic> was cloned by PCR amplifying human <italic>SMAD2</italic> pDONR221 (DNASU HsCD00045549, Tempe, AZ, USA) using the following primers to insert constitutively active mutations (Forward: <named-content content-type="sequence">CACCATGTCGTCCATCT</named-content> <named-content content-type="sequence">TGCCATTCACGCCGCC</named-content>;Reverse: <named-content content-type="sequence">CTATTCCATTTCTGAGCAACGCACTGAAGGGGATC</named-content>) (Sigma 11732641001, St. Louis, MO, USA), gel purifying (Qiagen #28604) and inserting into a pENTR/D-TOPO vector (Invitrogen #45–0218). This middle entry vector was Gateway recombined using a 5’ entry zebrafish ubiquitious promoter (Addgene #2732, Watertown, MA, USA), a 3’ entry pA vector, and a pDestTol2pA2 backbone (ThermoFisher #12538120). <italic>Ubi:caSMAD3</italic> was cloned by PCR amplifying human constitutively active <italic>SMAD3</italic> from <italic>Smad3 pCMV-SPORT6</italic> (Harvard Plasmid Repository #HSCD00339271, Boston, MA, USA) (Sigma 11732641001), gel purifying (Qiagen #28604) and inserting into a pENTR/D- TOPO vector (Invitrogen #45–0218). This middle entry vector was Gateway recombined using a 5’ entry zebrafish ubiquitious promoter, a 3’ entry pA vector, and a pDestTol2pA2 backbone (ThermoFisher #12538120). <italic>Ubi:BFP</italic> was cloned via Gateway recombination using a 5’ entry zebrafish ubiquitious promoter, a 3’ entry pA vector, and a pDestTol2pA2 backbone (ThermoFisher #12538120). <italic>Mitfa:BFP</italic> was cloned via Gateway recombination using a 5’ entry zebrafish <italic>mitfa</italic> promoter, a 3’ entry pA vector, and a pDestTol2pA2 backbone (ThermoFisher #12538120). <italic>MCR:SATB2</italic> and <italic>MCR:MCS</italic> are from <xref ref-type="bibr" rid="bib19">Fazio et al., 2021</xref>. <italic>MCR:BRAF<sup>V600E</sup></italic> (Addgene #118846) and <italic>2xU6:p53/tyr gRNA mitfa:Cas9</italic> (Addgene #118844) are published (<italic>tyr</italic> gRNA: <named-content content-type="sequence">GGACTGGAGGACTTCTGGGG</named-content>; <italic>p53</italic> gRNA = <named-content content-type="sequence">GGTGGGAGAGTGGATGG CTG</named-content>) (<xref ref-type="bibr" rid="bib1">Ablain et al., 2018</xref>).</p></sec><sec id="s4-2"><title>Reporter line creation</title><p><italic>TIE:EGFP</italic> reporter fish were created by injecting <italic>TIE:Beta-globin-minimal-promoter- EGFP:pA pDestTol2pA2</italic> at 6 ng/µL into single cell <italic>Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup></italic> zebrafish embryos (referred to as <italic>TIE:EGFP;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup></italic>) (<xref ref-type="bibr" rid="bib54">Patton et al., 2005</xref>). F0s were screened at 5 dpf for EGFP. At approximately 2 months post fertilization, F0s were crossed to <italic>Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup></italic> fish and F1s were screened as embryos for EGFP. EGFP<sup>+</sup> fish were raised to adulthood.</p></sec><sec id="s4-3"><title>Electroporation</title><p>Electroporation protocols were adapted from <xref ref-type="bibr" rid="bib12">Callahan et al., 2018</xref>. <italic>Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup></italic> zebrafish were anesthetized using 4% MS-222 (Pentair, TRS1, Minneapolis, MN, USA). Zebrafish were subcutaneously injected with 2 µL mix using a Hamilton syringe (Hamilton #80300, Reno, NV, USA) anterior to the dorsal fin. The following amounts of vectors were injected into each fish: 200 ng <italic>TIE:Beta-globin-minimal-promoter-EGFP:pA pDestTol2pA2</italic>, 400 ng <italic>ubi:caSMAD2</italic>, 400 ng <italic>ubi:caSMAD3</italic>, 666 ng <italic>ubi:BFP</italic>, and 266 ng <italic>Tol2 pCS2FA-transposase</italic> (<xref ref-type="bibr" rid="bib37">Kwan et al., 2007</xref>). DNA was prepped using Qiagen HiSpeed Plasmid Maxi Kit (QIAGEN #12662). Zebrafish were then electroporated with a BTX ECM 830 machine (BTX #45–0662 Holliston, MA, USA) using the following parameters: LV Mode; 45 V; 60ms pulse length; 5 pulses, 1 second interval. The cathode paddle was placed on the side of the fish that was injected. Electroporated fish were imaged approximately one week post electroporation using a Nikon SMZ18 Stereomicroscope (Nikon, Tokyo, Japan). To quantify TIE activity, we imaged each electroporated fish, quantified GFP intensity, and divided by the area of BFP to account for variation in electroporation efficiency.</p></sec><sec id="s4-4"><title>Stereomicroscope and confocal imaging</title><p>For stereoscope imaging, zebrafish were anesthetized using 4% MS-222 (Pentair, TRS1) and imaged using a Nikon SMZ18 Stereomicroscope using consistent imaging parameters. For confocal imaging, tumors represented in <xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref> tumors were imaged using Nikon C2si Laser Scanning confocal using a 10 X objective at 1 X magnification. Z-stacks were aligned, and images minimally processed using Imaris (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_007370">SCR_007370</ext-link>) or ImageJ software (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003070">SCR_003070</ext-link>). <italic>TIE:EGFP<sup>+</sup></italic> tumors depicted in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>, B were imaged using Zeiss LSM 980 NLO Multi-photon microscope using confocal detection at 15 X (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>, left), 45 X (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>, right), 20 X (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Z-stacks were aligned, and images were minimally processed using Imaris.</p></sec><sec id="s4-5"><title>Inhibitor treatment</title><p><italic>TIE:EGFP;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup></italic> F1s were crossed and F2 embryos were screened for EGFP, dechorionated at 24 hpf, and placed in a 24 well plate. Embryos were treated with either E3 zebrafish water, DMSO vehicle control (Sigma #D2650), 50 µM or 100 µM SB 431542 hydrate (Sigma # S4317-5MG). Twenty-four hours post treatment embryos were imaged using a Nikon SMZ18 Stereomicroscope (1 x objective; 3 x zoom; 7ms white light and 300ms GFP exposure used for all conditions).</p></sec><sec id="s4-6"><title>In situ hybridization</title><p>SB-treated 48 hpf embryos (<italic>TIE:EGFP</italic>) were fixed with 4% PFA overnight at 4°C. The embryos were then dehydrated by washes of 1:2 MeOH:PBST, then 2:1 MeOH:PBST, then 100% MeOH, and stored in 100% MeOH. Embryos were re-hydrated using washes of 2:1 MeOH:PBT, then 1:2 MeOH:PBT, then 100% PBT. Samples were then digested with Proteinase K (Sigma Aldrich, #03115828001) at 10 µg/mL and washed with PBT. Samples were then re-fixed in 4% PFA, followed by several PBT washes. Samples were incubated in ‘PreHyb’ solution (50% formamide, 5 X SSC, 0.1% Tween 20, citric acid to pH6, 50 µg/mL heparin, 500 µg/mL tRNA) for 4.5 hr at 70 °C. They were then incubated in ‘ProbeHyb’ solution (same as PreHyb with addition of GFP1 probe at final concentration of 200 ng/500 µL) overnight at 70 °C. Samples were then consecutively washed in ‘WashHyb’ solution (50% formamide, 5 X SSC, 0.1% Tween 20, citric acid to pH6) at concentrations of 75%, then 50%, then 25% (in 2 X SSC) at 70 °C. Samples were then washed in 2 X SSC, then 0.2 X SSC (75%, then 50%, then 25%) in PBT. They were then incubated in blocking solution (PBT, 2% sheep serum, 2 mg/mL BSA) for 4 hr, then incubated in antibody solution (1:4000 of anti-DIG-AP (Sigma Aldrich, #11093274910) in blocking solution) overnight at 4 °C. Samples then underwent multiple PBT washes, then washing with staining wash solution (100 mM Tris HCL pH9.5, 50 mM MgCl2, 100 mM NaCl, 0.1% Tween 20). Samples were then stained (NBT 50 mg/mL, BCIP 50 mg/mL) for 30 min, then washed with PBT. Samples were post-fixed using 4% PFA at 4 °C overnight. Samples were then cleared using a series of MeOH washes: 1:2 MeOH:PBT, 2:1 MeOH:PBT, 100% MeOH. Samples were then washed with a series of glycerol washes: 30% glycerol (in PBT), 50% glycerol, 70% glycerol. They were then imaged in 70% glycerol using a stereomicroscope. Intensity of probe staining was analyzed, and embryos were binned into categories representing ‘low’, ‘medium’, or ‘high’, GFP intensity.</p></sec><sec id="s4-7"><title>Melanoma generation</title><p>Melanocyte development is conserved between zebrafish and mammals (<xref ref-type="bibr" rid="bib51">Mort et al., 2015</xref>). The master regulator of the melanocyte lineage, MITF, is conserved in zebrafish (<italic>mitfa</italic>) and required for melanocyte development (<xref ref-type="bibr" rid="bib41">Lister et al., 1999</xref>). Expression of <italic>mitfa:BRAF<sup>V600E</sup></italic> together with a homozygous <italic>p53</italic> missense mutation, leads to development of zebrafish melanomas (<xref ref-type="bibr" rid="bib54">Patton et al., 2005</xref>). A <italic>mitfa<sup>−/−</sup></italic> mutation in <italic>Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>−/−</sup></italic> fish prevents melanocyte development and spontaneous melanoma formation. Melanocyte development can then be mosaically rescued via injection of MiniCoopR (MCR), a transposon-based vector that contains a <italic>mitfa</italic> minigene, often alongside a candidate oncogene driven by the <italic>mitfa</italic> promoter (<xref ref-type="bibr" rid="bib14">Ceol et al., 2011</xref>). In the absence of a candidate oncogene, the <italic>mitfa</italic> promoter is followed by an empty multiple cloning site (<italic>MCR:MCS),</italic> which is sufficient to generate melanomas in a genetic background already containing the <italic>BRAF<sup>V600E</sup></italic> and <italic>p53<sup>-/-</sup></italic> mutations. <italic>Tyrosinase,</italic> an enzyme required for melanocyte pigmentation, is also knocked out in our model to generate unpigmented melanomas, allowing for easy imaging of fluorescent reporters. <italic>TIE:EGFP;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup></italic> tumors were generated by injecting single cell <italic>TIE:EGFP;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa<sup>-/-</sup></italic> zebrafish embryos with MiniCoopR Multiple Cloning Site (<italic>MCR:MCS</italic>) at 20 ng/µL, <italic>mitfa:mCherry</italic> at 10 ng/µL, <italic>tyr</italic> gRNA (<named-content content-type="sequence">GGACTGGAGGACTTCTGGGG</named-content>) at 10 ng/µL, Cas9 protein (PNA Bio CP02) at 50 ng/µL, and <italic>Tol2</italic> mRNA at 20 ng/µL (<xref ref-type="bibr" rid="bib83">White et al., 2008</xref>). Experiments involving the <italic>mpeg:mCherry</italic> reporter line required us to cross the <italic>TIE:EGFP;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup></italic> zebrafish line with a Casper (<italic>roy<sup>-/-</sup>;mitfa<sup>-/-</sup>) mpeg:mCherry</italic> line, so progeny would be heterozygous for the <italic>BRAF<sup>V600E</sup> and p53<sup>-/-</sup></italic> mutations. We therefore generated <italic>TIE:EGFP;mpeg:mCherry;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup></italic> tumors by injecting into the one-cell stage <italic>MCR:BRAF<sup>V600E</sup></italic> at 10 ng/µL, <italic>2x U6:p53/Tyr gRNA mitfa:Cas9</italic> at 10 ng/µL, <italic>mitfa:BFP</italic> at 10 ng/µL, <italic>tyr</italic> gRNA at 10 ng/µL, Cas9 protein at 50 ng/µL, and <italic>Tol2</italic> mRNA at 20 ng/µL. <italic>Tyrosinase</italic> gRNA was created by annealing a <italic>tyr</italic> oligo template (<named-content content-type="sequence">CCTCCATACGATTTAGGTGACACTATAGGACTGGAGGACTTCTGGGGGTTTTAGAG</named-content> <named-content content-type="sequence">CTAGAAATAGCAAG</named-content>) to a constant oligonucleotide (<named-content content-type="sequence">AAAAGCACCGACTCGGTGCCACTT</named-content> <named-content content-type="sequence">TTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC</named-content>). The annealed oligo was filled in using T4 DNA polymerase (New England BioLabs, M0203S, Ipswich, MA, USA), PCR amplified, gel purified, transcribed (MEGAscript T7/SP6 Thermo Fisher Scientific, AM1333), and cleaned up (Zymo Research, R2051, Irvine, CA, USA). Embryos were grown to adulthood and were monitored for tumor development around 8–12 wpf.</p></sec><sec id="s4-8"><title>Zebrafish work</title><p>All zebrafish (<italic>Danio rerio</italic>) work was performed in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animal research protocols were approved by the Institutional Animal Care and Use Committee of Boston Children’s Hospital, Protocol #20-10-4254R. All zebrafish work operated according to the guidelines of the Institutional Animal Care and Use Committee of Boston Children’s Hospital.</p></sec><sec id="s4-9"><title>SORT-seq</title><p>Tumors were excised and dissociated for 30 min with occasional chopping using 0.075 mg/mL Liberase (Sigma #5401119001) in DMEM (Gibco #11965–092, Waltham, MA, USA) with 1% Penstrep (Corning #30–002 CI, Corning, NY, USA). Casper zebrafish skin was used to exclude autofluorescence when setting gates (<xref ref-type="bibr" rid="bib83">White et al., 2008</xref>). A <italic>mitfa:mCherry<sup>+</sup>/EGFP<sup>-</sup></italic> tumor from a <italic>TIE:EGFP;mpeg:mCherry;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup></italic> fish or <italic>mitfa:mCherry;crestin:EGFP;tyr<sup>-/-</sup></italic> zebrafish skin was used to set the gates for mCherry intensity. <italic>Ubi:EGFP</italic> zebrafish skin was used to set the gate for EGFP intensity. Dissociated samples were filtered through a 40 µm filter and resuspended in FACS buffer (PBS/10%FBS/1% Penstrep) before filtering through a FACS tube (Corning #352235). Single cells were sorted into 384-well-cell-capture plates containing barcoded primers from Single Cell Discoveries (<ext-link ext-link-type="uri" xlink:href="https://www.scdiscoveries.com/">https://www.scdiscoveries.com/</ext-link>) using a BD FACS ARIA II sorter. SYTOX was used as a live/dead marker (ThermoFisher #S34857). Library preparation and Illumina sequencing was performed by Single Cell Discoveries (<xref ref-type="bibr" rid="bib52">Muraro et al., 2016</xref>). SORT-seq data are demultiplexed and aligned to zebrafish Ensembl GRCz11 annotation using scruff R packages with the following parameter (bcStart = 7, bcStop = 14, bcEdit = 1, umiStart = 1, umiStop = 6, keep = 60) (<xref ref-type="bibr" rid="bib23">Hao et al., 2021</xref>, <xref ref-type="bibr" rid="bib81">Wang et al., 2019</xref>). The 384 SORT-seq barcodes are downloaded from <ext-link ext-link-type="uri" xlink:href="https://github.com/anna-alemany/transcriptomics/blob/master/mapandgo/bwamap/bc_celseq2.tsv">https://github.com/anna-alemany/transcriptomics/blob/master/mapandgo/bwamap/bc_celseq2.tsv</ext-link> ( <xref ref-type="bibr" rid="bib6">Alemany, 2018</xref>). Analysis was completed in R Studio using Seurat (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016341">SCR_016341</ext-link>) (min.features=200; 600&lt;nFeature RNA &lt;10000; percent.mt &lt;10; obj.resolution=0.2; GFPhigh&gt;4000) (<xref ref-type="bibr" rid="bib23">Hao et al., 2021</xref>; <xref ref-type="bibr" rid="bib70">Stuart et al., 2019</xref>; <xref ref-type="bibr" rid="bib11">Butler et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Satija et al., 2015</xref>). Batch correction was performed using FindVariableFeatures and FindIntegrationAnchors, nfeatures = 15,000. Pathway analysis was conducted using Gene Set Enrichment Analysis (GSEA; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003199">SCR_003199</ext-link>) version 4.1.0 (<xref ref-type="bibr" rid="bib50">Mootha et al., 2003</xref>; <xref ref-type="bibr" rid="bib71">Subramanian et al., 2005</xref>). Zebrafish genes were converted to human using DIOPT Ortholog Finder version 8.5 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_021963">SCR_021963</ext-link>) and the best match was used for GSEA analysis (<xref ref-type="bibr" rid="bib26">Hu et al., 2011</xref>).</p></sec><sec id="s4-10"><title>Flow analysis</title><p>Tumors were excised and dissociated for 30 min with occasional chopping using 0.075 mg/mL Liberase (Sigma #5401119001) in DMEM (Gibco #11965–092) with 1% Penstrep (Corning #30–002 CI). Casper zebrafish skin was used to exclude autofluorescent cells (<xref ref-type="bibr" rid="bib83">White et al., 2008</xref>). <italic>Mpeg:mCherry<sup>+</sup></italic> and <italic>ubi:EGFP<sup>+</sup></italic> zebrafish skin was used to set the gates for mCherry and EGFP intensity, respectively. A <italic>mitfa:BFP<sup>+</sup></italic> patch of skin as well as <italic>flk:BFP<sup>+</sup></italic> skin were used to set the gates for BFP intensity. Dissociated samples were filtered through a 40 µm filter and resuspended in FACS buffer (PBS/10%FBS/1% Penstrep) before filtering through a FACS tube (Corning #352235). DRAQ7 was used as a live/dead marker (Abcam #ab109202, Cambridge, UK). Cells were analyzed using a BD FACS Aria II 5 Laser System. Two technical replicates of 1 million cells were sorted from each tumor, for a total of 2 million cells per tumor. Data was processed using FlowJo version 10.8.1 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link>). Debris, doublets, and autofluorescent cells were removed from the analysis and viable cells were separated into <italic>TIE:EGFP<sup>-</sup></italic> and <italic>TIE:EGFP<sup>+</sup></italic>.</p></sec><sec id="s4-11"><title>Human and zebrafish melanoma cell culture and treatment</title><p>Human melanoma A375 and zebrafish melanoma ZMEL1 cells were grown in filter sterilized DMEM (Gibco #11965–092) supplemented with 10% heat-inactivated FBS (Gemini # 900–108), 1% PenStrep (Corning #30–002 CI), and 1% Glutamine (ThermoFisher # 25030164). A375 cells were obtained from ATCC (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CV-CL_0132">CV-CL_0132</ext-link>) and grown at 37 °C, 5% CO<sub>2</sub>. Cell identity was confirmed by fingerprint every 2 years and tested for mycoplasma approximately every 2–4 weeks using Lonza’s second generation myco PLUS kit. ZMEL1 cells were grown at 28 °C, 5% CO<sub>2</sub> and tested for mycoplasma approximately every 2–4 weeks (<xref ref-type="bibr" rid="bib24">Heilmann et al., 2015</xref>). Human recombinant TGFB1 (R&amp;D 240-B-002, Minneapolis, MN, USA) was reconstituted at 20 µg/mL in sterile 4 mM HCl containing 1 mg/mL BSA according to manufacturer’s instructions. To activate the TGFb pathway, cells were serum starved for 2 hr, then treated with 10 ng/mL human recombinant TGFB1 or 4 mM HCl containing 1 mg/mL BSA vehicle control for an additional 2 hr.</p></sec><sec id="s4-12"><title>RNA-sequencing</title><p>RNA-seq was performed in triplicate using A375 or ZMEL1 melanoma cells. RNA was collected from adherent cells using the Qiagen RNeasy Plus Mini Kit (Qiagen #74134). RNA quality was confirmed using a Fragment Analyzer. One microgram of RNA was ribodepleted using NEBNext rRNA Depletion Kit (NEB #E6310). Ribodepleted RNA was fragmented, reverse transcribed, and library prepped (NEB #E7530, NEB #E7335). Samples were sequenced on an Illumina Hi-Seq 4000 sequencer. Quality control of RNA-Seq datasets was performed by FastQC (<ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/fastqc/">https://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>) (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014583">SCR_014583</ext-link>) and Cutadapt (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_011841">SCR_011841</ext-link>) to remove adaptor sequences and low quality regions (<xref ref-type="bibr" rid="bib45">Martin, 2011</xref>). The high-quality reads were aligned to Ensembl build version GRCh38 of human genome or zebrafish Ensembl GRCz11 annotation (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002334">SCR_002334</ext-link>) using Tophat 2.0.11 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_013035">SCR_013035</ext-link>) without novel splicing form calls (<xref ref-type="bibr" rid="bib75">Trapnell et al., 2009</xref>). Transcript abundance and differential expression were calculated with Cufflinks 2.2.1 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014597">SCR_014597</ext-link>) (<xref ref-type="bibr" rid="bib76">Trapnell et al., 2010</xref>). FPKM values were used to normalize and quantify each transcript; the resulting list of differentially expressed genes were filtered by log fold-change and q-value. Pathway analysis was conducted using Gene Set Enrichment Analysis (GSEA) version 4.1.0 Hallmark gene sets (<xref ref-type="bibr" rid="bib50">Mootha et al., 2003</xref>; <xref ref-type="bibr" rid="bib71">Subramanian et al., 2005</xref>). Deseq2 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015687">SCR_015687</ext-link>) was used to create differential expression heatmaps and volcano plots. Read counts less than 10 were excluded.</p></sec><sec id="s4-13"><title>ChIP-sequencing</title><p>A375 cells were fixed directly in 15 cm plates with 11% formaldehyde and collected by scraping. Approximately 100,000,000 cells were used per condition. Cells were lysed using lysis buffers with protease inhibitors (Roche #05056489001, Basel, Switzerland) and sonicated such that fragmented chromatin was 200–300 bp long. Optimal chromatin length was confirmed by gel electrophoresis. Prior to antibody addition, 50 µL chromatin was collected for input sample. The remaining sonicated chromatin was incubated overnight at 4 °C with 10 µg antibody attached to Dynabeads (Invitrogen #10004D). Samples (including inputs) were washed with wash buffers and eluted for 6 hr at 70 °C, treated with RNaseA (Sigma #R4642) and Proteinase K (Life Technologies #AM2546, Carlsbad, CA, USA), and purified using Zymo ChIP DNA Concentrator kit (Genesee Scientific #11–379 C, San Diego, CA, USA). Libraries were end repaired (VWR #ER81050, Radnor, PA, USA), polyA tailed (Invitrogen #18252–015, NEB #M0212L), adaptor ligated (NEB #E7335), size selected using Ampure XP beads (Beckman Coulter #A63881, Brea, CA, USA, Life Technologies #12027), and PCR amplified (NEB #M0531). Libraries were run on an Illumina Hi-Seq 4000 sequencer. The following antibodies were used: H3K27ac (Abcam #4729; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2118291">AB_2118291</ext-link>), SMAD2/3 (Abcam #202445), MITF (Sigma #HPA003259; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1079381">AB_1079381</ext-link>), ATF3 (Abcam #207434; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2734728">AB_2734728</ext-link>), JUNB (CST #3753, Danvers, MA, USA; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2130002">AB_2130002</ext-link>). Using HOMER analysis (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_010881">SCR_010881</ext-link>) we confirmed that JUNB and ATF3 binding motifs were present under their respective ChIP peaks (ATF3, p=1e<sup>–4983</sup>) (JUNB, p=1e<sup>–15697</sup>). All ChIP-Seq datasets were aligned to Ensembl build version GRCh38 of the human genome using Bowtie2 (version 2.2.1; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016368">SCR_016368</ext-link>) with the following parameters: <monospace>--end-to-end</monospace>, -N0, -L2086. MACS2 version 2.1.0 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_013291">SCR_013291</ext-link>) peak finding algorithm was used to identify regions of ChIP-Seq peaks, with a q-value threshold of enrichment of 0.05 for all datasets (<xref ref-type="bibr" rid="bib39">Langmead and Salzberg, 2012</xref>; <xref ref-type="bibr" rid="bib87">Zhang et al., 2008</xref>). Uropa (Universal Robust Peak Annotator) is utilized to annotate ChIP-seq peaks to neighboring genes according to Ensembl gene annotation (<xref ref-type="bibr" rid="bib34">Kondili et al., 2017</xref>). The parameters are defined as proximal promoter: 500 bp upstream – 50 bp downstream of TSS; distal promoter: 2 k bp upstream – 500 bp downstream of TSS; enhancer: 100 k bp from TSS. The genome-wide transcription factor SMAD2/3, JUNB, ATF3 occupancy profile figures were generated by deeptools2 according to two computation modes (<xref ref-type="bibr" rid="bib58">Ramírez et al., 2016</xref>). In the reference-point mode, a set of genomic positions (e.g. the center of ChIP peak) are used as anchor point, 2 kb upstream and downstream of these position are plotted in the profile figure. HOMER analysis was performed to confirm transcription factor binding under peaks (<xref ref-type="bibr" rid="bib25">Heinz et al., 2010</xref>). The hg19 genome was used with a random set of background peaks for motif enrichment.</p></sec><sec id="s4-14"><title>Luciferase assays</title><p>Firefly luciferase reporter constructs (pGL4.24) were created by cloning the full and mutated TGFb enhancers upstream of the minimal promoter using BglII and XhoI sites (see <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref> for sequences). A375 cells were plated in opaque-walled 96-well plates (Thermo Fisher #136101) and approximately 5000 cells were co-transfected with 100 ng firefly and 10 ng Renilla luciferase plasmids using Lipofectamine 3000 (Invitrogen #L3000008). After 48 hr cells were serum starved for 2 hr and treated with 10 ng/mL TGFB1 or 4 mM HCl containing 1 mg/mL BSA vehicle control for an additional 2 hr. Firefly and Renilla luciferase were then measured using the Dual-Glo Luciferase Assay (Promega #E2920, Madison, WI, USA) according to the manufacturer’s instructions. Luminescence was read on a Synergy Neo plate reader and the ratio of firefly to Renilla luminescence was calculated. Empty firefly luciferase vector was used as a negative control and Renilla luciferase was used as control for transfection efficiency. Experiments were performed in biological triplicate with three technical replicates each.</p></sec><sec id="s4-15"><title>qPCR</title><p>Two <italic>TIE:EGFP;mpeg:mCherry;Tg(mitfa:BRAF<sup>V600E</sup>);p53<sup>-/-</sup>;mitfa:BFP</italic> tumors were dissociated for 30 min with occasional chopping using 0.075 mg/mL Liberase (Sigma #5401119001) in DMEM/F12 (Gibco # 11580546), and the reaction was inactivated by adding a solution of 15% FBS in DMEM/F12. Dissociated samples were filtered through a 40 µm filter and resuspended in FACS buffer (PBS/5% BSA). Casper zebrafish skin was used to exclude autofluorescent cells, and <italic>mpeg:mCherry<sup>+</sup></italic> zebrafish skin was used to set the mCherry gate. SYTOX red dead cell stain was used as a live/dead marker (Invitrogen #S34859). Cells were sorted into FACS buffer in two separate tubes: <italic>mpeg:mCherry<sup>+</sup> TIE:EGFP<sup>+</sup></italic> and <italic>mpeg:mCherry<sup>+</sup> TIE:EGFP<sup>-</sup></italic>. RNA was extracted from cells sorted by FACS using the Direct-zol RNA MicroPrep Kit (Zymo Research #2060), and reverse transcribed to cDNA using the SuperScript VILO cDNA Synthesis Kit (Invitrogen #11754–050). qPCR was performed using SYBR Green qPCR Mix (ThermoFisher # 4309155), and samples were run using the QuantStudio 6 Flex system (ThermoFisher). <italic>Mitfa</italic> primer sequences (FP: 5’<named-content content-type="sequence">CTACGACAGCCCAAACAAGG</named-content>, RP: 5 ’<named-content content-type="sequence">GCCATTGTCATGTTCGTCCA</named-content>). <italic>Sox10</italic> primer sequences (FP: 5 ’<named-content content-type="sequence">ACGCTACAGGTCAGAGT</named-content> CAC, RP: <named-content content-type="sequence">ATGTTGGCCATCACGTCATG</named-content>). Data was analyzed using the delta delta Ct method. Ct values were normalized to those of housekeeping gene, <italic>b-actin. B-actin</italic> primer sequences (FP: <named-content content-type="sequence">CGAGCAGGAGATGGGAACC</named-content>, RP: <named-content content-type="sequence">CAACGGAAACGCTCATTGC</named-content>).</p></sec><sec id="s4-16"><title>Statistics</title><p>To calculate significance of electroporation and flow analysis assays, a two-tailed unpaired t-test with Welch’s correction was performed using GraphPad Prism version 9.0.2 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link>) for Mac (GraphPad Software, San Diego, California USA, <ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com">https://www.graphpad.com</ext-link>). To calculate significance of luciferase assays, a 2-way multiple comparison ANOVA test was performed using GraphPad Prism version 9.0.2 for Mac. For the qPCR experiment in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>, 2-tailed unpaired t-tests was performed using GraphPad Prism for Mac.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>L.I.Z. is a founder and stockholder of Fate Therapeutics, CAMP4 Therapeutics, Amagma Therapeutics, Scholar Rock, and Branch Biosciences. He is a consultant for Celularity and Cellarity</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Validation, Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con4"><p>Data curation, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis</p></fn><fn fn-type="con" id="con7"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con8"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All zebrafish (<italic>Danio rerio</italic>) work was performed in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animal research protocols were approved by the Institutional Animal Care and Use Committee of Boston Children's Hospital, Protocol #20-10-4254R. All zebrafish work operated according to the guidelines of the Institutional Animal Care and Use Committee of Boston Children's Hospital.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83527-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Sequencing datasets can be accessed on GEO at # GSE213360. The Tgfb-Induced-Enhancer:Beta-globin-minimal-promoter-EGFP:pA pDestTol2pA2 plasmid is available on Addgene (Plasmid #<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:addgene_220508">220508</ext-link>), and the TIE:EGFP zebrafish reporter line is available upon request.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Noonan</surname><given-names>HR</given-names></name><name><surname>Thornock</surname><given-names>AM</given-names></name><name><surname>Barbano</surname><given-names>J</given-names></name><name><surname>Xifaras</surname><given-names>M</given-names></name><name><surname>Baron</surname><given-names>CS</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Koczirka</surname><given-names>K</given-names></name><name><surname>McConnell</surname><given-names>AM</given-names></name><name><surname>Zon</surname><given-names>LI</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>A chronic signaling TGFb zebrafish reporter identifies immune response in melanoma</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE213360">GSE213360</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Christian Lawrence, Kara Maloney, Shane Hurley, Lauren McKay, Li- Kun Zhang, and Andrew Kowalczyk for fish care throughout this study. We also thank the Boston Children’s Hospital Flow Cytometry Research Facility for assistance with FACS experiments, as well as Single Cell Discoveries for processing SORT-seq samples.</p><p>We thank the Harvard Center for Biological Imaging (RRID:SCR_018673) for infrastructure and support. The authors thank their colleagues for discussion and reading of this manuscript. Figures were created with <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">Biorender.com</ext-link>. Leonard I Zon is a Howard Hughes Medical Institute Investigator. Additional funding for this work was provided by the Human Frontier Science Program (HFSP LT000494/2020 L, to C.S.B.).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ablain</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Rothschild</surname><given-names>H</given-names></name><name><surname>Jordan</surname><given-names>RC</given-names></name><name><surname>Mito</surname><given-names>JK</given-names></name><name><surname>Daniels</surname><given-names>BH</given-names></name><name><surname>Bell</surname><given-names>CF</given-names></name><name><surname>Joseph</surname><given-names>NM</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Bastian</surname><given-names>BC</given-names></name><name><surname>Zon</surname><given-names>LI</given-names></name><name><surname>Yeh</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Human tumor genomics and zebrafish modeling identify <italic>SPRED1</italic> loss as a driver of mucosal melanoma</article-title><source>Science</source><volume>362</volume><fpage>1055</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1126/science.aau6509</pub-id><pub-id pub-id-type="pmid">30385465</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmadzadeh</surname><given-names>M</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells</article-title><source>Journal of Immunology</source><volume>174</volume><fpage>5215</fpage><lpage>5223</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.9.5215</pub-id><pub-id pub-id-type="pmid">15843517</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbani</surname><given-names>R</given-names></name><name><surname>Akdemir</surname><given-names>KC</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Albert</surname><given-names>M</given-names></name><name><surname>Ally</surname><given-names>A</given-names></name><name><surname>Amin</surname><given-names>SB</given-names></name><name><surname>Arachchi</surname><given-names>H</given-names></name><name><surname>Arora</surname><given-names>A</given-names></name><name><surname>Auman</surname><given-names>JT</given-names></name><name><surname>Ayala</surname><given-names>B</given-names></name><name><surname>Baboud</surname><given-names>J</given-names></name><name><surname>Balasundaram</surname><given-names>M</given-names></name><name><surname>Balu</surname><given-names>S</given-names></name><name><surname>Barnabas</surname><given-names>N</given-names></name><name><surname>Bartlett</surname><given-names>J</given-names></name><name><surname>Bartlett</surname><given-names>P</given-names></name><name><surname>Bastian</surname><given-names>BC</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Behera</surname><given-names>M</given-names></name><name><surname>Belyaev</surname><given-names>D</given-names></name><name><surname>Benz</surname><given-names>C</given-names></name><name><surname>Bernard</surname><given-names>B</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Bir</surname><given-names>N</given-names></name><name><surname>Black</surname><given-names>AD</given-names></name><name><surname>Bodenheimer</surname><given-names>T</given-names></name><name><surname>Boice</surname><given-names>L</given-names></name><name><surname>Boland</surname><given-names>GM</given-names></name><name><surname>Bono</surname><given-names>R</given-names></name><name><surname>Bootwalla</surname><given-names>MS</given-names></name><name><surname>Bosenberg</surname><given-names>M</given-names></name><name><surname>Bowen</surname><given-names>J</given-names></name><name><surname>Bowlby</surname><given-names>R</given-names></name><name><surname>Bristow</surname><given-names>CA</given-names></name><name><surname>Brockway-Lunardi</surname><given-names>L</given-names></name><name><surname>Brooks</surname><given-names>D</given-names></name><name><surname>Brzezinski</surname><given-names>J</given-names></name><name><surname>Bshara</surname><given-names>W</given-names></name><name><surname>Buda</surname><given-names>E</given-names></name><name><surname>Burns</surname><given-names>WR</given-names></name><name><surname>Butterfield</surname><given-names>YSN</given-names></name><name><surname>Button</surname><given-names>M</given-names></name><name><surname>Calderone</surname><given-names>T</given-names></name><name><surname>Cappellini</surname><given-names>GA</given-names></name><name><surname>Carter</surname><given-names>C</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Cherney</surname><given-names>L</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><name><surname>Chevalier</surname><given-names>A</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Cho</surname><given-names>RJ</given-names></name><name><surname>Choi</surname><given-names>Y-L</given-names></name><name><surname>Chu</surname><given-names>A</given-names></name><name><surname>Chudamani</surname><given-names>S</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Ciriello</surname><given-names>G</given-names></name><name><surname>Clarke</surname><given-names>A</given-names></name><name><surname>Coons</surname><given-names>S</given-names></name><name><surname>Cope</surname><given-names>L</given-names></name><name><surname>Crain</surname><given-names>D</given-names></name><name><surname>Curley</surname><given-names>E</given-names></name><name><surname>Danilova</surname><given-names>L</given-names></name><name><surname>D’Atri</surname><given-names>S</given-names></name><name><surname>Davidsen</surname><given-names>T</given-names></name><name><surname>Davies</surname><given-names>MA</given-names></name><name><surname>Delman</surname><given-names>KA</given-names></name><name><surname>Demchok</surname><given-names>JA</given-names></name><name><surname>Deng</surname><given-names>QA</given-names></name><name><surname>Deribe</surname><given-names>YL</given-names></name><name><surname>Dhalla</surname><given-names>N</given-names></name><name><surname>Dhir</surname><given-names>R</given-names></name><name><surname>DiCara</surname><given-names>D</given-names></name><name><surname>Dinikin</surname><given-names>M</given-names></name><name><surname>Dubina</surname><given-names>M</given-names></name><name><surname>Ebrom</surname><given-names>JS</given-names></name><name><surname>Egea</surname><given-names>S</given-names></name><name><surname>Eley</surname><given-names>G</given-names></name><name><surname>Engel</surname><given-names>J</given-names></name><name><surname>Eschbacher</surname><given-names>JM</given-names></name><name><surname>Fedosenko</surname><given-names>KV</given-names></name><name><surname>Felau</surname><given-names>I</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>Ferguson</surname><given-names>ML</given-names></name><name><surname>Fisher</surname><given-names>S</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Frazer</surname><given-names>S</given-names></name><name><surname>Frick</surname><given-names>J</given-names></name><name><surname>Fulidou</surname><given-names>V</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Gardner</surname><given-names>J</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Gastier-Foster</surname><given-names>JM</given-names></name><name><surname>Gaudioso</surname><given-names>C</given-names></name><name><surname>Gehlenborg</surname><given-names>N</given-names></name><name><surname>Genovese</surname><given-names>G</given-names></name><name><surname>Gerken</surname><given-names>M</given-names></name><name><surname>Gershenwald</surname><given-names>JE</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Gomez-Fernandez</surname><given-names>C</given-names></name><name><surname>Gribbin</surname><given-names>T</given-names></name><name><surname>Grimsby</surname><given-names>J</given-names></name><name><surname>Gross</surname><given-names>B</given-names></name><name><surname>Guin</surname><given-names>R</given-names></name><name><surname>Gutschner</surname><given-names>T</given-names></name><name><surname>Hadjipanayis</surname><given-names>A</given-names></name><name><surname>Halaban</surname><given-names>R</given-names></name><name><surname>Hanf</surname><given-names>B</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name><name><surname>Haydu</surname><given-names>LE</given-names></name><name><surname>Hayes</surname><given-names>DN</given-names></name><name><surname>Hayward</surname><given-names>NK</given-names></name><name><surname>Heiman</surname><given-names>DI</given-names></name><name><surname>Herbert</surname><given-names>L</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Hersey</surname><given-names>P</given-names></name><name><surname>Hoadley</surname><given-names>KA</given-names></name><name><surname>Hodis</surname><given-names>E</given-names></name><name><surname>Holt</surname><given-names>RA</given-names></name><name><surname>Hoon</surname><given-names>DSB</given-names></name><name><surname>Hoppough</surname><given-names>S</given-names></name><name><surname>Hoyle</surname><given-names>AP</given-names></name><name><surname>Huang</surname><given-names>FW</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Hutter</surname><given-names>CM</given-names></name><name><surname>Ibbs</surname><given-names>M</given-names></name><name><surname>Iype</surname><given-names>L</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Jakrot</surname><given-names>V</given-names></name><name><surname>Janning</surname><given-names>A</given-names></name><name><surname>Jeck</surname><given-names>WR</given-names></name><name><surname>Jefferys</surname><given-names>SR</given-names></name><name><surname>Jensen</surname><given-names>MA</given-names></name><name><surname>Jones</surname><given-names>CD</given-names></name><name><surname>Jones</surname><given-names>SJM</given-names></name><name><surname>Ju</surname><given-names>Z</given-names></name><name><surname>Kakavand</surname><given-names>H</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Kefford</surname><given-names>RF</given-names></name><name><surname>Khuri</surname><given-names>FR</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Klode</surname><given-names>J</given-names></name><name><surname>Korkut</surname><given-names>A</given-names></name><name><surname>Korski</surname><given-names>K</given-names></name><name><surname>Krauthammer</surname><given-names>M</given-names></name><name><surname>Kucherlapati</surname><given-names>R</given-names></name><name><surname>Kwong</surname><given-names>LN</given-names></name><name><surname>Kycler</surname><given-names>W</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Lai</surname><given-names>PH</given-names></name><name><surname>Laird</surname><given-names>PW</given-names></name><name><surname>Lander</surname><given-names>E</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name><name><surname>Łaźniak</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Leporowska</surname><given-names>E</given-names></name><name><surname>Leraas</surname><given-names>KM</given-names></name><name><surname>Li</surname><given-names>HI</given-names></name><name><surname>Lichtenberg</surname><given-names>TM</given-names></name><name><surname>Lichtenstein</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Ling</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>O</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Mackiewicz</surname><given-names>A</given-names></name><name><surname>Mahadeshwar</surname><given-names>HS</given-names></name><name><surname>Malke</surname><given-names>J</given-names></name><name><surname>Mallery</surname><given-names>D</given-names></name><name><surname>Manikhas</surname><given-names>GM</given-names></name><name><surname>Mann</surname><given-names>GJ</given-names></name><name><surname>Marra</surname><given-names>MA</given-names></name><name><surname>Matejka</surname><given-names>B</given-names></name><name><surname>Mayo</surname><given-names>M</given-names></name><name><surname>Mehrabi</surname><given-names>S</given-names></name><name><surname>Meng</surname><given-names>S</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Mieczkowski</surname><given-names>PA</given-names></name><name><surname>Miller</surname><given-names>JP</given-names></name><name><surname>Miller</surname><given-names>ML</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Moiseenko</surname><given-names>F</given-names></name><name><surname>Moore</surname><given-names>RA</given-names></name><name><surname>Morris</surname><given-names>S</given-names></name><name><surname>Morrison</surname><given-names>C</given-names></name><name><surname>Morton</surname><given-names>D</given-names></name><name><surname>Moschos</surname><given-names>S</given-names></name><name><surname>Mose</surname><given-names>LE</given-names></name><name><surname>Muller</surname><given-names>FL</given-names></name><name><surname>Mungall</surname><given-names>AJ</given-names></name><name><surname>Murawa</surname><given-names>D</given-names></name><name><surname>Murawa</surname><given-names>P</given-names></name><name><surname>Murray</surname><given-names>BA</given-names></name><name><surname>Nezi</surname><given-names>L</given-names></name><name><surname>Ng</surname><given-names>S</given-names></name><name><surname>Nicholson</surname><given-names>D</given-names></name><name><surname>Noble</surname><given-names>MS</given-names></name><name><surname>Osunkoya</surname><given-names>A</given-names></name><name><surname>Owonikoko</surname><given-names>TK</given-names></name><name><surname>Ozenberger</surname><given-names>BA</given-names></name><name><surname>Pagani</surname><given-names>E</given-names></name><name><surname>Paklina</surname><given-names>OV</given-names></name><name><surname>Pantazi</surname><given-names>A</given-names></name><name><surname>Parfenov</surname><given-names>M</given-names></name><name><surname>Parfitt</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>PJ</given-names></name><name><surname>Park</surname><given-names>W-Y</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Passarelli</surname><given-names>F</given-names></name><name><surname>Penny</surname><given-names>R</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Pihl</surname><given-names>TD</given-names></name><name><surname>Potapova</surname><given-names>O</given-names></name><name><surname>Prieto</surname><given-names>VG</given-names></name><name><surname>Protopopov</surname><given-names>A</given-names></name><name><surname>Quinn</surname><given-names>MJ</given-names></name><name><surname>Radenbaugh</surname><given-names>A</given-names></name><name><surname>Rai</surname><given-names>K</given-names></name><name><surname>Ramalingam</surname><given-names>SS</given-names></name><name><surname>Raman</surname><given-names>AT</given-names></name><name><surname>Ramirez</surname><given-names>NC</given-names></name><name><surname>Ramirez</surname><given-names>R</given-names></name><name><surname>Rao</surname><given-names>U</given-names></name><name><surname>Rathmell</surname><given-names>WK</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Reynolds</surname><given-names>SM</given-names></name><name><surname>Roach</surname><given-names>J</given-names></name><name><surname>Robertson</surname><given-names>AG</given-names></name><name><surname>Ross</surname><given-names>MI</given-names></name><name><surname>Roszik</surname><given-names>J</given-names></name><name><surname>Russo</surname><given-names>G</given-names></name><name><surname>Saksena</surname><given-names>G</given-names></name><name><surname>Saller</surname><given-names>C</given-names></name><name><surname>Samuels</surname><given-names>Y</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Sandusky</surname><given-names>G</given-names></name><name><surname>Santoso</surname><given-names>N</given-names></name><name><surname>Saul</surname><given-names>M</given-names></name><name><surname>Saw</surname><given-names>RPM</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Schein</surname><given-names>JE</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Schumacher</surname><given-names>SE</given-names></name><name><surname>Schwallier</surname><given-names>C</given-names></name><name><surname>Scolyer</surname><given-names>RA</given-names></name><name><surname>Seidman</surname><given-names>J</given-names></name><name><surname>Sekhar</surname><given-names>PC</given-names></name><name><surname>Sekhon</surname><given-names>HS</given-names></name><name><surname>Senbabaoglu</surname><given-names>Y</given-names></name><name><surname>Seth</surname><given-names>S</given-names></name><name><surname>Shannon</surname><given-names>KF</given-names></name><name><surname>Sharpe</surname><given-names>S</given-names></name><name><surname>Sharpless</surname><given-names>NE</given-names></name><name><surname>Shaw</surname><given-names>KRM</given-names></name><name><surname>Shelton</surname><given-names>C</given-names></name><name><surname>Shelton</surname><given-names>T</given-names></name><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Sheth</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Shiau</surname><given-names>CJ</given-names></name><name><surname>Shmulevich</surname><given-names>I</given-names></name><name><surname>Sica</surname><given-names>GL</given-names></name><name><surname>Simons</surname><given-names>JV</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Sipahimalani</surname><given-names>P</given-names></name><name><surname>Sofia</surname><given-names>HJ</given-names></name><name><surname>Soloway</surname><given-names>MG</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Spillane</surname><given-names>AJ</given-names></name><name><surname>Spychała</surname><given-names>A</given-names></name><name><surname>Stretch</surname><given-names>JR</given-names></name><name><surname>Stuart</surname><given-names>J</given-names></name><name><surname>Suchorska</surname><given-names>WM</given-names></name><name><surname>Sucker</surname><given-names>A</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Synott</surname><given-names>M</given-names></name><name><surname>Tabak</surname><given-names>B</given-names></name><name><surname>Tabler</surname><given-names>TR</given-names></name><name><surname>Tam</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>D</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Tarnuzzer</surname><given-names>R</given-names></name><name><surname>Tarvin</surname><given-names>K</given-names></name><name><surname>Tatka</surname><given-names>H</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Teresiak</surname><given-names>M</given-names></name><name><surname>Thiessen</surname><given-names>N</given-names></name><name><surname>Thompson</surname><given-names>JF</given-names></name><name><surname>Thorne</surname><given-names>L</given-names></name><name><surname>Thorsson</surname><given-names>V</given-names></name><name><surname>Trent</surname><given-names>JM</given-names></name><name><surname>Triche</surname><given-names>TJJr</given-names></name><name><surname>Tsai</surname><given-names>KY</given-names></name><name><surname>Tsou</surname><given-names>P</given-names></name><name><surname>Van Den Berg</surname><given-names>DJ</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Veluvolu</surname><given-names>U</given-names></name><name><surname>Verhaak</surname><given-names>RG</given-names></name><name><surname>Voet</surname><given-names>D</given-names></name><name><surname>Voronina</surname><given-names>O</given-names></name><name><surname>Walter</surname><given-names>V</given-names></name><name><surname>Walton</surname><given-names>JS</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Waring</surname><given-names>S</given-names></name><name><surname>Watson</surname><given-names>IR</given-names></name><name><surname>Weinhold</surname><given-names>N</given-names></name><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Weisenberger</surname><given-names>DJ</given-names></name><name><surname>White</surname><given-names>P</given-names></name><name><surname>Wilkerson</surname><given-names>MD</given-names></name><name><surname>Wilmott</surname><given-names>JS</given-names></name><name><surname>Wise</surname><given-names>L</given-names></name><name><surname>Wiznerowicz</surname><given-names>M</given-names></name><name><surname>Woodman</surname><given-names>SE</given-names></name><name><surname>Wu</surname><given-names>C-J</given-names></name><name><surname>Wu</surname><given-names>C-C</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Xi</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>AW</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zack</surname><given-names>TI</given-names></name><name><surname>Zenklusen</surname><given-names>JC</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>Zimmer</surname><given-names>L</given-names></name><name><surname>Zmuda</surname><given-names>E</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genomic classification of cutaneous melanoma</article-title><source>Cell</source><volume>161</volume><fpage>1681</fpage><lpage>1696</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.044</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alavi</surname><given-names>S</given-names></name><name><surname>Stewart</surname><given-names>AJ</given-names></name><name><surname>Kefford</surname><given-names>RF</given-names></name><name><surname>Lim</surname><given-names>SY</given-names></name><name><surname>Shklovskaya</surname><given-names>E</given-names></name><name><surname>Rizos</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Interferon signaling is frequently downregulated in melanoma</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>1414</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.01414</pub-id><pub-id pub-id-type="pmid">29977240</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albino</surname><given-names>AP</given-names></name><name><surname>Davis</surname><given-names>BM</given-names></name><name><surname>Nanus</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Induction of growth factor RNA expression in human malignant melanoma: markers of transformation</article-title><source>Cancer Research</source><volume>51</volume><fpage>4815</fpage><lpage>4820</lpage><pub-id pub-id-type="pmid">1716514</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="data"><person-group person-group-type="author"><name><surname>Alemany</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Transcriptomics</data-title><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/anna-alemany/transcriptomics/blob/master/mapandgo/bwamap/bc_celseq2.tsv">https://github.com/anna-alemany/transcriptomics/blob/master/mapandgo/bwamap/bc_celseq2.tsv</ext-link></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>JB</given-names></name><name><surname>Manthey</surname><given-names>CL</given-names></name><name><surname>Hand</surname><given-names>AR</given-names></name><name><surname>Ohura</surname><given-names>K</given-names></name><name><surname>Ellingsworth</surname><given-names>L</given-names></name><name><surname>Wahl</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta</article-title><source>The Journal of Experimental Medicine</source><volume>171</volume><fpage>231</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1084/jem.171.1.231</pub-id><pub-id pub-id-type="pmid">2295877</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arwert</surname><given-names>EN</given-names></name><name><surname>Harney</surname><given-names>AS</given-names></name><name><surname>Entenberg</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sahai</surname><given-names>E</given-names></name><name><surname>Pollard</surname><given-names>JW</given-names></name><name><surname>Condeelis</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A unidirectional transition from migratory to perivascular macrophage is required for tumor cell intravasation</article-title><source>Cell Reports</source><volume>23</volume><fpage>1239</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.04.007</pub-id><pub-id pub-id-type="pmid">29719241</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>P</given-names></name><name><surname>Lyu</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Zuo</surname><given-names>C</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Wan</surname><given-names>Q</given-names></name><name><surname>Wan</surname><given-names>N</given-names></name><name><surname>Jia</surname><given-names>D</given-names></name><name><surname>Lyu</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Macrophage-Derived Legumain Promotes Pulmonary Hypertension by Activating the MMP (Matrix Metalloproteinase)-2/TGF (Transforming Growth Factor)-β1 Signaling</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>39</volume><fpage>e130</fpage><lpage>e145</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.118.312254</pub-id><pub-id pub-id-type="pmid">30676070</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batlle</surname><given-names>E</given-names></name><name><surname>Massagué</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transforming growth factor-β signaling in immunity and cancer</article-title><source>Immunity</source><volume>50</volume><fpage>924</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.024</pub-id><pub-id pub-id-type="pmid">30995507</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Papalexi</surname><given-names>E</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Integrating single-cell transcriptomic data across different conditions, technologies, and species</article-title><source>Nature Biotechnology</source><volume>36</volume><fpage>411</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1038/nbt.4096</pub-id><pub-id pub-id-type="pmid">29608179</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callahan</surname><given-names>SJ</given-names></name><name><surname>Tepan</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>YM</given-names></name><name><surname>Lindsay</surname><given-names>H</given-names></name><name><surname>Burger</surname><given-names>A</given-names></name><name><surname>Campbell</surname><given-names>NR</given-names></name><name><surname>Kim</surname><given-names>IS</given-names></name><name><surname>Hollmann</surname><given-names>TJ</given-names></name><name><surname>Studer</surname><given-names>L</given-names></name><name><surname>Mosimann</surname><given-names>C</given-names></name><name><surname>White</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cancer modeling by Transgene Electroporation in Adult Zebrafish (TEAZ)</article-title><source>Disease Models &amp; Mechanisms</source><volume>11</volume><elocation-id>dmm034561</elocation-id><pub-id pub-id-type="doi">10.1242/dmm.034561</pub-id><pub-id pub-id-type="pmid">30061297</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casari</surname><given-names>A</given-names></name><name><surname>Schiavone</surname><given-names>M</given-names></name><name><surname>Facchinello</surname><given-names>N</given-names></name><name><surname>Vettori</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>D</given-names></name><name><surname>Tiso</surname><given-names>N</given-names></name><name><surname>Moro</surname><given-names>E</given-names></name><name><surname>Argenton</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A Smad3 transgenic reporter reveals TGF-beta control of zebrafish spinal cord development</article-title><source>Developmental Biology</source><volume>396</volume><fpage>81</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2014.09.025</pub-id><pub-id pub-id-type="pmid">25286120</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceol</surname><given-names>CJ</given-names></name><name><surname>Houvras</surname><given-names>Y</given-names></name><name><surname>Jane-Valbuena</surname><given-names>J</given-names></name><name><surname>Bilodeau</surname><given-names>S</given-names></name><name><surname>Orlando</surname><given-names>DA</given-names></name><name><surname>Battisti</surname><given-names>V</given-names></name><name><surname>Fritsch</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>WM</given-names></name><name><surname>Hollmann</surname><given-names>TJ</given-names></name><name><surname>Ferré</surname><given-names>F</given-names></name><name><surname>Bourque</surname><given-names>C</given-names></name><name><surname>Burke</surname><given-names>CJ</given-names></name><name><surname>Turner</surname><given-names>L</given-names></name><name><surname>Uong</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Mermel</surname><given-names>CH</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Ait-Si-Ali</surname><given-names>S</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name><name><surname>Zon</surname><given-names>LI</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset</article-title><source>Nature</source><volume>471</volume><fpage>513</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/nature09806</pub-id><pub-id pub-id-type="pmid">21430779</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Byrne</surname><given-names>CJ</given-names></name><name><surname>Heuer</surname><given-names>ML</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Antipin</surname><given-names>Y</given-names></name><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Goldberg</surname><given-names>AP</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title><source>Cancer Discovery</source><volume>2</volume><fpage>401</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmid">22588877</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derynck</surname><given-names>R</given-names></name><name><surname>Turley</surname><given-names>SJ</given-names></name><name><surname>Akhurst</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TGFβ biology in cancer progression and immunotherapy</article-title><source>Nature Reviews. Clinical Oncology</source><volume>18</volume><fpage>9</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1038/s41571-020-0403-1</pub-id><pub-id pub-id-type="pmid">32710082</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donkor</surname><given-names>MK</given-names></name><name><surname>Sarkar</surname><given-names>A</given-names></name><name><surname>Savage</surname><given-names>PA</given-names></name><name><surname>Franklin</surname><given-names>RA</given-names></name><name><surname>Johnson</surname><given-names>LK</given-names></name><name><surname>Jungbluth</surname><given-names>AA</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name><name><surname>Li</surname><given-names>MO</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine</article-title><source>Immunity</source><volume>35</volume><fpage>123</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.04.019</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellett</surname><given-names>F</given-names></name><name><surname>Pase</surname><given-names>L</given-names></name><name><surname>Hayman</surname><given-names>JW</given-names></name><name><surname>Andrianopoulos</surname><given-names>A</given-names></name><name><surname>Lieschke</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>mpeg1 promoter transgenes direct macrophage-lineage expression in zebrafish</article-title><source>Blood</source><volume>117</volume><fpage>e49</fpage><lpage>e56</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-10-314120</pub-id><pub-id pub-id-type="pmid">21084707</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazio</surname><given-names>M</given-names></name><name><surname>van Rooijen</surname><given-names>E</given-names></name><name><surname>Dang</surname><given-names>M</given-names></name><name><surname>van de Hoek</surname><given-names>G</given-names></name><name><surname>Ablain</surname><given-names>J</given-names></name><name><surname>Mito</surname><given-names>JK</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Michael</surname><given-names>J</given-names></name><name><surname>Fabo</surname><given-names>T</given-names></name><name><surname>Modhurima</surname><given-names>R</given-names></name><name><surname>Pessina</surname><given-names>P</given-names></name><name><surname>Kaufman</surname><given-names>CK</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>White</surname><given-names>RM</given-names></name><name><surname>Zon</surname><given-names>LI</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SATB2 induction of a neural crest mesenchyme-like program drives melanoma invasion and drug resistance</article-title><source>eLife</source><volume>10</volume><elocation-id>e64370</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.64370</pub-id><pub-id pub-id-type="pmid">33527896</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fridlender</surname><given-names>ZG</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kapoor</surname><given-names>V</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Ling</surname><given-names>L</given-names></name><name><surname>Worthen</surname><given-names>GS</given-names></name><name><surname>Albelda</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN</article-title><source>Cancer Cell</source><volume>16</volume><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.06.017</pub-id><pub-id pub-id-type="pmid">19732719</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Dresdner</surname><given-names>G</given-names></name><name><surname>Gross</surname><given-names>B</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>2004088</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id><pub-id pub-id-type="pmid">23550210</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgoudaki</surname><given-names>A-M</given-names></name><name><surname>Prokopec</surname><given-names>KE</given-names></name><name><surname>Boura</surname><given-names>VF</given-names></name><name><surname>Hellqvist</surname><given-names>E</given-names></name><name><surname>Sohn</surname><given-names>S</given-names></name><name><surname>Östling</surname><given-names>J</given-names></name><name><surname>Dahan</surname><given-names>R</given-names></name><name><surname>Harris</surname><given-names>RA</given-names></name><name><surname>Rantalainen</surname><given-names>M</given-names></name><name><surname>Klevebring</surname><given-names>D</given-names></name><name><surname>Sund</surname><given-names>M</given-names></name><name><surname>Brage</surname><given-names>SE</given-names></name><name><surname>Fuxe</surname><given-names>J</given-names></name><name><surname>Rolny</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Ravetch</surname><given-names>JV</given-names></name><name><surname>Karlsson</surname><given-names>MCI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis</article-title><source>Cell Reports</source><volume>15</volume><fpage>2000</fpage><lpage>2011</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.04.084</pub-id><pub-id pub-id-type="pmid">27210762</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Andersen-Nissen</surname><given-names>E</given-names></name><name><surname>Mauck</surname><given-names>WM</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Wilk</surname><given-names>AJ</given-names></name><name><surname>Darby</surname><given-names>C</given-names></name><name><surname>Zager</surname><given-names>M</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Stoeckius</surname><given-names>M</given-names></name><name><surname>Papalexi</surname><given-names>E</given-names></name><name><surname>Mimitou</surname><given-names>EP</given-names></name><name><surname>Jain</surname><given-names>J</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Fleming</surname><given-names>LM</given-names></name><name><surname>Yeung</surname><given-names>B</given-names></name><name><surname>Rogers</surname><given-names>AJ</given-names></name><name><surname>McElrath</surname><given-names>JM</given-names></name><name><surname>Blish</surname><given-names>CA</given-names></name><name><surname>Gottardo</surname><given-names>R</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Integrated analysis of multimodal single-cell data</article-title><source>Cell</source><volume>184</volume><fpage>3573</fpage><lpage>3587</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.04.048</pub-id><pub-id pub-id-type="pmid">34062119</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heilmann</surname><given-names>S</given-names></name><name><surname>Ratnakumar</surname><given-names>K</given-names></name><name><surname>Langdon</surname><given-names>E</given-names></name><name><surname>Kansler</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>I</given-names></name><name><surname>Campbell</surname><given-names>NR</given-names></name><name><surname>Perry</surname><given-names>E</given-names></name><name><surname>McMahon</surname><given-names>A</given-names></name><name><surname>Kaufman</surname><given-names>C</given-names></name><name><surname>van Rooijen</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Iacobuzio-Donahue</surname><given-names>C</given-names></name><name><surname>Hynes</surname><given-names>R</given-names></name><name><surname>Zon</surname><given-names>L</given-names></name><name><surname>Xavier</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A quantitative system for studying metastasis using transparent zebrafish</article-title><source>Cancer Research</source><volume>75</volume><fpage>4272</fpage><lpage>4282</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-3319</pub-id><pub-id pub-id-type="pmid">26282170</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinz</surname><given-names>S</given-names></name><name><surname>Benner</surname><given-names>C</given-names></name><name><surname>Spann</surname><given-names>N</given-names></name><name><surname>Bertolino</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Laslo</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>JX</given-names></name><name><surname>Murre</surname><given-names>C</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities</article-title><source>Molecular Cell</source><volume>38</volume><fpage>576</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.05.004</pub-id><pub-id pub-id-type="pmid">20513432</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Flockhart</surname><given-names>I</given-names></name><name><surname>Vinayagam</surname><given-names>A</given-names></name><name><surname>Bergwitz</surname><given-names>C</given-names></name><name><surname>Berger</surname><given-names>B</given-names></name><name><surname>Perrimon</surname><given-names>N</given-names></name><name><surname>Mohr</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>An integrative approach to ortholog prediction for disease-focused and other functional studies</article-title><source>BMC Bioinformatics</source><volume>12</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1186/1471-2105-12-357</pub-id><pub-id pub-id-type="pmid">21880147</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Ylaya</surname><given-names>K</given-names></name><name><surname>Chung</surname><given-names>EJ</given-names></name><name><surname>Kitano</surname><given-names>H</given-names></name><name><surname>Perry</surname><given-names>C</given-names></name><name><surname>Hanaoka</surname><given-names>J</given-names></name><name><surname>Fukuoka</surname><given-names>J</given-names></name><name><surname>Chung</surname><given-names>JY</given-names></name><name><surname>Hewitt</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients</article-title><source>Journal of Translational Medicine</source><volume>18</volume><elocation-id>443</elocation-id><pub-id pub-id-type="doi">10.1186/s12967-020-02618-z</pub-id><pub-id pub-id-type="pmid">33228719</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javelaud</surname><given-names>D</given-names></name><name><surname>Alexaki</surname><given-names>VI</given-names></name><name><surname>Mauviel</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Transforming growth factor-beta in cutaneous melanoma</article-title><source>Pigment Cell &amp; Melanoma Research</source><volume>21</volume><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1111/j.1755-148X.2008.00450.x</pub-id><pub-id pub-id-type="pmid">18426405</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeannin</surname><given-names>P</given-names></name><name><surname>Paolini</surname><given-names>L</given-names></name><name><surname>Adam</surname><given-names>C</given-names></name><name><surname>Delneste</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The roles of CSFs on the functional polarization of tumor-associated macrophages</article-title><source>The FEBS Journal</source><volume>285</volume><fpage>680</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1111/febs.14343</pub-id><pub-id pub-id-type="pmid">29171156</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsuno</surname><given-names>Y</given-names></name><name><surname>Meyer</surname><given-names>DS</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>Akhurst</surname><given-names>RJ</given-names></name><name><surname>Miyazono</surname><given-names>K</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition</article-title><source>Science Signaling</source><volume>12</volume><elocation-id>eaau8544</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aau8544</pub-id><pub-id pub-id-type="pmid">30808819</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>A</given-names></name><name><surname>Gunaltay</surname><given-names>S</given-names></name><name><surname>McEntee</surname><given-names>CP</given-names></name><name><surname>Shuttleworth</surname><given-names>EE</given-names></name><name><surname>Smedley</surname><given-names>C</given-names></name><name><surname>Houston</surname><given-names>SA</given-names></name><name><surname>Fenton</surname><given-names>TM</given-names></name><name><surname>Levison</surname><given-names>S</given-names></name><name><surname>Mann</surname><given-names>ER</given-names></name><name><surname>Travis</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Human monocytes and macrophages regulate immune tolerance via integrin αvβ8-mediated TGFβ activation</article-title><source>The Journal of Experimental Medicine</source><volume>215</volume><fpage>2725</fpage><lpage>2736</lpage><pub-id pub-id-type="doi">10.1084/jem.20171491</pub-id><pub-id pub-id-type="pmid">30355614</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>BG</given-names></name><name><surname>Malek</surname><given-names>E</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Ignatz-Hoover</surname><given-names>JJ</given-names></name><name><surname>Driscoll</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Novel therapies emerging in oncology to target the TGF-β pathway</article-title><source>Journal of Hematology &amp; Oncology</source><volume>14</volume><elocation-id>55</elocation-id><pub-id pub-id-type="doi">10.1186/s13045-021-01053-x</pub-id><pub-id pub-id-type="pmid">33823905</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobie</surname><given-names>JJ</given-names></name><name><surname>Wu</surname><given-names>RS</given-names></name><name><surname>Kurt</surname><given-names>RA</given-names></name><name><surname>Lou</surname><given-names>S</given-names></name><name><surname>Adelman</surname><given-names>MK</given-names></name><name><surname>Whitesell</surname><given-names>LJ</given-names></name><name><surname>Ramanathapuram</surname><given-names>LV</given-names></name><name><surname>Arteaga</surname><given-names>CL</given-names></name><name><surname>Akporiaye</surname><given-names>ET</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines</article-title><source>Cancer Research</source><volume>63</volume><fpage>1860</fpage><lpage>1864</lpage><pub-id pub-id-type="pmid">12702574</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondili</surname><given-names>M</given-names></name><name><surname>Fust</surname><given-names>A</given-names></name><name><surname>Preussner</surname><given-names>J</given-names></name><name><surname>Kuenne</surname><given-names>C</given-names></name><name><surname>Braun</surname><given-names>T</given-names></name><name><surname>Looso</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>UROPA: a tool for Universal RObust Peak Annotation</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>2593</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-02464-y</pub-id><pub-id pub-id-type="pmid">28572580</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krasagakis</surname><given-names>K</given-names></name><name><surname>Thölke</surname><given-names>D</given-names></name><name><surname>Farthmann</surname><given-names>B</given-names></name><name><surname>Eberle</surname><given-names>J</given-names></name><name><surname>Mansmann</surname><given-names>U</given-names></name><name><surname>Orfanos</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma</article-title><source>British Journal of Cancer</source><volume>77</volume><fpage>1492</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1038/bjc.1998.245</pub-id><pub-id pub-id-type="pmid">9652767</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulakovskiy</surname><given-names>IV</given-names></name><name><surname>Vorontsov</surname><given-names>IE</given-names></name><name><surname>Yevshin</surname><given-names>IS</given-names></name><name><surname>Sharipov</surname><given-names>RN</given-names></name><name><surname>Fedorova</surname><given-names>AD</given-names></name><name><surname>Rumynskiy</surname><given-names>EI</given-names></name><name><surname>Medvedeva</surname><given-names>YA</given-names></name><name><surname>Magana-Mora</surname><given-names>A</given-names></name><name><surname>Bajic</surname><given-names>VB</given-names></name><name><surname>Papatsenko</surname><given-names>DA</given-names></name><name><surname>Kolpakov</surname><given-names>FA</given-names></name><name><surname>Makeev</surname><given-names>VJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>HOCOMOCO: towards a complete collection of transcription factor binding models for human and mouse via large-scale ChIP-Seq analysis</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D252</fpage><lpage>D259</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1106</pub-id><pub-id pub-id-type="pmid">29140464</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwan</surname><given-names>KM</given-names></name><name><surname>Fujimoto</surname><given-names>E</given-names></name><name><surname>Grabher</surname><given-names>C</given-names></name><name><surname>Mangum</surname><given-names>BD</given-names></name><name><surname>Hardy</surname><given-names>ME</given-names></name><name><surname>Campbell</surname><given-names>DS</given-names></name><name><surname>Parant</surname><given-names>JM</given-names></name><name><surname>Yost</surname><given-names>HJ</given-names></name><name><surname>Kanki</surname><given-names>JP</given-names></name><name><surname>Chien</surname><given-names>CBin</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The Tol2kit: A multisite gateway-based construction kit for Tol2 transposon transgenesis constructs</article-title><source>Developmental Dynamics</source><volume>236</volume><fpage>3088</fpage><lpage>3099</lpage><pub-id pub-id-type="doi">10.1002/dvdy.21343</pub-id><pub-id pub-id-type="pmid">17937395</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Hance</surname><given-names>KW</given-names></name><name><surname>Marelli</surname><given-names>B</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Qin</surname><given-names>G</given-names></name><name><surname>Sircar</surname><given-names>A</given-names></name><name><surname>Hernández</surname><given-names>VM</given-names></name><name><surname>Jenkins</surname><given-names>MH</given-names></name><name><surname>Fontana</surname><given-names>RE</given-names></name><name><surname>Deshpande</surname><given-names>A</given-names></name><name><surname>Locke</surname><given-names>G</given-names></name><name><surname>Sabzevari</surname><given-names>H</given-names></name><name><surname>Radvanyi</surname><given-names>L</given-names></name><name><surname>Lo</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β</article-title><source>Science Translational Medicine</source><volume>10</volume><elocation-id>eaan5488</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aan5488</pub-id><pub-id pub-id-type="pmid">29343622</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname><given-names>B</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fast gapped-read alignment with Bowtie 2</article-title><source>Nature Methods</source><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauden</surname><given-names>L</given-names></name><name><surname>Siewiera</surname><given-names>J</given-names></name><name><surname>Boukouaci</surname><given-names>W</given-names></name><name><surname>Ramgolam</surname><given-names>K</given-names></name><name><surname>Mourah</surname><given-names>S</given-names></name><name><surname>Lebbe</surname><given-names>C</given-names></name><name><surname>Charron</surname><given-names>D</given-names></name><name><surname>Aoudjit</surname><given-names>F</given-names></name><name><surname>Jabrane-Ferrat</surname><given-names>N</given-names></name><name><surname>Al-Daccak</surname><given-names>RT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TGF-β-induced (TGFBI) protein in melanoma: A signature of high metastatic potential</article-title><source>The Journal of Investigative Dermatology</source><volume>134</volume><fpage>1675</fpage><lpage>1685</lpage><pub-id pub-id-type="doi">10.1038/jid.2014.20</pub-id><pub-id pub-id-type="pmid">24499734</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lister</surname><given-names>JA</given-names></name><name><surname>Robertson</surname><given-names>CP</given-names></name><name><surname>Lepage</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>SL</given-names></name><name><surname>Raible</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>nacre encodes a zebrafish microphthalmia-related protein that regulates neural-crest-derived pigment cell fate</article-title><source>Development</source><volume>126</volume><fpage>3757</fpage><lpage>3767</lpage><pub-id pub-id-type="doi">10.1242/dev.126.17.3757</pub-id><pub-id pub-id-type="pmid">10433906</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>JA</given-names></name><name><surname>Fisher</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The melanoma revolution: from UV carcinogenesis to a new era in therapeutics</article-title><source>Science</source><volume>346</volume><fpage>945</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1126/science.1253735</pub-id><pub-id pub-id-type="pmid">25414302</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Sozzani</surname><given-names>S</given-names></name><name><surname>Locati</surname><given-names>M</given-names></name><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes</article-title><source>TRENDS in Immunology</source><volume>23</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/s1471-4906(02)02302-5</pub-id><pub-id pub-id-type="pmid">12401408</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariathasan</surname><given-names>S</given-names></name><name><surname>Turley</surname><given-names>SJ</given-names></name><name><surname>Nickles</surname><given-names>D</given-names></name><name><surname>Castiglioni</surname><given-names>A</given-names></name><name><surname>Yuen</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Kadel</surname><given-names>EE</given-names><suffix>III</suffix></name><name><surname>Koeppen</surname><given-names>H</given-names></name><name><surname>Astarita</surname><given-names>JL</given-names></name><name><surname>Cubas</surname><given-names>R</given-names></name><name><surname>Jhunjhunwala</surname><given-names>S</given-names></name><name><surname>Banchereau</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Chalouni</surname><given-names>C</given-names></name><name><surname>Ziai</surname><given-names>J</given-names></name><name><surname>Şenbabaoğlu</surname><given-names>Y</given-names></name><name><surname>Santoro</surname><given-names>S</given-names></name><name><surname>Sheinson</surname><given-names>D</given-names></name><name><surname>Hung</surname><given-names>J</given-names></name><name><surname>Giltnane</surname><given-names>JM</given-names></name><name><surname>Pierce</surname><given-names>AA</given-names></name><name><surname>Mesh</surname><given-names>K</given-names></name><name><surname>Lianoglou</surname><given-names>S</given-names></name><name><surname>Riegler</surname><given-names>J</given-names></name><name><surname>Carano</surname><given-names>RAD</given-names></name><name><surname>Eriksson</surname><given-names>P</given-names></name><name><surname>Höglund</surname><given-names>M</given-names></name><name><surname>Somarriba</surname><given-names>L</given-names></name><name><surname>Halligan</surname><given-names>DL</given-names></name><name><surname>van der Heijden</surname><given-names>MS</given-names></name><name><surname>Loriot</surname><given-names>Y</given-names></name><name><surname>Rosenberg</surname><given-names>JE</given-names></name><name><surname>Fong</surname><given-names>L</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>DS</given-names></name><name><surname>Green</surname><given-names>M</given-names></name><name><surname>Derleth</surname><given-names>C</given-names></name><name><surname>Fine</surname><given-names>GD</given-names></name><name><surname>Hegde</surname><given-names>PS</given-names></name><name><surname>Bourgon</surname><given-names>R</given-names></name><name><surname>Powles</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells</article-title><source>Nature</source><volume>554</volume><fpage>544</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1038/nature25501</pub-id><pub-id pub-id-type="pmid">29443960</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cutadapt removes adapter sequences from high-throughput sequencing reads</article-title><source>EMBnet.Journal</source><volume>17</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.14806/ej.17.1.200</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>CJ</given-names></name><name><surname>Datta</surname><given-names>A</given-names></name><name><surname>Littlefield</surname><given-names>C</given-names></name><name><surname>Kalra</surname><given-names>A</given-names></name><name><surname>Chapron</surname><given-names>C</given-names></name><name><surname>Wawersik</surname><given-names>S</given-names></name><name><surname>Dagbay</surname><given-names>KB</given-names></name><name><surname>Brueckner</surname><given-names>CT</given-names></name><name><surname>Nikiforov</surname><given-names>A</given-names></name><name><surname>Danehy</surname><given-names>FT</given-names></name><name><surname>Streich</surname><given-names>FC</given-names></name><name><surname>Boston</surname><given-names>C</given-names></name><name><surname>Simpson</surname><given-names>A</given-names></name><name><surname>Jackson</surname><given-names>JW</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Danek</surname><given-names>N</given-names></name><name><surname>Faucette</surname><given-names>RR</given-names></name><name><surname>Raman</surname><given-names>P</given-names></name><name><surname>Capili</surname><given-names>AD</given-names></name><name><surname>Buckler</surname><given-names>A</given-names></name><name><surname>Carven</surname><given-names>GJ</given-names></name><name><surname>Schürpf</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape</article-title><source>Science Translational Medicine</source><volume>12</volume><elocation-id>eaay8456</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aay8456</pub-id><pub-id pub-id-type="pmid">32213632</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>FO</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The M1 and M2 paradigm of macrophage activation: time for reassessment</article-title><source>F1000prime Reports</source><volume>6</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.12703/P6-13</pub-id><pub-id pub-id-type="pmid">24669294</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massagué</surname><given-names>J</given-names></name><name><surname>Blain</surname><given-names>SW</given-names></name><name><surname>Lo</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>TGFbeta signaling in growth control, cancer, and heritable disorders</article-title><source>Cell</source><volume>103</volume><fpage>295</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)00121-5</pub-id><pub-id pub-id-type="pmid">11057902</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazawa</surname><given-names>K</given-names></name><name><surname>Miyazono</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Regulation of TGF-β Family Signaling by Inhibitory Smads</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>9</volume><elocation-id>a022095</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a022095</pub-id><pub-id pub-id-type="pmid">27920040</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><name><surname>Eriksson</surname><given-names>K-F</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Sihag</surname><given-names>S</given-names></name><name><surname>Lehar</surname><given-names>J</given-names></name><name><surname>Puigserver</surname><given-names>P</given-names></name><name><surname>Carlsson</surname><given-names>E</given-names></name><name><surname>Ridderstråle</surname><given-names>M</given-names></name><name><surname>Laurila</surname><given-names>E</given-names></name><name><surname>Houstis</surname><given-names>N</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Patterson</surname><given-names>N</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Spiegelman</surname><given-names>B</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Groop</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes</article-title><source>Nature Genetics</source><volume>34</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/ng1180</pub-id><pub-id pub-id-type="pmid">12808457</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mort</surname><given-names>RL</given-names></name><name><surname>Jackson</surname><given-names>IJ</given-names></name><name><surname>Patton</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The melanocyte lineage in development and disease</article-title><source>Development</source><volume>142</volume><fpage>620</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1242/dev.106567</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muraro</surname><given-names>MJ</given-names></name><name><surname>Dharmadhikari</surname><given-names>G</given-names></name><name><surname>Grün</surname><given-names>D</given-names></name><name><surname>Groen</surname><given-names>N</given-names></name><name><surname>Dielen</surname><given-names>T</given-names></name><name><surname>Jansen</surname><given-names>E</given-names></name><name><surname>van Gurp</surname><given-names>L</given-names></name><name><surname>Engelse</surname><given-names>MA</given-names></name><name><surname>Carlotti</surname><given-names>F</given-names></name><name><surname>de Koning</surname><given-names>EJP</given-names></name><name><surname>van Oudenaarden</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A single-cell transcriptome atlas of the human pancreas</article-title><source>Cell Systems</source><volume>3</volume><fpage>385</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2016.09.002</pub-id><pub-id pub-id-type="pmid">27693023</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naganuma</surname><given-names>H</given-names></name><name><surname>Sasaki</surname><given-names>A</given-names></name><name><surname>Satoh</surname><given-names>E</given-names></name><name><surname>Nagasaka</surname><given-names>M</given-names></name><name><surname>Nakano</surname><given-names>S</given-names></name><name><surname>Isoe</surname><given-names>S</given-names></name><name><surname>Tasaka</surname><given-names>K</given-names></name><name><surname>Nukui</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Transforming Growth Factor-β Inhibits Interferon-γ Secretion by Lymph okine-activated Killer Cells Stimulated with Tumor Cells</article-title><source>Neurologia Medico-Chirurgica</source><volume>36</volume><fpage>789</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.2176/nmc.36.789</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patton</surname><given-names>EE</given-names></name><name><surname>Widlund</surname><given-names>HR</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name><name><surname>Kopani</surname><given-names>KR</given-names></name><name><surname>Amatruda</surname><given-names>JF</given-names></name><name><surname>Murphey</surname><given-names>RD</given-names></name><name><surname>Berghmans</surname><given-names>S</given-names></name><name><surname>Mayhall</surname><given-names>EA</given-names></name><name><surname>Traver</surname><given-names>D</given-names></name><name><surname>Fletcher</surname><given-names>CDM</given-names></name><name><surname>Aster</surname><given-names>JC</given-names></name><name><surname>Granter</surname><given-names>SR</given-names></name><name><surname>Look</surname><given-names>AT</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Fisher</surname><given-names>DE</given-names></name><name><surname>Zon</surname><given-names>LI</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma</article-title><source>Current Biology</source><volume>15</volume><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2005.01.031</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paz-Ares</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>TM</given-names></name><name><surname>Vicente</surname><given-names>D</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Lin</surname><given-names>C-C</given-names></name><name><surname>Flor</surname><given-names>MJ</given-names></name><name><surname>Di Nicola</surname><given-names>M</given-names></name><name><surname>Alvarez</surname><given-names>RM</given-names></name><name><surname>Dussault</surname><given-names>I</given-names></name><name><surname>Helwig</surname><given-names>C</given-names></name><name><surname>Ojalvo</surname><given-names>LS</given-names></name><name><surname>Gulley</surname><given-names>JL</given-names></name><name><surname>Cho</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial</article-title><source>Journal of Thoracic Oncology</source><volume>15</volume><fpage>1210</fpage><lpage>1222</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2020.03.003</pub-id><pub-id pub-id-type="pmid">32173464</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrot</surname><given-names>CY</given-names></name><name><surname>Javelaud</surname><given-names>D</given-names></name><name><surname>Mauviel</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma</article-title><source>Annals of Dermatology</source><volume>25</volume><fpage>135</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.5021/ad.2013.25.2.135</pub-id><pub-id pub-id-type="pmid">23717002</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rak</surname><given-names>J</given-names></name><name><surname>Filmus</surname><given-names>J</given-names></name><name><surname>Kerbel</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Reciprocal paracrine interactions between tumour cells and endothelial cells: the “angiogenesis progression” hypothesis</article-title><source>European Journal of Cancer</source><volume>32A</volume><fpage>2438</fpage><lpage>2450</lpage><pub-id pub-id-type="doi">10.1016/s0959-8049(96)00396-6</pub-id><pub-id pub-id-type="pmid">9059332</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramírez</surname><given-names>F</given-names></name><name><surname>Ryan</surname><given-names>DP</given-names></name><name><surname>Grüning</surname><given-names>B</given-names></name><name><surname>Bhardwaj</surname><given-names>V</given-names></name><name><surname>Kilpert</surname><given-names>F</given-names></name><name><surname>Richter</surname><given-names>AS</given-names></name><name><surname>Heyne</surname><given-names>S</given-names></name><name><surname>Dündar</surname><given-names>F</given-names></name><name><surname>Manke</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>deepTools2: a next generation web server for deep-sequencing data analysis</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>W160</fpage><lpage>W165</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw257</pub-id><pub-id pub-id-type="pmid">27079975</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>IB</given-names></name><name><surname>Rifkin</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>8</volume><elocation-id>a021907</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a021907</pub-id><pub-id pub-id-type="pmid">27252363</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodeck</surname><given-names>U</given-names></name><name><surname>Melber</surname><given-names>K</given-names></name><name><surname>Kath</surname><given-names>R</given-names></name><name><surname>Menssen</surname><given-names>HD</given-names></name><name><surname>Varello</surname><given-names>M</given-names></name><name><surname>Atkinson</surname><given-names>B</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes</article-title><source>The Journal of Investigative Dermatology</source><volume>97</volume><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1111/1523-1747.ep12477822</pub-id><pub-id pub-id-type="pmid">2056188</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodeck</surname><given-names>U</given-names></name><name><surname>Bossler</surname><given-names>A</given-names></name><name><surname>Graeven</surname><given-names>U</given-names></name><name><surname>Fox</surname><given-names>FE</given-names></name><name><surname>Nowell</surname><given-names>PC</given-names></name><name><surname>Knabbe</surname><given-names>C</given-names></name><name><surname>Kari</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells</article-title><source>Cancer Research</source><volume>54</volume><fpage>575</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">8275496</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>H</given-names></name><name><surname>Koma</surname><given-names>Y-I</given-names></name><name><surname>Higashino</surname><given-names>N</given-names></name><name><surname>Kodama</surname><given-names>T</given-names></name><name><surname>Tanigawa</surname><given-names>K</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Fujikawa</surname><given-names>M</given-names></name><name><surname>Nishio</surname><given-names>M</given-names></name><name><surname>Shigeoka</surname><given-names>M</given-names></name><name><surname>Kakeji</surname><given-names>Y</given-names></name><name><surname>Yokozaki</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>PAI-1 derived from cancer-associated fibroblasts in esophageal squamous cell carcinoma promotes the invasion of cancer cells and the migration of macrophages</article-title><source>Laboratory Investigation; a Journal of Technical Methods and Pathology</source><volume>101</volume><fpage>353</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1038/s41374-020-00512-2</pub-id><pub-id pub-id-type="pmid">33311557</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satija</surname><given-names>R</given-names></name><name><surname>Farrell</surname><given-names>JA</given-names></name><name><surname>Gennert</surname><given-names>D</given-names></name><name><surname>Schier</surname><given-names>AF</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Spatial reconstruction of single-cell gene expression data</article-title><source>Nature Biotechnology</source><volume>33</volume><fpage>495</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1038/nbt.3192</pub-id><pub-id pub-id-type="pmid">25867923</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>P</given-names></name><name><surname>Itin</surname><given-names>P</given-names></name><name><surname>Rufli</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma</article-title><source>Carcinogenesis</source><volume>16</volume><fpage>1499</fpage><lpage>1503</lpage><pub-id pub-id-type="doi">10.1093/carcin/16.7.1499</pub-id><pub-id pub-id-type="pmid">7614683</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seoane</surname><given-names>J</given-names></name><name><surname>Gomis</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TGF-β Family Signaling in Tumor Suppression and Cancer Progression</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>9</volume><elocation-id>a022277</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a022277</pub-id><pub-id pub-id-type="pmid">28246180</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Giaquinto</surname><given-names>AN</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Cancer statistics, 2024</article-title><source>CA</source><volume>74</volume><fpage>12</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.3322/caac.21820</pub-id><pub-id pub-id-type="pmid">38230766</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sounni</surname><given-names>NE</given-names></name><name><surname>Dehne</surname><given-names>K</given-names></name><name><surname>van Kempen</surname><given-names>L</given-names></name><name><surname>Egeblad</surname><given-names>M</given-names></name><name><surname>Affara</surname><given-names>NI</given-names></name><name><surname>Cuevas</surname><given-names>I</given-names></name><name><surname>Wiesen</surname><given-names>J</given-names></name><name><surname>Junankar</surname><given-names>S</given-names></name><name><surname>Korets</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Morrison</surname><given-names>CJ</given-names></name><name><surname>Overall</surname><given-names>CM</given-names></name><name><surname>Krane</surname><given-names>SM</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name><name><surname>Boudreau</surname><given-names>N</given-names></name><name><surname>Coussens</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Stromal regulation of vessel stability by MMP14 and TGFbeta</article-title><source>Disease Models &amp; Mechanisms</source><volume>3</volume><fpage>317</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1242/dmm.003863</pub-id><pub-id pub-id-type="pmid">20223936</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Standiford</surname><given-names>TJ</given-names></name><name><surname>Kuick</surname><given-names>R</given-names></name><name><surname>Bhan</surname><given-names>U</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Newstead</surname><given-names>M</given-names></name><name><surname>Keshamouni</surname><given-names>VG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>TGF-β-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth</article-title><source>Oncogene</source><volume>30</volume><fpage>2475</fpage><lpage>2484</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.619</pub-id><pub-id pub-id-type="pmid">21278795</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strauss</surname><given-names>J</given-names></name><name><surname>Heery</surname><given-names>CR</given-names></name><name><surname>Schlom</surname><given-names>J</given-names></name><name><surname>Madan</surname><given-names>RA</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Kang</surname><given-names>Z</given-names></name><name><surname>Lamping</surname><given-names>E</given-names></name><name><surname>Marté</surname><given-names>JL</given-names></name><name><surname>Donahue</surname><given-names>RN</given-names></name><name><surname>Grenga</surname><given-names>I</given-names></name><name><surname>Cordes</surname><given-names>L</given-names></name><name><surname>Christensen</surname><given-names>O</given-names></name><name><surname>Mahnke</surname><given-names>L</given-names></name><name><surname>Helwig</surname><given-names>C</given-names></name><name><surname>Gulley</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors</article-title><source>Clinical Cancer Research</source><volume>24</volume><fpage>1287</fpage><lpage>1295</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-2653</pub-id><pub-id pub-id-type="pmid">29298798</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Hafemeister</surname><given-names>C</given-names></name><name><surname>Papalexi</surname><given-names>E</given-names></name><name><surname>Mauck</surname><given-names>WM</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Stoeckius</surname><given-names>M</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Comprehensive Integration of Single-Cell Data</article-title><source>Cell</source><volume>177</volume><fpage>1888</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.05.031</pub-id><pub-id pub-id-type="pmid">31178118</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suriyamurthy</surname><given-names>S</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>Ten Dijke</surname><given-names>P</given-names></name><name><surname>Iyengar</surname><given-names>PV</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Epigenetic Reprogramming of TGF-β Signaling in Breast Cancer</article-title><source>Cancers</source><volume>11</volume><elocation-id>726</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11050726</pub-id><pub-id pub-id-type="pmid">31137748</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Gifford</surname><given-names>CC</given-names></name><name><surname>Samarakoon</surname><given-names>R</given-names></name><name><surname>Higgins</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Deregulation of Negative Controls on TGF-β1 Signaling in Tumor Progression</article-title><source>Cancers</source><volume>10</volume><elocation-id>159</elocation-id><pub-id pub-id-type="doi">10.3390/cancers10060159</pub-id><pub-id pub-id-type="pmid">29799477</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tauriello</surname><given-names>DVF</given-names></name><name><surname>Palomo-Ponce</surname><given-names>S</given-names></name><name><surname>Stork</surname><given-names>D</given-names></name><name><surname>Berenguer-Llergo</surname><given-names>A</given-names></name><name><surname>Badia-Ramentol</surname><given-names>J</given-names></name><name><surname>Iglesias</surname><given-names>M</given-names></name><name><surname>Sevillano</surname><given-names>M</given-names></name><name><surname>Ibiza</surname><given-names>S</given-names></name><name><surname>Cañellas</surname><given-names>A</given-names></name><name><surname>Hernando-Momblona</surname><given-names>X</given-names></name><name><surname>Byrom</surname><given-names>D</given-names></name><name><surname>Matarin</surname><given-names>JA</given-names></name><name><surname>Calon</surname><given-names>A</given-names></name><name><surname>Rivas</surname><given-names>EI</given-names></name><name><surname>Nebreda</surname><given-names>AR</given-names></name><name><surname>Riera</surname><given-names>A</given-names></name><name><surname>Attolini</surname><given-names>CSO</given-names></name><name><surname>Batlle</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis</article-title><source>Nature</source><volume>554</volume><fpage>538</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1038/nature25492</pub-id><pub-id pub-id-type="pmid">29443964</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>TopHat: discovering splice junctions with RNA-Seq</article-title><source>Bioinformatics</source><volume>25</volume><fpage>1105</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp120</pub-id><pub-id pub-id-type="pmid">19289445</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>Cole</given-names></name><name><surname>Williams</surname><given-names>BA</given-names></name><name><surname>Pertea</surname><given-names>G</given-names></name><name><surname>Mortazavi</surname><given-names>A</given-names></name><name><surname>Kwan</surname><given-names>G</given-names></name><name><surname>van Baren</surname><given-names>MJ</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name><name><surname>Wold</surname><given-names>BJ</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation</article-title><source>Nature Biotechnology</source><volume>28</volume><fpage>511</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1038/nbt.1621</pub-id><pub-id pub-id-type="pmid">20436464</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Belle</surname><given-names>P</given-names></name><name><surname>Rodeck</surname><given-names>U</given-names></name><name><surname>Nuamah</surname><given-names>I</given-names></name><name><surname>Halpern</surname><given-names>AC</given-names></name><name><surname>Elder</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Melanoma-associated expression of transforming growth factor-beta isoforms</article-title><source>The American Journal of Pathology</source><volume>148</volume><fpage>1887</fpage><lpage>1894</lpage><pub-id pub-id-type="pmid">8669474</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verrecchia</surname><given-names>F</given-names></name><name><surname>Chu</surname><given-names>ML</given-names></name><name><surname>Mauviel</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>17058</fpage><lpage>17062</lpage><pub-id pub-id-type="doi">10.1074/jbc.M100754200</pub-id><pub-id pub-id-type="pmid">11279127</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viola</surname><given-names>A</given-names></name><name><surname>Munari</surname><given-names>F</given-names></name><name><surname>Sánchez-Rodríguez</surname><given-names>R</given-names></name><name><surname>Scolaro</surname><given-names>T</given-names></name><name><surname>Castegna</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The metabolic signature of macrophage responses</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>1462</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.01462</pub-id><pub-id pub-id-type="pmid">31333642</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahl</surname><given-names>SM</given-names></name><name><surname>Allen</surname><given-names>JB</given-names></name><name><surname>Weeks</surname><given-names>BS</given-names></name><name><surname>Wong</surname><given-names>HL</given-names></name><name><surname>Klotman</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes</article-title><source>PNAS</source><volume>90</volume><fpage>4577</fpage><lpage>4581</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.10.4577</pub-id><pub-id pub-id-type="pmid">8506302</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>WE</given-names></name><name><surname>Campbell</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>scruff: an R/Bioconductor package for preprocessing single-cell RNA-sequencing data</article-title><source>BMC Bioinformatics</source><volume>20</volume><elocation-id>222</elocation-id><pub-id pub-id-type="doi">10.1186/s12859-019-2797-2</pub-id><pub-id pub-id-type="pmid">31046658</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsh</surname><given-names>BT</given-names></name><name><surname>Faucette</surname><given-names>R</given-names></name><name><surname>Bilic</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>CJ</given-names></name><name><surname>Schürpf</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Nicholls</surname><given-names>S</given-names></name><name><surname>Lansita</surname><given-names>J</given-names></name><name><surname>Kalra</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors</article-title><source>International Journal of Toxicology</source><volume>40</volume><fpage>226</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1177/1091581821998945</pub-id><pub-id pub-id-type="pmid">33739172</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>RM</given-names></name><name><surname>Sessa</surname><given-names>A</given-names></name><name><surname>Burke</surname><given-names>C</given-names></name><name><surname>Bowman</surname><given-names>T</given-names></name><name><surname>LeBlanc</surname><given-names>J</given-names></name><name><surname>Ceol</surname><given-names>C</given-names></name><name><surname>Bourque</surname><given-names>C</given-names></name><name><surname>Dovey</surname><given-names>M</given-names></name><name><surname>Goessling</surname><given-names>W</given-names></name><name><surname>Burns</surname><given-names>CE</given-names></name><name><surname>Zon</surname><given-names>LI</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Transparent adult zebrafish as a tool for in vivo transplantation analysis</article-title><source>Cell Stem Cell</source><volume>2</volume><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2007.11.002</pub-id><pub-id pub-id-type="pmid">18371439</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>SOCS Proteins in Macrophage Polarization and Function</article-title><source>Frontiers in Immunology</source><volume>5</volume><elocation-id>357</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2014.00357</pub-id><pub-id pub-id-type="pmid">25120543</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Shao</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>TNF-a mediated inflammatory macrophage polarization contributes to the pathogenesis of steroid-induced osteonecrosis in mice</article-title><source>International Journal of Immunopathology and Pharmacology</source><volume>28</volume><fpage>351</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1177/0394632015593228</pub-id><pub-id pub-id-type="pmid">26197804</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>An</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ALOX5AP Predicts Poor Prognosis by Enhancing M2 Macrophages Polarization and Immunosuppression in Serous Ovarian Cancer Microenvironment</article-title><source>Frontiers in Oncology</source><volume>11</volume><elocation-id>675104</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.675104</pub-id><pub-id pub-id-type="pmid">34094977</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Meyer</surname><given-names>CA</given-names></name><name><surname>Eeckhoute</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>DS</given-names></name><name><surname>Bernstein</surname><given-names>BE</given-names></name><name><surname>Nusbaum</surname><given-names>C</given-names></name><name><surname>Myers</surname><given-names>RM</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Model-based analysis of ChIP-Seq (MACS)</article-title><source>Genome Biology</source><volume>9</volume><elocation-id>R137</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2008-9-9-r137</pub-id><pub-id pub-id-type="pmid">18798982</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Alexander</surname><given-names>PB</given-names></name><name><surname>Wang</surname><given-names>XF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TGF-β Family Signaling in the Control of Cell Proliferation and Survival</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>9</volume><elocation-id>a022145</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a022145</pub-id><pub-id pub-id-type="pmid">27920038</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83527.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tamplin</surname><given-names>Owen J</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01y2jtd41</institution-id><institution>University of Wisconsin–Madison</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.09.29.510035" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.29.510035"/></front-stub><body><p>This is an important study that discovered a TGFb-inducible enhancer region in a human melanoma cell line that functions across vertebrates and was used to generate a zebrafish melanoma TGFb reporter model. The data is solid and provides interesting insights into TGFb signaling that is only activated in advanced melanoma. The study also shows TGFb reporter-positive melanoma cells are preferentially phagocytosed by macrophages, making this paper of interest to biologists studying melanoma and cancer immunotherapy.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83527.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Tamplin</surname><given-names>Owen J</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01y2jtd41</institution-id><institution>University of Wisconsin–Madison</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Mione</surname><given-names>Marina C</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05trd4x28</institution-id><institution>University of Trento</institution></institution-wrap><country>Italy</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.29.510035">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.09.29.510035v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;A chronic signaling TGFb zebrafish reporter identifies immune response in melanoma&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Paivi Ojala as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Marina C Mione (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions (for the authors):</p><p>Although the reviewers are very positive about the manuscript, there are several areas that could be explored further. There was a consensus that the role of macrophages in particular needs more data for the model to be supported.</p><p>1. There are multiple issues with Figures 1 and Extended Data Figure 1 as seen in the reviewers' comments below. These relate to quality and quantification and should be addressed.</p><p>2. The reviewers also suggested that Figure 3 data be improved with better confocal images and time-lapse imaging.</p><p>3. In Figure 4, SATB2 data should be compared to Figures 1-3 without SATB2. Does SATB2 facilitate melanoma progression?</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Data exists of spatially mapped transcriptomes in zebrafish melanoma:</p><p>Hunter, et al. Spatially resolved transcriptomics reveals the architecture of the tumor-microenvironment interface. Nat Commun 12, 6278 (2021).</p><p>Are the results in this study showing regions of active TGFb signaling in advanced melanoma consistent with existing data of endogenous expression patterns?</p><p>The proposed model of preferential phagocytosis of TIE:GFP+ cells vs negative cells is interesting, however, the data is still somewhat preliminary. Higher resolution imaging data and possibly time-lapse would better support the model. Could the authors provide some candidate factors produced by TIE:GFP+ cells that could trigger this response?</p><p>In the Extended Data Figure 1C-D experiments, if the mitf:mCherry is transiently injected, then the conclusions may be overstated. Line 90: &quot;TIE:EGFP was also never expressed in mitfa:mCherry high early melanomas (Extended Data Figure 1D)&quot;. How many melanomas were observed? What level of GFP expression is required to score as positive in TIE:GFP fish? The conclusions should be reconsidered because transient F0 transgenics are inherently mosaic.</p><p>Extended data 1B images are small and difficult to evaluate. Need better images that are quantified for fluorescence intensity.</p><p>In the Figure 1C (20 and 22 wpf) panels, why is there a yellow signal in the mitfa:mCherry channel alone in the majority of the tumor but not in the merged image?</p><p>Which data does S1B refer to in this line?</p><p>Line 115: melanomas were processed for single-cell RNA-sequencing at 23 and 42 weeks post-fertilization (wpf), respectively (Figure 1C and S1B).</p><p>Could the authors describe the marco marker and its significance here?</p><p>Line: 120 melanoma cells expressing mitfa and/or sox10, but we identified a marco-expressing TIE:EGFP+.</p><p>Does the analysis of Figure S2B include macrophages or is it only the melanomas? Is there any independent validation of the GSEA results? This is regarding:</p><p>Line: 130 in TIE:EGFPhigh cells were interferon α and γ (Figure S2B).</p><p>In the following line, which genes are referred to specifically? Are these genes associated with a specific table or figure?</p><p>Line: 293 of melanoma patients exhibit up-regulation of these genes52,53.</p><p>Are there experiments that could better support the following statement:</p><p>Line: 306 Our work identified macrophage subclusters that contain low levels of mitfa and/or sox10 expression suggestive of phagocytosis of melanoma cells.</p><p>Is there a GFP/mCherry merged image to support this statement, as it is not clear from the figure?</p><p>311 Figure 3C, there is co-localization of mpeg:mCherry and TIE:EGFP signal.</p><p>The following figure legend is insufficient and needs more details (e.g. live or fixed sample? Optical section or z projection? Single frame of time-lapse?):</p><p>Line: 943 Supplement Figure 4. Example of a macrophage actively phagocytosing a TIE:EGFP+ cell in a melanoma.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. Figure 1, Extended data 1 and supplemental Figure 1: better characterization of the reporter lines is important at different ages and in melanomas. Only one melanoma is shown in Figure 1C and another one in S1B, and, curiously, the pattern of TIE:EGFP expression is completely different: clusters vs homogenous expression. More pictures and quantitation of TIE:EGFP+ and TIE:EGFP- cells are required.</p><p>2. Figure 3 and results about macrophages: Figure 3A: most macrophages do not express mitfa and sox10. Figure 3B is not convincing: I do not see any white cells that would represent macrophages taken up TIE:EGFP+ melanoma cells. I can see several green macrophages that may indicate that macrophages express the TIE:EGFP construct. Additional pictures and video, if possible are needed.</p><p>3. Figure 3D: I do not understand why Q1 represent non-melanoma cells that were phagocytosed. I think these are non-phagocytosing macrophages. So, Q2 has to be plotted not Q1+Q2. Anyway, I think that allotransplant experiments of melanoma cells from TIE:EGFP fish need to be performed in mpeg1:cherry recipient, and vice versa, to demonstrate that macrophages are phagocytosing TIE:GFP+ cells rather than expressing the construct. In addition.</p><p>4. Figure 4 and SATB2 data: these data should be compared with those obtained in Figure 1-3 w/o SATB2. Does SATB2 facilitate melanoma progression? Is there any difference in the TGFB targets between control and SATB2 TIE:EGFP+ cells?</p><p>5. Lines 286-295: it is speculated that the novel chronic TGFB targets are involved in cell migration. I think it would be a nice complement to perform an allotransplant of TIE:EGFP+ and TIE:EGF- melanoma cells and study their aggressiveness.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1) The confocal pictures in Figure 3B are not convincing. We cannot see the edge of the cells to make sure that they are not debris. At the same time, how do we expect that melanoma cells that have been phagocytosed by macrophages and that are present in fragments (only puncta of TIE:EGFP signal are seen in macrophages) would maintain intact the mitfa and sox10 mRNAs retrieved in the single cell RNA analysis? This is why we need absolutely perfect confocal images of tumor sections with clearly visible macrophages and tumor cells to support the hypothesis that macrophages preferentially phagocyte TGFbeta-expressing melanoma cells. In addition, this claim should be supported by some in vivo live observation to test the ability of macrophages to recognize TGFbeta-expressing melanoma cells versus other melanoma cells.</p><p>The doubt that this reporter labels a subpopulation of macrophages or macrophages in a particular status of activation induced by the presence of the tumor, rather than macrophages that have phagocytosed a rare population of melanoma cells that turn on the TGFb reporter remains.</p><p>2) To understand if the overexpression of SATB2 would activate the reporter, and generate melanomas with a larger proportion of TIE:EGFP positive cells, they produced tumors overexpressing SATB2 in the TIE:EGFP background. Then, they searched for differences in the macrophage populations. Here the authors admit that TGFbeta is known to convert macrophages from a pro-inflammatory M1-like to an anti-inflammatory M2-like state, thus implicitly suggesting that the reporter, which is not specific for melanoma but could be expressed in any cell of these transgenic fish, could be activated directly in the macrophages, with no need to justify its expression with the phagocytosis of a rare population of melanoma cells expressing it.</p><p>Related to Figure 1C, sections through the melanoma would help to distinguish whether the green fluorescence signal is part of the tumor and not just the residual brain tissue that express the reporter, and that we see clearly also in extended data Figure 1D.</p><p>One of the arrowheads in Figure 1C, in the 22 wks image, does not point to gfp signal. What is the yellow halo in the middle panel mitfa:mcherry at 20 and 22 weeks?</p><p>In Extended data 1 what is the GFP halo that we see in figures C and D that does not correspond to mitfa:mCherry? Please explain.</p><p>TIE:EGFP expressing melanoma cells downregulate interferon signaling</p><p>What are the controls here that were used for comparisons, please state in the figure legend (Suppl Figure 2B). It would be interesting to know how the expression of interferon-related genes compares to surrounding non-tumoral cells for the TIE:EGFP negative tumor cells.</p><p>In Figure 4 A the mCherry signal is too high and gives a yellow halo which is not due to co-expression with TIE:EGFP (as clearly visible in the TIE:EGFP upper panel). It is necessary to reduce the intensity of the mCherry signal until no spurious yellow is seen. The same applies to Figure 4D.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83527.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions (for the authors):</p><p>Although the reviewers are very positive about the manuscript, there are several areas that could be explored further. There was a consensus that the role of macrophages in particular needs more data for the model to be supported.</p><p>1. There are multiple issues with Figures 1 and Extended Data Figure 1 as seen in the reviewers' comments below. These relate to quality and quantification and should be addressed.</p><p>2. The reviewers also suggested that Figure 3 data be improved with better confocal images and time-lapse imaging.</p><p>3. In Figure 4, SATB2 data should be compared to Figures 1-3 without SATB2. Does SATB2 facilitate melanoma progression?</p><p>Reviewer #1 (Recommendations for the authors):</p><p>Data exists of spatially mapped transcriptomes in zebrafish melanoma:</p><p>Hunter, et al. Spatially resolved transcriptomics reveals the architecture of the tumor-microenvironment interface. Nat Commun 12, 6278 (2021).</p><p>Are the results in this study showing regions of active TGFb signaling in advanced melanoma consistent with existing data of endogenous expression patterns?</p></disp-quote><p>This is an excellent connection that would help to confirm the existence of regional TGFb signaling hubs through transcriptional analyses. In collaboration with Dr. Richard White’s lab, we analyzed this spatially resolved transcriptomics data set for regional expression of a TGFb pathway target gene signature.<sup>1</sup> In order to confidently determine cells in which the TGFb pathway was activated, this required a given “gene expression spot” (10X Visium Spatial Gene Expression) that expressed many TGFb target genes. However, Dr. White’s data only identified spots in which two TGFb target genes were simultaneously expressed, lacking the resolution needed to identify regions of active TGFb signaling. This analysis was not performed targeting TGFb target genes with probes, and so the limited identification of simultaneous TGFb target gene expression in a single cell was likely due to low detection sensitivity.</p><disp-quote content-type="editor-comment"><p>The proposed model of preferential phagocytosis of TIE:GFP+ cells vs negative cells is interesting, however, the data is still somewhat preliminary. Higher resolution imaging data and possibly time-lapse would better support the model. Could the authors provide some candidate factors produced by TIE:GFP+ cells that could trigger this response?</p></disp-quote><p>We thank the reviewer for this feedback and agree that additional imaging would provide more solid evidence of phagocytosis. To address this, we have performed additional high-resolution confocal imaging of <italic>TIE:EGFP</italic><sup>+</sup> cells and macrophages in the tumor. These images reveal a subset of macrophages that express the <italic>TIE:EGFP</italic> reporter endogenously as well as a subset of macrophages that contain <italic>TIE:EGFP<sup>+</sup></italic> fragments, often in endosome-like structures Figure 3—figure supplement 1 (previously Figure S4). We have found active phagocytosis to be difficult to capture in snapshots, making it challenging to quantify preferential phagocytosis by imaging. Our FACS experiment presented in Figure 3D provides a robust measurement of preferential phagocytosis of <italic>TIE:EGFP</italic><sup>+</sup> melanoma cells (vs. <italic>TIE:EGFP</italic><sup>-</sup> melanoma cells) by macrophages.</p><p>We have looked into identifying several candidate factors regulated in <italic>TIE:EGFP<sup>+</sup></italic> cells that could trigger macrophage-mediated phagocytosis. Our single cell RNA-seq data showed differential upregulation of <italic>serpine1</italic> mRNA expression in <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells compared to <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells, and the <italic>serpine1</italic> receptor, <italic>lrp1ab</italic>, is upregulated in <italic>TIE:EGFP</italic><sup>+</sup> macrophages compared to <italic>TIE:EGFP<sup>-</sup></italic> macrophages. This may indicate that macrophages are recruited to and subsequently phagocytose <italic>serpine1</italic>-expressing <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells. Indeed, SERPINE1, which encodes plasminogen activator inhibitor-1 (PAI-1), has been shown to promote cancer cell invasiveness and macrophage recruitment in an esophageal squamous cell carcinoma model.<sup>2</sup> Multiple reports indicate a role for PAI-1 in macrophages recruitment and polarization.<sup>3,4,5</sup> Furthermore, <italic>TIE:EGFP<sup>high</sup></italic> macrophages differentially express <italic>mmp14b</italic> and the cysteine protease <italic>legumain</italic>, both of which have been described to promote TGFb bioavailability.<sup>6,7,8</sup> These preliminary transcriptional data may indicate a mechanism by which macrophages are recruited to <italic>TIE:EGFP<sup>+</sup></italic> regions by PAI-1 gradients. Recruited macrophages may subsequently amplify the pool of active, bioavailable TGFb through the activity of enzymes such as <italic>mmp14b</italic> and <italic>lgmn</italic>. Such a model would explain the local clustering of macrophages in TGFb-responding regions of the tumor, and their subsequent endogenous activation of TGFb signaling and phagocytic behavior in these regions. (Figure 3B and C). In the paper, we have discussed this hypothesis in the Discussion, lines 350-363.</p><p>Chronic exposure to TGFb may affect macrophage polarization, resulting in the induction of M2-like markers, including <italic>mrc1b</italic> and <italic>vegfaa.</italic> Notably, in addition to M2-like markers, <italic>TIE:EGFP<sup>high</sup></italic> macrophages differentially express a number of genes involved in cholesterol efflux, lipid metabolism, and apoptosis including <italic>abca1a, abca1b, lipf, npc2, adipor2, caspa,</italic> and <italic>casp3b</italic>. Recent reports indicate that TGFb signaling can drive lipid droplet formation and ABCA1 expression in macrophages.<sup>9,10</sup> Thus, chronic zonal TGFb exposure and uptake may skew macrophages toward a stressed, anti-inflammatory phenotype. In this model, macrophages are continuously recruited to TGFb-high zones, where they facilitate TGFb amplification, phagocytose TGFb-responsive cells, and are gradually rendered incapable of tumoricidal activity. This effect on macrophages is discussed in the Discussion section, lines 364-376.</p><disp-quote content-type="editor-comment"><p>In the Extended Data Figure 1C-D experiments, if the mitf:mCherry is transiently injected, then the conclusions may be overstated. Line 90: &quot;TIE:EGFP was also never expressed in mitfa:mCherry high early melanomas (Extended Data Figure 1D)&quot;. How many melanomas were observed? What level of GFP expression is required to score as positive in TIE:GFP fish? The conclusions should be reconsidered because transient F0 transgenics are inherently mosaic.</p></disp-quote><p>It is true that <italic>mitfa:mCherry</italic> is transiently expressed. We have changed the word “never” to “has yet to be observed” to address this overstatement in line 92 (previously line 90). 56 tumors were observed, as stated in line 101. While FACS of each tumor may be able to give a quantitative threshold of EGFP expression by which to score <italic>TIE:EGFP<sup>+</sup></italic> tumors, we used stereomicroscope imaging to identify <italic>TIE:EGFP<sup>+</sup></italic> tumors due to feasibility and to track changes during further tumor progression. Using imaging, it is not easy to give a quantitative threshold of EGFP expression due to differences of EGFP brightness resulting from several factors including the depth at which the cells are located in the tumor volume. To identify <italic>TIE:EGFP<sup>+</sup></italic> tumors, we looked for tumors in which there were several visible <italic>EGFP<sup>+</sup></italic> cells or an <italic>EGFP<sup>+</sup></italic> patch of cells. We also tracked the expansion of these <italic>EGFP<sup>+</sup></italic> zones over several months, confirming that they were not imaging artifacts.</p><disp-quote content-type="editor-comment"><p>Extended data 1B images are small and difficult to evaluate. Need better images that are quantified for fluorescence intensity.</p></disp-quote><p>For previous Extended Data 1B (current Figure 1—figure supplement 1B) images depicting EGFP signal, we have clarified using white arrows which regions containing EGFP fluorescence are referenced, making it easier to evaluate. In addition, we have added in situ hybridization (ISH) data probing for GFP, which has been quantified for staining intensity. These changes are now reflected in Figure 1—figure supplement 1B and C.</p><disp-quote content-type="editor-comment"><p>In the Figure 1C (20 and 22 wpf) panels, why is there a yellow signal in the mitfa:mCherry channel alone in the majority of the tumor but not in the merged image?</p></disp-quote><p>In the <italic>mitfa:mCherry</italic> channel, yellow signal is due to saturated high mCherry signal. In our melanoma model, high <italic>mitfa</italic> expression is characteristic of zebrafish tumors. Using a standard imaging protocol (with defined zoom and exposure) to define melanoma lesions, oversaturation of <italic>mitfa:mCherry</italic> is displayed by the imaging software in yellow. Using Image J, we have removed the yellow oversaturation signal in these images by rendering each mCherry channel image as an 8-bit image and re-coloring the pixels in red. This way, all pixels are treated the same and the pixel intensity is retained and represented by red color intensity in the new images. We then re-merged the EGFP and new mCherry channels for all tumors in all figures.</p><disp-quote content-type="editor-comment"><p>Which data does S1B refer to in this line?</p><p>Line 115: melanomas were processed for single-cell RNA-sequencing at 23 and 42 weeks post-fertilization (wpf), respectively (Figure 1C and S1B).</p></disp-quote><p>The two tumors that were processed for single-cell RNA-sequencing and referred to in previous Line 115 are (1) the tumor shown in manuscript Figure 1C (dissected at 23 wpf) and (2) the tumor shown in manuscript Figure 1—figure supplement 2B (dissected at 42 wpf).</p><disp-quote content-type="editor-comment"><p>Could the authors describe the marco marker and its significance here?</p><p>Line: 120 melanoma cells expressing mitfa and/or sox10, but we identified a marco-expressing TIE:EGFP+.</p></disp-quote><p><italic>Marco</italic> is a known marker of macrophages, as well as a marker of M2-polarized macrophages. To be more straightforward in identifying the macrophage population in Figures 3 and 4 (and previous line 120), we defined the macrophage cluster using <italic>mpeg1.1</italic> expression instead of <italic>marco</italic> expression.</p><disp-quote content-type="editor-comment"><p>Does the analysis of Figure S2B include macrophages or is it only the melanomas? Is there any independent validation of the GSEA results? This is regarding:</p><p>Line: 130 in TIE:EGFPhigh cells were interferon α and γ (Figure S2B).</p></disp-quote><p>Manuscript Figure 2—figure supplement 1B (previously Figure S2B) is labeled “Melanoma Cells,” it does not include macrophages. To provide an independent validation of the GSEA results showing down-regulation of IFNa and IFNγ pathway activation in <italic>TIE:EGFP<sup>high</sup></italic> melanoma cells, we have isolated <italic>TIE:EGFP<sup>high</sup></italic> and <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells from two additional tumors by FACS and performed qPCR for several IFN-response genes. This data confirms that IFN target genes go down in <italic>TIE:EGFP<sup>high</sup></italic> tumor cells.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>qPCR shows that IFN target genes are down-regulated in <italic>TIE:EGFP<sup>high</sup></italic> melanoma cells compared to <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells.</title><p>Two <italic>Tg(mitfa:BRAF<sup>V600E</sup>);p53</italic><sup>-<italic>/</italic>-</sup><italic>;mitfa</italic><sup>-<italic>/</italic>-</sup> tumors expressing <italic>TIE:EGFP</italic>, <italic>mitfa:BFP</italic> and <italic>mpeg:mCherry</italic> were dissociated for FACS. We sorted two populations of cells: <italic>TIE:EGFP<sup>high</sup> mitfa:BFP<sup>+</sup> mpeg:mCherry<sup>-</sup>,</italic> and <italic>TIE:EGFP<sup>-</sup> mitfa:BFP<sup>+</sup> mpeg:mCherry<sup>-</sup>.</italic> Here, we gated for <italic>mitfa:BFP<sup>+</sup></italic> melanoma cells, gating out the macrophage population which may contain <italic>mitfa:BFP</italic> due to tumor cell phagocytosis. We isolated RNA from these sorted populations, performed cDNA synthesis, and performed qPCR. We used housekeeping gene <italic>b-actin</italic> to normalize values according to loading differences. Here, we confirmed that 4 major IFN genes discussed in the manuscript are down-regulated<italic>: irf7, irf1b, stat1b, and b2m.</italic> We included 3 additional IFN genes here to further validate the IFN pathway trend: <italic>mxa, mxb, and isg15.</italic> Fold change of <italic>mitfa</italic> is included here as a negative control, as we do not expect its expression to change between the two conditions. N=2 tumors, 3 technical replicates each. 2-tailed, unpaired t-tests were performed.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83527-sa2-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>In the following line, which genes are referred to specifically? Are these genes associated with a specific table or figure?</p><p>Line: 293 of melanoma patients exhibit up-regulation of these genes52,53.</p></disp-quote><p>This sentence refers to the 29 upregulated chronic TGFb genes shown in manuscript Figure 2C (first 29 genes listed on the dot plot).</p><disp-quote content-type="editor-comment"><p>Are there experiments that could better support the following statement:</p><p>Line: 306 Our work identified macrophage subclusters that contain low levels of mitfa and/or sox10 expression suggestive of phagocytosis of melanoma cells.</p></disp-quote><p>To further support the claim that <italic>mitfa</italic> and <italic>sox10</italic> are expressed in macrophages due to melanoma cell phagocytosis, we have performed additional high-resolution imaging of <italic>TIE:EGFP</italic><sup>+</sup> cells and macrophages in zebrafish tumors (Figure 3—figure supplement 1). This imaging reveals fragments of <italic>TIE:EGFP</italic> within macrophages, occasionally contained in endosome-like structures. It also reveals co-localization of <italic>mitfa:BFP, mpeg:mCherry,</italic> and <italic>TIE:EGFP</italic>, suggesting phagocytosis of TGFb responsive melanoma cells.</p><p>Additionally, we isolated <italic>TIE:EGFP<sup>+</sup></italic> and <italic>TIE:EGFP</italic><sup>-</sup> macrophages (using the <italic>mpeg:mCherry</italic> reporter) by FACS and performed qPCR for <italic>mitfa</italic> and <italic>sox10.</italic> This data (shown in manuscript Figure 3—figure supplement 2) shows that <italic>mitfa</italic> and <italic>sox10</italic> expression is enriched in <italic>TIE:EGFP<sup>+</sup></italic> macrophages compared to <italic>TIE:EGFP</italic><sup>-</sup> macrophages, further supporting that macrophages preferentially phagocytose <italic>TIE:EGFP</italic><sup>+</sup> melanoma cells.</p><disp-quote content-type="editor-comment"><p>Is there a GFP/mCherry merged image to support this statement, as it is not clear from the figure?</p><p>311 Figure 3C, there is co-localization of mpeg:mCherry and TIE:EGFP signal.</p></disp-quote><p>Thank you for requesting this clarification. To address this, we have included a merged image of the EGFP and mCherry channels in manuscript Figure 3C and have indicated the region of co-localization of <italic>mpeg:mCherry</italic> and <italic>TIE:EGFP</italic> with a white arrow.</p><disp-quote content-type="editor-comment"><p>The following figure legend is insufficient and needs more details (e.g. live or fixed sample? Optical section or z projection? Single frame of time-lapse?):</p><p>Line: 943 Supplement Figure 4. Example of a macrophage actively phagocytosing a TIE:EGFP+ cell in a melanoma.</p></disp-quote><p>To address this, we have added additional imaging information to the legend for manuscript Figure 3—figure supplement 1 (previously S4), such as methods for live imaging of zebrafish tumors, and optical sectioning vs. Z projection.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. Figure 1, Extended data 1 and supplemental Figure 1: better characterization of the reporter lines is important at different ages and in melanomas. Only one melanoma is shown in Figure 1C and another one in S1B, and, curiously, the pattern of TIE:EGFP expression is completely different: clusters vs homogenous expression. More pictures and quantitation of TIE:EGFP+ and TIE:EGFP- cells are required.</p></disp-quote><p>To show more characterization of the <italic>TIE:EGFP</italic> reporter in melanoma, we have included an additional supplemental figure (Figure 1—figure supplement 3) showing its expression in 5 additional melanomas. Almost all tumors have only a small cluster of cells in which the <italic>TIE:EGFP</italic> reporter is activated, however an occasional tumor activates the reporter as highly as that represented in manuscript Figure 1—figure supplement 2B (previously Figure S1B). Although imaging was ideal for our purposes of tracking changes of EGFP expression over time during tumor progression, FACS would be able to more accurately quantify <italic>TIE:EGFP<sup>+</sup></italic> and <italic>TIE:EGFP<sup>-</sup></italic> cells in the tumor, since imaging does not capture internal EGFP expression. As written in previous line 192 (current line 202), FACS determined that less than 1% of total cells from a tumor are EGFP<sup>+</sup> (n=3).</p><disp-quote content-type="editor-comment"><p>2. Figure 3 and results about macrophages: Figure 3A: most macrophages do not express mitfa and sox10. Figure 3B is not convincing: I do not see any white cells that would represent macrophages taken up TIE:EGFP+ melanoma cells. I can see several green macrophages that may indicate that macrophages express the TIE:EGFP construct. Additional pictures and video, if possible are needed.</p></disp-quote><p>We thank the reviewers for this comment and agree this should be clarified. We do not expect all/most macrophages to express <italic>mitfa</italic> and <italic>sox10</italic>. Because only a subset of macrophages expresses these genes, this supports the hypothesis that some of them have phagocytosed melanoma cells, rather than the possibility that all macrophages express these genes endogenously. We have clarified in the legend for manuscript Figure 3B that if a macrophage expresses the <italic>TIE:EGFP</italic> reporter endogenously, we would expect to see the entire volume of the macrophage to express EGFP, rather than fragments. In lines 183-198, we have clarified that the majority of <italic>TIE:EGFP<sup>+</sup></italic> macrophages contain EGFP<sup>+</sup> fragments, suggesting that they phagocytosed <italic>TIE:EGFP<sup>+</sup></italic> cells.</p><p>In three out of thirteen tumors imaged by confocal microscopy, we did capture a cluster of <italic>TIE:EGFP<sup>+</sup> mitfa:BFP<sup>+</sup></italic> melanoma cells closely co-localized with macrophages, indicating that macrophages are engulfing these cells (Figure 3B, Figure 3—figure supplement 1B). To clarify which macrophages have engulfed <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells in manuscript Figure 3B and Figure 3—figure supplement 1, we have added boxes around areas including white cells (which represent <italic>mitfa:BFP<sup>+</sup> TIE:EGFP<sup>+</sup> mpeg:mCherry<sup>+</sup></italic> cells). It is rare to capture active phagocytosis in snapshots (as seen in Figure 3—figure supplement 1C). However, the FACS experiment shown in manuscript Figure 3D and qPCR in manuscript Figure 3—figure supplement 2 confirms that macrophages preferentially phagocytose <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells over <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells.</p><p>In the majority of tumors, however, most <italic>TIE:EGFP</italic><sup>+</sup> fragments within macrophages appear <italic>mitfa:BFP<sup>-</sup></italic> via imaging. We have mentioned in the manuscript, particularly in lines 183-198 and in the Figure 3 legend, that macrophages likely phagocytose <italic>TIE:EGFP</italic><sup>+</sup> non-melanoma cells (in addition to <italic>TIE:EGFP</italic><sup>+</sup> melanoma cells). These non-melanoma cells may not have been identified in our SORT-seq data because the tissue dissociation protocol used is ideal for tumor cell viability, but not for that of various immune cell populations. Indeed, by confocal imaging, the majority of <italic>TIE:EGFP<sup>+</sup></italic> signal appears to be within clusters of macrophages, while FACS analysis and SORT-seq analysis shows that a large proportion of <italic>TIE:EGFP<sup>+</sup></italic> cells are tumor cells. This may be attributed to the technicality that tumor dissociation using Liberase (used for FACS and SORT-seq) favors tumor cell survival/dissociation over immune cell populations.</p><p>One alternative reason we may not often observe (via imaging) three-way co-localization between <italic>TIE:EGFP, mpeg:mCherry,</italic> and <italic>mitfa:BFP</italic> may be attributed to timing of observation. We most often observe macrophages with <italic>TIE:EGFP</italic> fragments, which may be the remnants of previously engulfed <italic>TIE:EGFP<sup>+</sup>;mitfa:BFP<sup>+</sup></italic> tumor cells, and the BFP expression is no longer strong enough to see at the time of imaging. <italic>Mitfa:BFP</italic> is expressed mosaically in these tumor cells and may not be expressed in every tumor cell. Because we do occasionally observe macrophages engulfing clusters of <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells, and that FACS confirms that macrophages contain <italic>TIE:EGFP<sup>+</sup> mitfa:BFP<sup>+</sup></italic> fragments, we are confident that melanoma cells are one <italic>TIE:EGFP<sup>+</sup></italic> population being phagocytosed by macrophages. We focused our studies on this particular interaction to show that macrophages preferentially phagocytose <italic>TIE:EGFP</italic><sup>+</sup> melanoma cells compared to <italic>TIE:EGFP</italic><sup>-</sup> melanoma cells.</p><disp-quote content-type="editor-comment"><p>3. Figure 3D: I do not understand why Q1 represent non-melanoma cells that were phagocytosed. I think these are non-phagocytosing macrophages. So, Q2 has to be plotted not Q1+Q2. Anyway, I think that allotransplant experiments of melanoma cells from TIE:EGFP fish need to be performed in mpeg1:cherry recipient, and vice versa, to demonstrate that macrophages are phagocytosing TIE:GFP+ cells rather than expressing the construct. In addition.</p></disp-quote><p>We appreciate this being brought to our attention, and we agree that this alternative hypothesis is likely. Although imaging shows that the majority of <italic>TIE:EGFP<sup>+</sup></italic> macrophages contain only fragments of EGFP, suggesting phagocytosis, it is possible that Q1 can represent a subset of non-phagocytosing macrophages that express the <italic>TIE:EGFP</italic> construct endogenously, or macrophages that phagocytosed <italic>TIE:EGFP<sup>+</sup></italic> non-melanoma cells. We have clarified this in the figure legend and re-plotted Q2 only in manuscript Figure 3D.</p><p>While an allotransplant would help answer this question of phagocytosis, this experiment would have caveats in our system. Because we do not have isogenic lines expressing these reporters, macrophages from the recipient fish would phagocytose transplanted <italic>TIE:EGFP<sup>+</sup></italic> cells due to foreign recognition in a “graft vs. host” response, confounding our results.</p><disp-quote content-type="editor-comment"><p>4. Figure 4 and SATB2 data: these data should be compared with those obtained in Figure 1-3 w/o SATB2. Does SATB2 facilitate melanoma progression? Is there any difference in the TGFB targets between control and SATB2 TIE:EGFP+ cells?</p></disp-quote><p><italic>SATB2</italic> overexpression in our zebrafish model does facilitate melanoma progression, as stated in previous lines 204-206 (currently line 215-217), in which we referenced a paper previously published in our lab showing this data. We re-worded this sentence to include that <italic>SATB2</italic> overexpression accelerates melanoma onset. We have also revised manuscript Figure 4 to include images of tumor development and <italic>TIE:EGFP</italic> activation in a control <italic>MCR:MCS</italic> tumor for reference.</p><p>There are differences in TGFb target genes in <italic>TIE:EGFP<sup>+</sup></italic> tumor cells between <italic>MCR:MCS</italic> and <italic>MCR:SATB2</italic> tumors, although some genes are shared. Shown below is a table listing target genes that are upregulated in <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells in a control <italic>MCR:MCS</italic> tumor and a <italic>MCR:SATB2</italic> tumor, including those that are shared between the two genotypes (<xref ref-type="table" rid="sa2table1">Author response table 1</xref>). In manuscript Figure 4C, we have indicated the shared genes in red text.</p><table-wrap id="sa2table1" position="float"><label>Author response table 1.</label><caption><title>List of top up-regulated genes in <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells of <italic>MCR:MCS</italic> and <italic>MCR:SATB2</italic> tumors, as defined by SORT-seq.</title><p>These genes are also listed in manuscript Figures 2C and 4C.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">MCS</th><th align="left" valign="top">Shared</th><th align="left" valign="top">SATB2</th></tr></thead><tbody><tr><td align="left" valign="top">arhgdia</td><td align="left" valign="top">bsg</td><td align="left" valign="top">mmp14b</td></tr><tr><td align="left" valign="top">lama4</td><td align="left" valign="top">col6a1</td><td align="left" valign="top">igf2r</td></tr><tr><td align="left" valign="top">lrp1ab</td><td align="left" valign="top">itgb2</td><td align="left" valign="top">igfbp3</td></tr><tr><td align="left" valign="top">rhoq</td><td align="left" valign="top">marcksl1a</td><td align="left" valign="top">igfbp5b</td></tr><tr><td align="left" valign="top">rnd3a</td><td align="left" valign="top">nid1a</td><td align="left" valign="top">pak1</td></tr><tr><td align="left" valign="top">ddr1</td><td align="left" valign="top">rhoab</td><td align="left" valign="top">pxnb</td></tr><tr><td align="left" valign="top">fgd1</td><td align="left" valign="top">sparc</td><td align="left" valign="top">nme4</td></tr><tr><td align="left" valign="top">itga4</td><td align="left" valign="top">lamb1a</td><td align="left" valign="top">ephb2b</td></tr><tr><td align="left" valign="top">itga5</td><td align="left" valign="top">tnc</td><td align="left" valign="top">cdh2</td></tr><tr><td align="left" valign="top">col1a2</td><td align="left" valign="top"/><td align="left" valign="top">smad7</td></tr><tr><td align="left" valign="top">dv1b</td><td align="left" valign="top"/><td align="left" valign="top">sox2</td></tr><tr><td align="left" valign="top">cdkn2a</td><td align="left" valign="top"/><td align="left" valign="top">vim</td></tr><tr><td align="left" valign="top">cdkn2b</td><td align="left" valign="top"/><td align="left" valign="top">rac1a</td></tr><tr><td align="left" valign="top">serpine1</td><td align="left" valign="top"/><td align="left" valign="top">lrrc17</td></tr><tr><td align="left" valign="top">fn1a</td><td align="left" valign="top"/><td align="left" valign="top">sema3fb</td></tr><tr><td align="left" valign="top">snai1b</td><td align="left" valign="top"/><td align="left" valign="top">ctnnb1</td></tr><tr><td align="left" valign="top">twist1b</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">snai2</td><td align="left" valign="top"/><td align="left" valign="top"/></tr></tbody></table></table-wrap><disp-quote content-type="editor-comment"><p>5. Lines 286-295: it is speculated that the novel chronic TGFB targets are involved in cell migration. I think it would be a nice complement to perform an allotransplant of TIE:EGFP+ and TIE:EGF- melanoma cells and study their aggressiveness.</p></disp-quote><p>We agree that an allotransplant of <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells would be a nice experiment to determine if they are more migratory than <italic>TIE:EGFP<sup>-</sup></italic> melanoma cells. However, this is beyond the scope of this paper. In this manuscript, we merely speculate that TGFb signaling may promote migration of melanoma cells, and we plan to directly determine this in future experiments.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1) The confocal pictures in Figure 3B are not convincing. We cannot see the edge of the cells to make sure that they are not debris. At the same time, how do we expect that melanoma cells that have been phagocytosed by macrophages and that are present in fragments (only puncta of TIE:EGFP signal are seen in macrophages) would maintain intact the mitfa and sox10 mRNAs retrieved in the single cell RNA analysis? This is why we need absolutely perfect confocal images of tumor sections with clearly visible macrophages and tumor cells to support the hypothesis that macrophages preferentially phagocyte TGFbeta-expressing melanoma cells. In addition, this claim should be supported by some in vivo live observation to test the ability of macrophages to recognize TGFbeta-expressing melanoma cells versus other melanoma cells.</p><p>The doubt that this reporter labels a subpopulation of macrophages or macrophages in a particular status of activation induced by the presence of the tumor, rather than macrophages that have phagocytosed a rare population of melanoma cells that turn on the TGFb reporter remains.</p></disp-quote><p>We thank the reviewer for this comment and have made revisions to address this concern. We have performed additional confocal imaging of zebrafish tumors, for which we have included images in manuscript Figure 3—figure supplement 1. This consistently shows <italic>TIE:EGFP<sup>+</sup></italic> fragments contained in <italic>mpeg:mCherry<sup>+</sup></italic> macrophages, representing macrophages that have phagocytosed <italic>TIE:EGFP<sup>+</sup></italic> cells. These EGFP<sup>+</sup> fragments are not debris/imaging artifacts, since they are observed within the bounds of <italic>mpeg:mCherry</italic><sup>+</sup> cells, they are not fluorescent in every channel (as debris usually is), and they are contained in endosome-like structures in macrophages (manuscript Figure 3—figure supplement 1A, right). We have clarified in lines 183-198 and Figure 3 legend that macrophages likely phagocytose <italic>TIE:EGFP</italic><sup>+</sup> non-melanoma cells (in addition to <italic>TIE:EGFP</italic><sup>+</sup> melanoma cells), which may be why we observe a subset of macrophages containing <italic>TIE:EGFP</italic> fragments without <italic>mitfa:BFP</italic> fragments. One alternative reason we may not often observe (via imaging) three-way co-localization between <italic>TIE:EGFP, mpeg:mCherry,</italic> and <italic>mitfa:BFP</italic> may be attributed to timing of observation. We most often observe macrophages with <italic>TIE:EGFP</italic> fragments, which may be the remnants of previously engulfed <italic>TIE:EGFP<sup>+</sup>;mitfa:BFP<sup>+</sup></italic> tumor cells, and the BFP expression is no longer strong enough to see at the time of imaging. <italic>Mitfa:BFP</italic> is expressed mosaically in these tumor cells and may not be expressed in every tumor cell.</p><p>We have included additional images of tumors in which macrophages do contain <italic>TIE:EGFP</italic> and <italic>mitfa:BFP</italic> fragments (represented by white cells contained in boxes in manuscript Figure 3B and Figure 3—figure supplement 1B). Together with the FACS experiment depicted in Figure 3D, this data confirms that macrophages phagocytose <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells. While our imaging data suggests that macrophages likely phagocytose <italic>TIE:EGFP</italic><sup>+</sup> non-melanoma cells as well, we decided to focus our studies on the melanoma cell population to show that macrophages preferentially phagocytose <italic>TIE:EGFP</italic><sup>+</sup> melanoma cells compared to <italic>TIE:EGFP</italic><sup>-</sup> melanoma cells. It is possible for macrophages that have recently phagocytosed <italic>TIE:EGFP<sup>+</sup></italic> melanoma cells to maintain <italic>mitfa</italic> and <italic>sox10</italic> mRNAs, if these cells are contained in phagosomes that have not yet fused with lysosomes and undergone degradation. This is likely why <italic>mitfa</italic> and <italic>sox10</italic> mRNAs are retrieved in single cell RNA analysis in a subset of macrophages. The retainment of <italic>mitfa</italic> and <italic>sox10</italic> transcripts was validated in an additional qPCR we performed of <italic>TIE:EGFP<sup>+</sup></italic> and <italic>TIE:EGFP</italic><sup>-</sup> macrophages, as described in Figure 3—figure supplement 2.</p><p>In addition to clarifying the phagocytic behavior of <italic>TIE:EGFP<sup>+</sup></italic> cell populations, our additional imaging revealed a subset of macrophages that express <italic>TIE:EGFP</italic> endogenously (manuscript Figure 3—figure supplement 1A, left). A description of these two subsets of <italic>TIE:EGFP<sup>+</sup></italic> macrophages is included in lines 183-198.</p><disp-quote content-type="editor-comment"><p>2) To understand if the overexpression of SATB2 would activate the reporter, and generate melanomas with a larger proportion of TIE:EGFP positive cells, they produced tumors overexpressing SATB2 in the TIE:EGFP background. Then, they searched for differences in the macrophage populations. Here the authors admit that TGFbeta is known to convert macrophages from a pro-inflammatory M1-like to an anti-inflammatory M2-like state, thus implicitly suggesting that the reporter, which is not specific for melanoma but could be expressed in any cell of these transgenic fish, could be activated directly in the macrophages, with no need to justify its expression with the phagocytosis of a rare population of melanoma cells expressing it.</p></disp-quote><p>Indeed, additional confocal imaging reveals a subset of macrophages that express <italic>TIE:EGFP</italic> endogenously, which populations will be interesting to focus on going forward (manuscript Figure 3—figure supplement 1A, left). This imaging also reveals a subset of macrophages that phagocytose <italic>TIE:EGFP<sup>+</sup></italic> cells (manuscript Figure 3B and Figure 3—figure supplement B), which is a separate interesting phenomenon discussed in this manuscript. We have included a description of these two <italic>TIE:EGFP<sup>+</sup></italic> macrophage populations in lines 183-198.</p><disp-quote content-type="editor-comment"><p>Related to Figure 1C, sections through the melanoma would help to distinguish whether the green fluorescence signal is part of the tumor and not just the residual brain tissue that express the reporter, and that we see clearly also in extended data Figure 1D.</p></disp-quote><p>We are confident that the patch of EGFP fluorescence indicated by an arrowhead near the brain in manuscript Figure 1C is not residual brain fluorescence because it is expressed superficially and is expressed in individual cells, rather than the typical hazy, internal brain fluorescence pattern we see. We also observed this EGFP<sup>+</sup> patch grow over the course of a few weeks. However, to further show that tumors do indeed contain clusters of <italic>TIE:EGFP</italic> activation, we have included an additional supplemental figure (Figure 1—figure supplement 3) displaying images of five additional advanced tumors, including those at different anatomical locations.</p><disp-quote content-type="editor-comment"><p>One of the arrowheads in Figure 1C, in the 22 wks image, does not point to gfp signal. What is the yellow halo in the middle panel mitfa:mcherry at 20 and 22 weeks?</p></disp-quote><p>This arrowhead in manuscript Figure 1C does point to EGFP<sup>+</sup> cells, but they are hard to see at this magnification, so we deleted the arrowhead to minimize confusion.</p><p>In the <italic>mitfa:mCherry</italic> channel, yellow signal is due to saturated high mCherry signal. In our melanoma model, high <italic>mitfa</italic> expression is characteristic of zebrafish tumors. Using a standard imaging protocol (with defined zoom and exposure) to define melanoma lesions, oversaturation of <italic>mitfa:mCherry</italic> is displayed by the imaging software in yellow. Using Image J, we have removed the yellow oversaturation signal in these images by rendering each mCherry channel image as an 8-bit image and re-coloring the pixels in red. This way, all pixels are treated the same and the pixel intensity is retained and represented by red color intensity in the new images. We then re-merged the EGFP and new mCherry channels for all tumors in all figures.</p><disp-quote content-type="editor-comment"><p>In Extended data 1 what is the GFP halo that we see in figures C and D that does not correspond to mitfa:mCherry? Please explain.</p></disp-quote><p>The EGFP halo in previous Extended Data 1 (current Figure 1—figure supplement 1) indicates endogenous <italic>TIE:EGFP</italic> reporter expression in the spine (Figure 1—figure supplement 1D) and brain (Figure 1—figure supplement 1E). We have now clarified this in the legend for this figure.</p><disp-quote content-type="editor-comment"><p>TIE:EGFP expressing melanoma cells downregulate interferon signaling</p><p>What are the controls here that were used for comparisons, please state in the figure legend (Suppl Figure 2B). It would be interesting to know how the expression of interferon-related genes compares to surrounding non-tumoral cells for the TIE:EGFP negative tumor cells.</p></disp-quote><p>The internal control for this experiment was <italic>TIE:EGFP</italic><sup>-</sup> melanoma cells, to which we compared interferon stimulated gene (ISG) expression in <italic>TIE:EGFP<sup>low</sup></italic> and <italic>TIE:EGFP<sup>high</sup></italic> melanoma cells from the same tumor. We have clarified this in the legend of manuscript Figure 2—figure supplement 1 (previously S2B).</p><p>Using a scRNA-seq dataset we had available in the lab that contained melanocytes from zebrafish normal skin, early melanoma, and an advanced tumor, we analyzed relative interferon-related genes at these different stages (<xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>). Generally, it appears that interferon-related genes often increase in tumors compared to normal skin and precursor lesions. While IFN genes are generally up-regulated in melanoma cells within a tumor, the data in this manuscript describes a rare subset of tumor cells that up-regulate TGFb and thus down-regulate IFN.</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><caption><title>ScRNA-seq shows that expression of IFN target genes increases in tumors compared to normal skin and precursor lesions.</title><p><italic>Mitfa:BFP<sup>+</sup></italic> melanocytes were sorted via FACS from normal skin, an early melanoma, and an advanced melanoma and 10X single-cell RNA-seq was performed. Data was analyzed using Seurat and cell types were called based on gene expression signatures. Depicted here are violin plots of several IFN target genes in melanocytes across the three stages.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83527-sa2-fig2-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>In Figure 4 A the mCherry signal is too high and gives a yellow halo which is not due to co-expression with TIE:EGFP (as clearly visible in the TIE:EGFP upper panel). It is necessary to reduce the intensity of the mCherry signal until no spurious yellow is seen. The same applies to Figure 4D.</p></disp-quote><p>In manuscript Figure 4A, the yellow signal in the <italic>mitfa:mCherry</italic> channel represents saturated mCherry signal, indicative of characteristic <italic>mitfa</italic> high state of our zebrafish tumors. Using Image J, we have removed the yellow oversaturation signal in these images by rendering each mCherry channel image as an 8-bit image and re-coloring the pixels in red. This way, all pixels are treated the same and the pixel intensity is retained and represented by red color intensity in the new images. We have excluded the merged images in this panel to minimize confusion about the yellow signal, and to make space for a panel including development of a reference <italic>MCR:MCS</italic> tumor.</p><p>References:</p><p>Hunter, M.V., Moncada, R., Weiss, J.M. et al. Spatially resolved transcriptomics reveals the architecture of the tumor-microenvironment interface. <italic>Nat Commun</italic> 12, 6278 (2021).</p><p>Sakamoto, H., Koma, Yi., Higashino, N. et al. PAI-1 derived from cancer-associated fibroblasts in esophageal squamous cell carcinoma promotes the invasion of cancer cells and the migration of macrophages. Lab Invest 101, 353–368 (2021).</p><p>Kubala, M. H., Punj, V., Placencio-Hickok, V. R., Fang, H., Fernandez, G. E., Sposto, R., &amp; DeClerck, Y. A. Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer. Cell reports, 25(8), 2177–2191 (2018).</p><p>Honjo, K., Munakata, S., Tashiro, Y., Salama, Y., Shimazu, H., Eiamboonsert, S., Dhahri, D., Ichimura, A., Dan, T., Miyata, T., Takeda, K., Sakamoto, K., Hattori, K., &amp; Heissig, B. Plasminogen activator inhibitor-1 regulates macrophage-dependent postoperative adhesion by enhancing EGF-HER1 signaling in mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 31(6), 2625–2637 (2017).</p><p>Baumeier, C., Escher, F., Aleshcheva, G. et al. Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy. Basic Res Cardiol 116, 1 (2021).</p><p>Bai, P. et al. Macrophage-Derived Legumain Promotes Pulmonary Hypertension by Activating the MMP (Matrix Metalloproteinase)-2/TGF (Transforming Growth Factor)-β1 Signaling. Arteriosclerosis, Thrombosis, and Vascular Biology. 39 (4) (2019).</p><p>Sounni, N.E., Dehne, K., van Kempen, L., Egeblad, M., Affara, N.I., Cuevas, I., Wiesen, J., Junankar, S., Korets, L., Lee, J., Shen, J., Morrison, C.J., Overall, C.M., Krane, S.M., Werb, Z., Boudreau, N., Coussens, L.M. Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis Model Mech. 3, (2010).</p><p>Robertson, I.B., Rifkin, DB. Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins. Cold Spring Harb Perspect Biol. 8, (2016).</p><p>Hu, Y. W., Wang, Q., Ma, X., Li, X. X., Liu, X. H., Xiao, J., Liao, D. F., Xiang, J., &amp; Tang, C. K. TGF-beta1 up-regulates expression of ABCA1, ABCG1 and SR-BI through liver X receptor α signaling pathway in THP-1 macrophage-derived foam cells. Journal of atherosclerosis and thrombosis, 17(5), 493–502 (2010).</p><p>Bose, D., Banerjee, S., Chatterjee, N., Das, S., Saha, M., &amp; Saha, K. D. Inhibition of TGF-β induced lipid droplets switches M2 macrophages to M1 phenotype. Toxicology in vitro : an international journal published in association with BIBRA, 58, 207–214 (2019).</p></body></sub-article></article>